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Objectives: To evaluate the therapeutic efficacy  of the new artemisinin combinations 
therapies (ACTs), artesunate + Sulfadoxine/Pyrimethamine, and artemether/lumefantrine 
the first and second lines antimalarial respectively in Sudan, against uncomplicated 
falciparum malaria in Sudanese patients.  
To obtain the pharmacokinetics parameters of the first line antimalarial drug, artesunate 
plus sulfadoxine/pyrimethamine in healthy Sudanese volunteers.  
Methods:  The study was one arm prospective evaluation of clinical and parasitological 
response to directly observed treatment of (ASP) and (AL) in Sudanese patients with 
uncomplicated falciparum malaria. WHO protocol 2003 was applied in all procedures of 
the study. The study was conducted in 6 health facilities located in the capitals of 5 states; 
Juba, malakal, Damazin, Kosti and Kassala, representing epidemiological stratification 
and substrata of malaria in the country. All patients were assessed clinically and 
diagnostically, patients who met inclusion criteria were enrolled in the study. Each 
patient was followed 28 days in stipulated visits. On each time clinical examination was 
done and a blood film was taken for parasite count and recorded in patient report form. 
Data were collected and analyzed for treatment response for each patient automatically. 
It was an experimental cross- over clinical trial for determination of the pharmacokinetic 
parameters of (ASP) in healthy Sudanese subjects (n =16), taking artesunate alone as 
monotherapy in the first round and in combination with sulfadoxine/pyrimethamine (SP) 
in the second round, with a wash out period of 3 weeks interval. From each healthy adult 
volunteer 5 ml of venous blood was withdrawn and put in hepernized vial at schedulled 
time interval. Plasma was separated by centrifugation and pushed into cryo-tubes kept in 
-80 degree centigrade until analysis. Quantification of artesunate and dihydroartemisinin 
in Human Plasma was done by Liquid Chromatography-Tandem Mass Spectrometry. The 
pharmacokinetic computations were performed using WinNonLin software (Version 
5.10, Pharsight, USA, 2005). 
Results & Discussion A total of 4862 febrile patients were examined and screened of 
them 1518 patients found to be positive for plasmodium falciparum infection, of them 
409 patients fulfilled the inclusion criteria and were enrolled in the study for the 
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evaluation of efficacy and safety of the two combinations namely the first and second 
lines. The main outcome of the study was confirmed the high efficacy rates of 99.3% for 
(ASP) and 98.5% for (AL). The 2 combinations were well tolerated for both children and 
adults, mild side effects were observed in 5 (1.9%) and in 6 (4.3%) of the patients for the 
first and second lines respectively. Rapid parasite clearance and decrease gametocyte 
carriage was obtained, which consequently would assist the Control efforts in reduction 
of malaria prevalence. These findings support the good selection of the 2 lines by health 
authority, as a suitable option for malaria treatment in Sudan. The study is considered 
highly significant as it involve big sample size (409) from different states compared to 
other similar studies. These results are also in full agreement with studies carried out in 
Africa and globally with respect to efficacy and safety.  
Findings of the present study, concerning the derived parameters, statistical calculations, 
tables and figures perfectly complied with typical previous ones which described models 
assumes first-order input across the gut wall and first –order elimination from the body.  
The active metabolite dihydroartemisinin DHA which is assumed to give the antimalarial 
action was found to be produced rapidly from the pro drug artesunate.   
The common measures to assess the difference in absorption are AUC, (Cmax) and (Tmax). 
Both (Cmax) and (Tmax) were lower with artesunate whether as monotherapy or 
combination compared to DHA.  AUC of DHA is (P=0.001) significantly increased  
(p=0,001)  when given in combination compared to monotherapy. The addition of 
sulfadoxine/pyrimethamine to artesunate was found to increase the total exposure of 
dihydroartemisinin in blood, consequently increases the therapeutic efficacy, which 
support findings of efficacy. The half-life of DHA alone is significantly shorter than in 
combination with SP (P=0.002). in practice vast majority of drugs are eliminated by 5 
half –lives, then the effect of DHA combination with SP expected to cease at mean time 
of 8.5 (8.85) hours. This part of the study confirmed that ; the established dose mentioned 
in the national treatment protocol is the optimum dose for the treatment uncomplicated 
falciparum malaria in Sudan.  
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 ﺧـــﻼﺻـــﺔ اﻷطـــﺮوﺣــﺔ 
ة ﺑﺄدوﻳﺔ اﻟﻣﻼرﻳﺎ اﻟﻣﺷﺗﺮﻛﺔ ﻣﻊ ﻣﺷﺗﻘﺎت اﻷرﺗﻣﻳﺳﻧﻳن ﻟﻌﻼج اإﻟﻰ ﺗﻘﻳﻳم ﻧﺟﺎﻋﺔ اﻟﻣداودف ھذه اﻟدراﺳﺔ ﺗﮫ :اﻟﮫــدف
 \ﺳﻠﻔﺎدوﻛﺳﻳن +أرﺗوﺳﻧﻳت)اﻟﻣﺮﺿﻰ اﻟﺳوداﻧﻳﻳن اﻟﻣﺻﺎﺑﻳن ﺑﺎﻟﻣﻼرﻳﺎ اﻟﻣﻧﺟﻠﻳﺔ ﻏﻳﺮ اﻟﻣﺗﺮاﻓﻘﺔ ﺑﻣﺿﺎﻋﻔﺎت وھﻲ 
 .ﺧطﻲ اﻟﻌﻼج اﻷول واﻟﺛﺎﻧﻲ ﻋﻠﻰ اﻟﺗواﻟﻲ( ﺎﻧﺗﺮﻳن  ﻟوﻣﻔ\آرﺗﻳﻣﺛﻳﺮ )و( ﺑﺎرﻳﻣﺛﺎﻣﻳن 
 اﻟﻣﺗطوﻋﻳن داﺧل ﺟﺳم  ه اﻟﺣﻳويﻓﺮاوﺗو (ﺑﺎرﻳﻣﺛﺎﻣﻳن \ﺳﻠﻔﺎدوﻛﺳﻳن +أرﺗوﺳﻧﻳت)ﮫدف إﻟﻰ ﺗﺣدﻳد ﺣﺮﻛﻳﺔ ﺗ
 .اﻟﺳوداﻧﻳﻳن اﻷﺻﺣﺎء
 ﻟﻠﺗﻘﻳﻳم اﻟﻣﺳﺗﻘﺑﻠﻲ ﻟﻼﺳﺗﺟﺎﺑﺔ اﻟﻌﻳﺎدﻳﺔ واﻟطﻔﻳﻠﻳﺔ ﻟدى اﻟﻣﺮﺿﻰ اﺟﺮﻳت ھذه اﻟدراﺳﺔ :طــﺮﻳﻘــﺔ اﻟﺑﺣـــث
اﺗﺑﻌت ھذه اﻟدراﺳﺔ . ﺳوداﻧﻳﻳن اﻟﻣﺻﺎﺑﻳن ﺑﺎﻟﻣﻼرﻳﺎ ﺑﻌد ﺗﻧﺎوﻟﮫم اﻟﺟﺮﻋﺎت اﻟﻣوﺻﻰ ﺑﮫﺎ ﻟﻸدوﻳﺔ اﻟﻣﺷﺎر اﻟﻳﮫﺎاﻟ
أﺟﺮﻳت ھذه اﻟدراﺳﺔ ﻓﻲ ﺳت .  ﻟدراﺳﺎت ﻧﺟﺎﻋﺔ اﻟﻣداواة ﺑﺄدوﻳﺔ اﻟﻣﻼرﻳﺎ3002ﺑﺮﺗوﻛول ﻣﻧظﻣﺔ اﻟﺻﺣﺔ اﻟﻌﺎﻟﻣﻳﺔ 
ﻳن، ﻛوﺳﺗﻲ و ﻛﺳﻼ اﺧﺗﻳﺮت ﻟﺗﻐطﻲ ﻣؤﺳﺳﺎت ﺻﺣﻳﺔ ﻣوزﻋﺔ ﻓﻲ ﺧﻣﺳﺔ ﻣدن ﻛﺑﻳﺮة وھﻲ ﺟوﺑﺎ، ﻣﻠﻛﺎل، اﻟدﻣﺎز
ﻳﺗﺎﺑﻊ اﻟﻔﺮﻳق اﻟطﺑﻲ . ﺑﻌد أﺧذ اﻟﺟﺮﻋﺎت ﻟﻠﻣﺮﺿﻰ اﻟﻣﺷﺎرﻛﻳن أﻣﺎم اﻟﻔﺮﻳق اﻟطﺑﻲ اﻟﻣدرب. اﻟﺗﺻﻧﻳف اﻟوﺑﺎﺋﻲ ﻟﻠﻣﻼرﻳﺎ
 ﻳﺟﺮى اﻟﻔﺣص اﻟطﺑﻲ اﻟﻛﺎﻣل واﻟﻔﺣص اﻟﻣﻌﻣﻠﻲ زﻳﺎرة ﻓﻲ ﻛل زﻳﺎرات ﺑواﺳطﺔ ﺟدول زﻣﻧﻲ ﻣﺻﻣم، اﻟﻣﺮﺿﻰ ﻓﻲ 
ﻣﺎت ﻛل ﻣﺮﻳض ﻋﻠﻰ ﺣدة ﻓﻲ اﺳﺗﻣﺎرة ﺧﺎﺻﺔ، ﺟﻣﻌت اﻟﺑﻳﺎﻧﺎت وأدﺧﻠت ﻟﻠﺗﺣﻠﻳل ﻟﻣﻌﺮﻓﺔ ﻛﺛﺎﻓﺔ اﻟطﻔﻳل وﺗﺳﺟل ﻣﻌﻠو
 اﻟﻣﺻﻣم ﻣن ﻣﻧظﻣﺔ اﻟﺻﺣﺔ اﻟﻌﺎﻟﻣﻳﺔ ﻟﻳﻌطﻲ ﺗﺻﻧﻳف ﻣدى اﺳﺗﺟﺎﺑﺔ اﻟﻣﺮﺿﻰ ﻟﻠﻌﻼج( lecxE)ﺑواﺳطﺔ ﺑﺮﻧﺎﻣﺞ 
 .ﻗﻳﺎﺳﻳﺔﺑطﺮﻳﻘﺔ اﻟﻳﺔ 
 ﻋﻘﺎر ﻋﻼج اﻟﻣﻼرﻳﺎ ھﻲ ﺗﺟﺮﻳﺑﻳﺔ ﻋﻳﺎدﻳﺔ وﻣﺧﺗﺑﺮﻳﺔ اﺟﺮﻳت ﻟﻐﺮض ﻣﻌﺮﻓﺔ اﻟﺣدود واﻟﻌواﻣل اﻟﺗﻲ ﺗؤﺛﺮ ﻋﻠﻲ ﺣﺮﻛﻳﺔ
اﻟﺣﻳوي داﺧل ﺟﺳم اﻟﻣﺗطوﻋﻳن اﻟﺑﺎﻟﻐﻳن  وﺗواﻓﺮه( ﺑﺎرﻳﻣﺛﺎﻣﻳن\اﻻرﺗوﺳﻧﻳت ﻣﻊ اﻟﺳﻠﻔﺎدوﻛﺳﻳن)اﻻول ﻓﻲ اﻟﺳودان 
 ﻣﻠﺟم اﺗوﺳﻧﻳت 002 ﻣن اﻟﻌﻘﺎر اﻋﻼه ﻣﻧﻔﺮدا وھﻲ  اﺟﻠﺳوا ﻓﻲ اﻟﻣﺮة اﻻوﻟﻲ ﻟﺗﻧﺎول ﺟﺮﻋﺔ واﺣدة، اﻻﺻﺣﺎء 
 002ﻓﻲ اﻟﻣﺮة اﻟﺛﺎﻧﻳﺔ اﻋطوا راﺗوﺳﻧﻳت . ﺛﺎﻧﻳﺔﺎر ﻣن دﻣﮫم اﺟﻠﺳوا ﺳل ﻟﻠﻌﻘ اﺳﺎﺑﻳﻊ ﻛﻔﺗﺮة ﻏ3وﺑﻌد ( ﺣﺑﺔ2)ﺣﺑوب 
 ﺳﻲ ﺳﻲ 5ﺔ اﺧذ ﻣن ﻛل ﻣﺗطوع وﻓﻲ اﺛﻧﺎء اﻟﺟﻠﺳ. ﺑﺎرﻳﻣﺛﺎﻣﻳن\ ﺣﺑﺎت ﻣن اﻟﺳﻠﻔﺎدوﻛﺳن3 ﺣﺑﺔ ﻣﺷﺗﺮﻛﺎ ﻣﻊ 2ﻣﻠﺟم 
  درﺟﺔ ﻣﺋوﻳﺔ ﺣﺗﻲ اﺟﺮاء اﻟﺗﺣﻠﻳل08-ﻋﻳﻧﺎت اﻟﺑﻼزﻣﺎ ﻓﻲ ﺣﻔظت ﻓﻲ  . زﻣﻧﻳﺔ ﻣﺣددة ﻓﺗﺮات ﻣن دم اﻟورﻳد ﻋﻠﻲ 
 yrtemortcepS ssaM mednaT-yhpargotamorhC diuqiLﺟﺮي اﻟﺗﺣﻠﻳل ﺑﺎﺳطﺔ ﺟﮫﺎز ا.
ﻓﻲ ﻋﻳﻧﺎت  AHD وﻣﺳﺗﻘﻠﺑﻪ اﻟﺣﻳوي اﻟداﻳﮫﺎﻳدروارﺗﻣﺳﻧﻳن   TRAﻟﻣﻌﺮﻓﺔ ﺣدود ﺣﺮﻛﻳﺔ وﺗواﻓﺮ اﻻرﺗوﺳﻧﻳت 
 ت اﻟﻧوع ﻣن اﻟدراﺳﺎ ﻟﺑﺮاﻣﺞ ﻣﺻﻣﻣﺔ ﻟﮫذااﺳطﺔ ﻣﻌﺎدﻻت ﻗﻳﺎﺳﻳﺔﺑو  اﺟﺮﻳت اﻟﻌﻣﻠﻳﺎت اﻟﺣﺳﺎﺑﻳﺔ. اﻟﺑﻼزﻣﺎ
 اﻟﻛﻠﻲ اﻟﻠذﻳن اﺟﺮي ﻋﻠﻳﮫم اﻟﻛﺷف اﻟطﺑﻲ ﺑواﺳطﺔ ﻓﺮﻳق اﻟدراﺳﺔ ﻻﺧﺗﻳﺎر  اﻟﻣﺮﺿﻰﻋدد: ﻧﺗﺎﺋﺞ وﻣﻧﺎﻗﺷﺗﮫﺎاﻟ
 ﻣﺮﻳض ﻣﺻﺎﺑﻳن 8151وﺟد أن ھﻧﺎﻟك .  ﻣﺮﻳض2684اﻟﻣﺮﺿﻲ اﻟﻣﺷﺎرﻛﻳن ﻓﻲ اﻟدراﺳﺔ ﻓﻲ اﻟﻣﺮاﻛﺰ اﻟﺳﺗﺔ ھو 
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راﺳﺔ ﺗم اﺧﺗﻳﺎر اﻟﻣﺮﺿﻰ ﺑﻌد اﺳﺗﺑﻌﺎد اﻟﻣﺮﺿﻰ اﻟذﻳن ﻻ ﺗﻧطﺑق ﻋﻠﻳﮫم ﻣﻌﺎﻳﻳﺮ اﻟد%( 13)ﺑﺎﻟﻣﻼرﻳﺎ اﻟﻣﻧﺟﻠﻳﺔ 
 :  وادﺧﻠت ﻟﻠﺗﺣﻠﻳلﺟﻣﻌت اﻟﻣﻌﻠوﻣﺎت. ﻣﺮﻳض ﻻﺋﻘﻳن ﻟﻠدﺧول ﻓﻲ اﻟدراﺳﺔ904اﻟﻣﺷﺎرﻛﻳن ﺑﻣﻌﺎﻳﻳﺮ ﻣﻌﻳﻧﺔ وﺟد ان 
أﺛﺑﺗت ھذه اﻟدراﺳﺔ ﻣدي ﻧﺟﺎﻋﺔ اﻟﻣداواة اﻟﻣﺷﺗﺮﻛﺔ ﻣﻊ ﻣﺷﺗﻘﺎت اﻷرﺗﻣﻳﺳﻧﻳن ﺣﻳث ﺑﻠﻐت ﻧﺳﺑﺔ اﻟﺷﻔﺎء اﻟﺗﺎم ﻟﻠﻣﺮﺿﻰ 
ﻣﺗﺮاﻓﻘﺔ ﻣﻊ ﻣﻊ اﻟﺧﻠو اﻟﺳﺮﻳﻊ ﻟﻠطﻔﻳل ،  اﻻول واﻟﺛﺎﻧﻲ ﻋﻠﻲ اﻟﺗواﻟﻲ ﻟﺧطﻲ اﻟﻌﻼج% 5.89و % 3.99اﻟﻣﺷﺎرﻛﻳن 
 ر اﻟﻣﻌدي واﻧﺣﺳﺎر اﻟﺣﻣﻲ ﻛﻣؤﺷﺮات ﻟﻠﺷﻔﺎء اﻟﺗﺎم ﻣﻊ ﻋدم ظﮫور اﻟطو ﺳﺎﻋﺔ27ﻓﻲ اﻟدم اﻟطﺮﻓﻲ ﻓﻲ اول 
اﺗﺿﺢ ﻣن اﻟدراﺳﺔ ان ھذه اﻻدوﻳﺔ اﻟﻣﺮﻛﺑﺔ ﻣن ﻣﺷﺗﻘﺎت اﻻرﺗﻳﻣﻳﺳﻧﻳن ﻟﮫﺎ ﺧﺎﺻﻳﺔ اﻟﻘﺿﺎء ﻋﻠﻲ اﻟطور اﻟﻣﻌدي ﻓﻲ 
 . ﻟﻣﺮﻳض، ھذه اﻟﺧﺎﺻﻳﺔ ﻟم ﺗﻛن ﻣﺗوﻓﺮه ﻓﻲ ادوﻳﺔ اﻟﻣﻼرﻳﺎ اﺗﻲ ﺳﺑﻘﺗﮫﺎ ﻣﻣﺎ ﺳﻳﺳﮫم ﻓﻲ ﺗﻘﻠﻳل اﻧﺗﺷﺎر اﻟﻣﺮضدم ا
 ﻣﺮﺿﻲ 5ﺑﺎﻟﻧﺳﺑﺔ ﻟﻠﻣﺄﻣوﻧﻳﺔ واﻟﻘﺑول ﻟدي اﻟﻣﺮﺿﻲ ﻛﺑﺎرا وﺻﻐﺎرا ﻟوﺣظ ظﮫور اﻋﺮاض ﺟﺎﻧﺑﻳﺔ ﺧﻔﻳﻔﺔ ﻓﻲ ﻋدد 
ﻟوﻣﻳﻔﺎﻧﺗﺮﻳن ﻟوﺣظت \ اﻻرﺗﻳﻣﺛﺮﺑﺮﻳﻣﺛﺎﻣﻳن، اﻣﺎ ﻓﻲ ﻣﺟﻣوﻋﺔ\ﺳﻠﻔﺎدوﻛﺳﻳت+ ﻟﻣﺟﻣوﻋﺔ اﻻرﺗوﺳﻧﻳت % 9.1ﺑﻧﺳﺑﺔ 
ﻟﻌﻠﻪ ﻣن اﻻھﻣﻳﺔﺑﻣﻛﺎن ان ﻧﺷﻳﺮ اﻟﻲ ان ھذه اﻟدراﺳﺔ ﺗﻌد اﻻﻛﺑﺮﻣﻘﺎرﻧﺔ ﻣﻊ ﻣﺛﻳﻼﺗﮫﺎ .% 3.4 ﻣﺮﺿﻲ ﺑﻧﺳﺑﺔ 6ﻓﻲ ﻋدد 
ﻧﺗﺎﺋﺞ  ﻣﻊ  اﺗﻔﺎق ﺗﺎمراﺳﺔدﺗﺗﻔق ﻧﺗﺎﺋﺞ ھذه اﻟ. ﻣﺮﻳض ﻣن ﻣﺧﺗﻠف اﻟوﻻﻳﺎت904ﻣﺣﻠﻳﺎ وﻋﺎﻟﻣﻳﺎ اذ ﺷﺎرك ﻓﻳﮫﺎ 
 وﻋﺎﻟﻣﻳﺎ،أ  اﻓﺮﻳﻘﻳﺎﺳواء ﻓﻲاﻟﺗﻲ ﺳﺑﻘﺗﮫﺎ اﻟدراﺳﺎت 
ﻧﺗﺎﺋﺞ ھذا اﻟﺑﺣث ﺗؤﻛد ان ﺣدود ﺣﺮﻛﻳﺔ وﺗواﻓﺮ اﻻرﺗوﺳﻧﻳت ﻓﻳﻣﺎ ﻳﺧﺗص ﺑﺎﻻﺷﻛﺎل واﻟﺟداول 
 ﻣﻊ ﺗﻠك اﻟﻧﻣوذﺣﻳﺔ اﻟﺗﻲ ﺗﺻدر  واﻻرﻗﺎم اﻟﺣﺳﺎﺑﻳﺔ اﻟﻧﺎﺗﺟﺔ ﻋن اﻟﻣﻌﺎدﻻت اﻟﺧﺎﺻﺔ ﺑﮫﺎ ﺗﺗﻔق ﻛﻠﻳﺔ
 وﻳﺻل اﻟدم ﻓﻲ ﻧﺎوﻟﻪ ﺑﺎﻟﻔموﺟد ان اﻻرﺗوﺳﻧﻳت ﺣﺑوب ﻳﻣﺗص ﺑﺳﺮﻋﻪ ﺑﻌد ﺗ، ﻋن اﻟدراﺳﺎت اﻟﻣﺛﻳﻠﺔ اﻟﺳﺎﺑﻘﺔ
ان ﻣؤﺷﺮات اﻟﻌﺎﻣﺔ ﻟﺗﻘﻳﻳم . واﻟذي ﻟﻪ ﺧﺎﺻﻳﺔ ﻋﻼج اﻟﻣﻼرﻳﺎ   AHDﺗﺣول اﻟﻲ ﻣﺳﺗﻘﻠﺑﻪ ال ﺧﻼل ﻧﺻف ﺳﺎﻋﻪ وﻳ
 ﻣﻧﻔﺮدا او TRA ﻟﻼرﺗوﺳﻧﻳت  xam T– xam C ووﺟد ان xam T-xam C-CUA اﻟﻔﺮق ﻓﻲ اﻻﻣﺗﺻﺎص ھﻲ 
( )100.0=Pﻣﻧﻔﺮدا وﻣﺷﺗﺮﻛﺎ ﺳواء ﻛﺎن ﻲ اﻟﺣﺎﻟﺗﻳن ﻓAHD ﻣﺷﺗﺮﻛﺎ اﻗل ﺑﻛﺛﻳﺮ ﻣﻘﺎرﻧﺔ  ﺑﺎﻟداﻳﮫﺎدروارﺗﻣﺳﻧﻳن 
 ﻟﻠﻣﺳﺗﻘﻠب اﺛﺑﺗت ان ﺗواﺟده اﻟﺣﻳوي اﻛﺑﺮ ﻓﻲ ﺣﺎﻟﺔ   اﻟﻣﺗوﺳطCUAﻓوﺟد ان ﻣﺗوﺳط اﻟﺗﻌﺮض ﻟﻠﻌﻘﺎر  ﺑﺣﺳﺎب 
 .  ﺑﺎرﻳﻣﺛﺎﻣﻳن ﻣﻘﺎرﻧﺔ ﺑﺗواﺟده اﻟﺣﻳوي ﺣﻳﻧﺎ ﻳﻌطﻲ ﻣﻧﻔﺮدا\ﻣﺷﺗﺮﻛﺎ ﻣﻊ اﻟﺳﻠﻔﺎدوﻛﺳﻳناﻋطﺎﺋﻪ 
ﻌﻘﺎر ﻟﻳﺻل اﻟﻲ ﻧﺻف ﺗواﺟده اﻟﺣﻳوي اﻗل ﻓﻲ ﺣﺎﻟﺔ اﻟﻌﻼج ﻣﻧﻔﺮدا وھو ان اﻟوﻗت اﻟذي ﻳﺣﺗﺎﺟﻪ ﻣﺳﺗﻘﻠب اﻟاﺗﺿﺢ 
  200.0=P ﺳﺎﻋﺔ  5.1_  +57.2ﻋطﺎﺋﻪ ﻓﻲ ﺣﺎﻟﺔ ﻣﺷﺗﺮﻛﺔ ﻣﻊ اﻟﺳﻠﻔﺎدوﻛﺳﻳن وھوﻣﻘﺎرﻧﺔ ﻻ  ﺳﺎﻋﺔ 7.0_ +6.1
ان ﻧﺳﺎن ، ﻣن ھذه اﻟدراﺳﺔ اﺗﺿﺢ ﻟﻳﻧﺗﮫﻲ ﻣﻔﻌوﻟﮫﺎ ﻣن ﺟﺳم اﻻﺣﻳﺎﺗﮫﺎ  اﻧﺻﺎف اوﻗﺎت 5ﻣﻌظم اﻻدوﻳﺔ ﺗﺣﺗﺎج اﻟﻲ 
 58.31 ھو ﻣﺷﺗﺮﻛﺎ ﻣﻊ اﻟﺳﻠﻔﺎدوﻛﺳﻳن ﻟﻳﻧﺗﮫﻲ ﻣﻔﻌوﻟﻪ ﻣن ﺟﺳم اﻟﻣﺗطوﻋﻳن   ﺣﺗﺎﺟﻪ ﻣﺳﺗﻘﻠب اﻟﻌﻘﺎرﻳﻗت اﻟذي اﻟو
ﺳﺎﻋﺔ، دﻋم ھذا اﻟﺟﺰء ﻣن اﻟدراﺳﺔ ﻧﺗﺎﺋﺞ اﻟﺟﺰء اﻻول ﻣن ﺣﻳث اﻟﻔﺎﻋﻠﻳﺔ ﻟﮫذا اﻟﻌﻼج ﺣﻳث ﺑﻠﻐت  (5.7_ +)
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1.1.1     Global Malaria Burden 
In 2004, 107 countries and territories have reported areas at risk of malaria. 
Although this number is considerably less than 1950s, with 140 endemic 
countries, 3.2 billion people are still at risk. Around 60% of the cases of 
clinical malaria and over 80% of the deaths occur in Africa, south of the 
Sahara. More than 1 million African who die from malaria each year, most are 
children under 5 years of age. In addition to acute disease episodes and deaths 
in African countries, malaria also contributes significantly to anaemia in 
children and pregnant women, adverse birth outcomes such as spontaneous 
abortion, stillbirth, premature delivery, low birth weight and overall child 
mortality. The disease is responsible for an estimated average annual reduction 
of 1.3% in economic growth for those countries with the highest burden 
(WHO 2005). 
The wide variation seen in the burden of malaria between different regions of 
the world is driven by several factors. First factor, there is great variation in 
parasite-vector-human transmission dynamics that favour or limit the 
transmission of malaria infection and the associated risk of disease and death. 
P. falciparum the most lethal species that cause severe disease and deaths 
attributed to malaria. It is prevalent in Africa south to the Sahara, certain areas 
of South East Asia and Western Pacific. The next species, P. vivax, is rarely 
fatal and commonly found in most Asia, and in parts of Americas, Europe and 
North Africa. There are over 40 species of anopheline mosquitoes that 
transmit human malaria, differ in their transmission potential. The most 
competent and efficient malaria vector is Anopheles gambiae. It occurs 
exclusively in African region and is also one of the most difficult to control. 
Climatic conditions determine the presence or absence of anopheline vectors. 
Tropical areas of the world have the best combination of adequate rainfall, 
temperature and humidity allowing for breeding and survival of anopheline 
(WHO 2005). 
The second factor is the differences in levels of socioeconomic development. 
Such as general poverty, quality of housing and access to health care and 
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health education, as well as the existence of active malaria control 
programmes providing access to malaria prevention and treatment measures. 
The poorest nations generally have the least resources for adequate control 
efforts. In many poor countries, exposure to malaria is enhanced by migrations 
enforced by poverty and/or conflict (WHO 2005). 
From available data, it is not yet possible to determine with sufficient 
confidence, whether the global burden of malaria has changed substantially, to 
better or worse. Since 2000, the first year of Roll Back Malaria (RBM) 
implementation began in many countries. In some areas, fluctuations from 
year to year potentially, confound evaluation of border trend. Therefore, 
conclusions typically require an analysis of epidemiological data over multiple 
years.  Nevertheless, for some countries and areas throughout the world there 
is evidence that successful control has had an impact on malaria disease 
burden (WHO 2005).      
1.1.2     Malaria Burden in African Region 
Africa remains the region that has the greatest burden of malaria cases and 
deaths in the world. In 2000, malaria was the principal cause of around 18%- 
803000- of deaths of children under 5 years of age. During the period of 1980s 
and the early 1990s, malaria mortality in rural areas increased considerably, 
probably as a result of increasing resistance to chloroquine. The disease is 
consequently causes malaria – related maternal anemia in pregnancy, low birth 
weight and premature delivery these estimated to cause 75 000-200 000 infant 
deaths per year. Overall, epidemics result in an estimated up to 12 million 
malaria episodes and 310 000 deaths per year in Africa (WHO 2005). 
1.1.3    Burden on Health System 
In African countries, south of Saharan, the case rates reported through national 
Health Information System (HIS), represent only a minor fraction of the actual 
burden of malaria. Access to clinical care is poor, especially in the most rural 
areas where malaria transmission is most intense. Furthermore, reporting from 
facilities to districts and from district to health ministries is incomplete and 
completeness and timeliness vary between and within countries. Finally, in 
clinics most cases of malaria are diagnosed on the basis of clinical symptoms 
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rather than on laboratory confirmation, which is rarely available at first line 
health facilities. Given the incompleteness of case and death reporting from 
health facilities, the proportion of reported cases and deaths caused by malaria 
relative to the total number of cases and deaths from all causes are more 
informative indicators than absolute number of reported malaria cases and 
deaths. Across endemic countries, generally, malaria is responsible for an 
average of 25% to 35% of all outpatients, between 20% and 45% of all 
hospital admissions. With high case fatality rates due to late presentation, 
inadequate clinical management and unavailability or stock-outs of effective 
drugs. The proportional malaria burden is somewhat lower in the southern 
Africa subregion than in the Central, East and West Africa sub regions (Fig. 1) 
(WHO 2005)  
1.1.4     Control Efforts and Targets- Abuja 
At the African Summit on Roll Back Malaria (RBM) in Abuja- Nigeria, in 
2000, African heads of States committed themselves to halving the burden of 
malaria by 2010 by achieving 60% coverage of all at- risk populations with 
suitable curative and preventive measures by 2005. However few countries are 
likely to reach the 60% target for coverage of access to prompt effective 
treatment, Insecticide Treated Nets ( ITNs) and Intermittent Preventive 
Treatment (IPT) for protection of pregnant women by using 2 full doses of 
sulfadoxine/pyrimethamine (SP) during the second trimester (first dose – 3 
tabs SP and a second one after one month later). Until very recently, the 
control efforts remained too fragmented and major international investment 
materialized too late. Around US$ 2 billion per year –of which US$ 1 billion 
is needed to effectively combat malaria in Africa. Only about one quarter of 
this amount is currently available. However, financial support for control 
programmes to prevent and treat malaria has increased rapidly over the past 
few years. Complemented by increased capacity development at all health 
system levels, through technical support to national control programmes and 
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1.1.5     Malaria Burden in Sudan 
Malaria is a major public health problem in Sudan. It leads to 7.5 million cases 
and 35000 deaths/ year (2000 estimates). Plasmodium falciparum is 
incriminated in more than 90% of cases. P. vivax, P.Ovale and P.malariae are 
responsible for the rest. Anopheles arabiensis is the main vector together with 
A.gambiae and A. funestus.  Endemicity is varying between in the country. 
The whole population is at risk. Five main epidemiological strata can be 
identified:  
• High perennial transmission in the south  
• High transmission due to irrigation in large agriculture schemes in the 
north. 
• Seasonal transmission followed rain fall season 
• Urban malaria in large towns (man-made) malaria due to broken water 
pipelines and air coolers 
• Desert-fringe malaria due to the Nile floods in the north  
The situation has been deteriorated in Sudan, due to appearance of parasite 
resistance to the previous first line chloroquine, and vector resistance to 
insecticides in use. Other factors include substantial extension in agriculture 
schemes, limited financial resources allocated for the programme, inadequate 
coordination, poor community participation and shortage of experienced staff. 
These are coupled with poor health coverage and weak health information 
system. Sudan, endorsed the global RBM strategic plan, accordingly a 
national strategic plan was developed in 2002 and it contains 4 main 
components:  
1. Early diagnosis and prompt treatment 
2. Vector Biology and Control 
3. Malaria Early Warning system and containment of epidemics 
4. Strengthening capacity building (NMCP 2004).  
Symptomatic malaria accounts for 20-40% of outpatient clinic visits and 
approximately 30% of hospital admissions. The infrastructure of the 
programme continues to be strengthened. The federal malaria control office 
and malaria control unites in priority states in Gazira, Khartoum and White 
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Nile states were established with full operations by the end of 2001(WHO 
2005). 
Malaria is not a difficult disease to be managed if early diagnosed and 
promptly treated. However, delay in treatment will lead to grave outcome. 
Early diagnosis and prompt treatment is the cornerstone in the global strategy 
of malaria control and should be a fundamental right of all population at risk. 
As for the treatment, the situation is alarming. Irrational prescription of 
antimalarial drugs with different dosages and regimen used by the medical 
personnel with over prescription of chloroquine injections is noticeably 
common practice (NMCP 2004). In addition to, over-the-counter dispensing of 
all antimalarial drugs (Increase risk for self medication with antimalarials 
were, however, found to be significantly associated with male gender and 
younger age group of < 40 years and middle income earners and less educated 
respondents. The main reason that was indicated for the self-medication was 
financial constraints. The main source of medicines was the private 
pharmacies, which were regarded as a cheaper alternative to other primary 
healthcare sources.  The prevalence of self-medication with 
antibiotics/antimalarials in Khartoum State, Sudan is alarmingly high. Self 
medication behaviour varies significantly with a number of socio-economic 
characteristics.  (Awad AI et al 2007).  
Moreover, the widely accepted misbelieve that quinine causes renal failure 
and abortion had led to grave consequences when patients with severe malaria 
refuse to use such life saving drug, in previous local study conducted to 
determine the effect of quinine on renal function in severe  malaria cases, 
obtained results by researcher indicated that quinine is a safe, strong 
schizontocidal drug when used in the treatment of p. falciparum severe 
infections and does not cause renal failure, as believed by the majority of the 
community (SB Elamin 2001). For all those reasons, plans were formulated to 
update the national antimalarial drug policy. Treatment protocol for 
management of malaria is of a priority to ensure rational use of antimalarial 
drugs and meet the following criteria: 
• Patient suffering from malaria receive a treatment which cures the disease 
and prevents complications 
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• non-toxic treatment regimens  
• Affordable drugs cost-wise for the patients and the government 
• Minimize unnecessary drug pressure which could lead to development of 
drug resistance 
• Acceptable by the patients, providers and health workers (National Malaria 
treatment Protocol 2004). 
1.1.6     Global Antimalarial Drug Resistance 
Falciparum malaria remains a major occupational illness that accounts for 
several deaths per year and numerous lost working days among the expatriate 
population, working or living in high risk malarious areas. (Anna et al 2008) 
Drug resistant malaria is mostly due to Plasmodium falciparum, the highly 
prevalent species in tropical Africa, Amazon, and Southeast Asia. P. 
falciparum is responsible for severe involvement of fever or anemia causing 
more than a million deaths per year. Rationale for treatment is becoming weak 
as multiple drug resistance against well-tolerated drugs develops. P. 
falciparum drug resistant malaria originates from chromosomal mutations. 
Analyses using molecular, genetic and biochemical approaches showed that: 
1) impaired uptake of chloroquine by the parasite vacuole is a common 
characteristic of resistant strains, this phenotype correlates with pfmdr1 and 
pfcrt gene mutations; 2) one S108N to four (N51I, C59R, I164L) point 
mutations of dihydrofolate reductase, the enzyme target of antifolinics 
(pyrimethamine and proguanil), give moderate to high level of resistance to 
these drugs; 3) resistance to sulfonamides and sulfones involves mutations of 
dihydropteroate synthase (A437G, K540E), their enzyme target, impairing 
their capacity to potentiate antifolinic drugs; 4) resistance to atovaquone plus 
proguanil involves one single mutation on atovaquone target, cytochrome b 
(Y268S, C or N); 5) resistance to mefloquine is thought to be linked to the 
over expression of pfmdr1, a pump expelling toxic waste from eukaryotic 
cells. P. falciparum resistance levels may differ according to places and time, 
depending on malaria transmission and drug pressure. Coupling in vivo to in 
vitro tests and using molecular tests is essential for the surveillance of 
replacement drugs. Low cost biochemical tools are urgently needed for a 
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prospective monitoring of resistance antimalarial drugs such as the artemisinin 
derivatives to improve efficacy and to delay the development of parasite 
resistance is essential. (Le Bras J et al 2006) 
Molecular epidemiological investigations have uncovered the patterns of 
emergence and global spread of Plasmodium falciparum resistance to 
chloroquine and sulfadoxine-pyrimethamine. Malaria parasites highly resistant 
to chloroquine and pyrimethamine spread from Asian origins to Africa, at 
great cost to human health and life. If artemisinin-resistant falciparum malaria 
follows the same pattern, renewed efforts to eliminate and eradicate malaria 
will be gravely threatened. This paper, adapted from a talk given in honour of 
Professor Malcolm Molyneux in Liverpool in September 2008, reviews the 
rise and fall of clinically important forms of drug-resistant falciparum malaria 
and considers how lessons learned from studying the evolution of drug-
resistant malaria can be applied to efforts to prevent and deter resistance 
(Plowe CV. 2008) 
Drug resistance in malaria parasites is a serious public health burden, and 
resistance to most of the antimalarial drugs currently in use has been reported. 
A better understanding of the molecular mechanisms of drug resistance is 
urgently needed to slow or circumvent the spread of resistance, to allow local 
treatments to be deployed more effectively to prolong the life span of the 
current drugs, and to develop new drugs. Although mutations in genes 
determining resistance to drugs such as chloroquine and the antifolates have 
been identified, we still do not have a full understanding of the resistance 
mechanisms, and genes that contribute to resistance to many other drugs 
remain to be discovered. Genetic mapping is a powerful tool for the 
identification of mutations conferring drug resistance in malaria parasites 
because most drug-resistant phenotypes were selected within the past 60 years. 
High-throughput methods for genotyping large numbers of single nucleotide 
polymorphisms (SNPs) and micro satellites (MSs) are now available or are 
being developed, and genome-wide association studies for malaria traits will 
soon become a reality. Here we discuss strategies and issues related to 
mapping genes contributing to drug resistance in the human malaria parasite 
Plasmodium falciparum (Hayton K, Su XZ 2008). 
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Emphasis on retaining chloroquine as the first-line therapy for Plasmodium 
falciparum infections in most of sub-Saharan Africa for as long as it remains 
effective has resulted in widespread reliance on chloroquine in areas where it 
can have little effect on P. falciparum parasitemia. To address this issue, 
clinical, parasitological, and hematological responses to chloroquine or 
pyrimethamine/sulfadoxine treatment were assessed by researchers among 
very young children in Malawi and Kenya. Children treated with 
pyrimethamine/sulfadoxine maintained clinical improvement and had greater 
increases in their hemoglobin concentration during the follow-up period than 
did children treated with chloroquine (Bloland B et al 1993). 
Researchers compared atovaquone-proguanil with other antimalarial drugs 
(alone or in combination) for treating children and adults with uncomplicated 
Plasmodium falciparum malaria. By searched the Cochrane Infectious 
Diseases Group Specialized Register (June 2005), CENTRAL (The Cochrane 
Library Issue 2, 2005), MEDLINE (1966 to June 2005), EMBASE (1980 to 
June 2005), LILACS (1982 to June 2005), reference lists, conference 
abstracts, pharmaceutical manufacturers and researchers. Ten trials, with a 
total of 2345 participants, met the inclusion criteria. Atovaquone-proguanil 
had fewer treatment failures by day 28 than chloroquine, amodiaquine, and 
mefloquine. There were insufficient data to draw a conclusion from 
comparisons with sulfadoxine-pyrimethamine, artesunate plus mefloquine, 
quinine plus tetracycline and dihydroartemisinin-piperaquine-trimethoprim-
primaquine. Adverse events were mainly common symptoms of malaria and 
did not differ in frequency between groups There were not enough data to 
assess safety, but a number of adverse events were identified with all drugs. 
Large trials comparing atovaquone-proguanil with other new combination 
therapies are needed (Osei-Akoto A et al 2007). 
1.1.7      Monitoring Chloroquine Resistance In Africa  
The development of chloroquine as an antimalarial drug and the subsequent 
evolution of drug-resistant Plasmodium strains had major impacts on global 
public health in the 20th century. In P. falciparum, the cause of the most lethal 
human malaria, chloroquine resistance is linked to multiple mutations in 
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PfCRT, a protein that likely functions as a transporter in the parasite's 
digestive vacuole membrane (Wellems TE, Plowe CV 2001). 
Up to 1970 chloroquine (CQ) resistant P.falciparum had not been confirmed in 
African region. The drug was cheap, effective and tolerable. It is widely 
believed that the first confirmed cases of CQ- resistant falciparum malaria 
were those of the American tourists returning from Kenya in 1979. On 
reporting the cases, Kean made a very dramatic statement," All malariologists 
have dreaded the day when chloroquine –resistance malaria from Africa would 
be described. Alas, evidence presented in two case reports would indicate that 
the day is here"(Abdel-Hameed 2003 a).  
Most countries in resource-poor, malaria-endemic areas lack current and 
comprehensive information on antimalarial drug efficacy, resulting in sub-
optimal antimalarial treatment policies. Many African countries continue to 
use chloroquine despite very high rates of resistance, and others have changed 
policies based on limited data, with mixed success. Methods for measuring 
antimalarial drug efficacy and resistance include in vivo studies of clinical 
efficacy and parasitological resistance, in vitro susceptibility assays and 
molecular markers for resistance to some drugs. These methods have the 
potential to be used in an integrated fashion to provide timely information that 
is useful to policy makers, and the combined use of in vivo and molecular 
surveys could greatly extend the coverage of resistance monitoring (Plowe CV 
2003).   
Over 12 years, from 1984 to 1995, a prospective study was conducted of 
overall and malaria specific mortality among three rural populations in the 
Sahel, savanna and forest areas of Senegal. The emergence of chloroquine 
resistance has been associated with a dramatic increase in malaria mortality in 
each of the studied populations. After the emergence of chloroquine 
resistance, the risk of malaria death among children 0-9 years old in the three 
populations was multiplied by 2.1, 2.5 and 5.5, respectively.  
It was the first study to document malaria mortality at the community level in 
Africa before and after the emergence of chloroquine resistance. Findings 
suggest that the spread of chloroquine resistance has had a dramatic impact on 
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the level of malaria mortality in most epidemiological contexts in tropical 
Africa (Trape JE et al 1998).  
Between 1978 and 1988 Plasmodium falciparum resistance to chloroquine has 
been reported in all tropical African countries. Despite the intensification of 
resistance during the last 2 decades, chloroquine remains in 2000 the first-line 
treatment for malaria in most of these countries. Hospital studies in various 
African countries have documented a 2- or 3-fold increase in malaria deaths 
and admissions for severe malaria, an increase temporally related to the 
emergence of chloroquine resistance. Data from sentinel demographic 
surveillance systems in Senegal indicated that mortality attributable to malaria 
in children increased by as much as 6-fold among populations where low 
levels of malaria mortality had been achieved because of efficient health 
services before the emergence of chloroquine resistance. Increasing incidence 
of severe malarial anemia also contributed to human immunodeficiency virus 
dissemination. There is an urgent need to change treatment policies in Africa 
(Trape JE 2001).  
Combination therapy should be available for home treatment of young 
children. The potential toxicity of most antimalarials will require special 
surveillance programs. The main contribution to malaria control using 
methods to reduce the entomological inoculation rate is expected in areas with 
low or unstable transmission. Classic vector-control methods could potentially 
eliminate malaria in most urban areas and such programs deserve high priority 
(Trape JE et al 2002).  
Causes of death among hospitalized children less than age 5 years in western 
Kenya, where identified using standardized clinical examinations and 
laboratory evaluations. Follow-up examinations were then conducted to 
determine the child's clinical status post hospitalization. Children admitted to 
Hospital during March-September 1991 were severely anemic. Of them 265 
children died; 32% of the deaths were associated with malaria. 121 of the 
deaths occurred in-hospital and 144 at home within 8 weeks after admission. 
The treatment of malaria with chloroquine was associated with a 33% case 
fatality rate compared with 11% for children treated with more effective 
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regimens of pyrimethamine/sulfa, quinine, or trimethoprim/sulfamethoxazole 
for 5 days. The risk of dying was associated with younger age and severe 
anemia, and was decreased by treatment with an effective antimalarial drug 
(Zucker et al 1996).   
The prevalence of chloroquine-resistant Plasmodium falciparum malaria has 
been increasing in sub-Saharan Africa and parts of South America over the 
last 2 decades, and has been associated with increased anaemia-associated 
morbidity and higher mortality rates. Prospectively collected clinical and 
parasitological data from a multicentre study of 788 children aged 6-59 
months with uncomplicated P. falciparum malaria were analyzed in order to 
identify risk factors for chloroquine treatment failure and to assess its impact 
on anaemia after therapy. The proportion of chloroquine treatment failures 
was higher in the central-eastern African countries (Tanzania, 53%; Uganda, 
80%; Zambia, 57%) and Ecuador (54%) than in Ghana (36%). Using logistic 
regression, predictors of early treatment failure included younger age, higher 
baseline temperature, and greater levels of parasitaemia. (Hamer et al 2003). 
Between 1994 and 1999, in Younde, Cameroon, the evolution of chloroquine 
resistance was studied in adults (aged > 15 years) and children aged 5-15 years 
by using tests of therapeutic efficacy and in vitro assays. The results obtained 
by the researchers of the semi-microtest and the microtest were expressed as 
the 50% inhibitory concentration (IC50), and the threshold level of resistance 
was set at IC50 > 100 nM. The overall percentages of clinical and 
parasitological failures were 39.7% and 48.8%, respectively. Similarly, the 
percentage of isolates that were resistant in vitro was 52.5%. During the study, 
IC50 geometric mean varied between 84, 6 nM and 149, 8 nM. The results of 
the in vitro assays agreed with those of tests of therapeutic efficacy (kappa 
coefficient = 0.69). The patients' chloroquine plasma levels were measured on 
day 0, day 3, day 7, and day 14. Drug measurement showed wide inter-
individual variations and higher plasma levels in adults than in children. Some 
cases of therapeutic failure were associated with inadequate plasma levels of 
chloroquine. (Ringwald P et al 2000).   
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In Kampala, Uganda the researchers identified resistance predictors. Among 
the 258 patients (88% follow-up), 47% were clinical failures and 70% had 
parasitological resistance. Investigators found that, an age less than five and a 
presenting temperature over 38.0 degrees were independent predictors of 
treatment failure. In addition, patients who last took chloroquine 3 to 14 days 
prior to study entry were significantly more likely to be treatment failures 
compared to patients with very recent (less than 3 days) or no recent 
chloroquine use (Dorsey G et al 2000).  
1.1.8     Monitoring Chloroquine Resistance In Sudan 
Chloroquine (CQ) -resistant falciparum malaria had already been suspected 
and confirmed in the Sudan,, in a small number of indigenous cases located in 
Sennar in 1978 (Kouzentsov RL et al 1980). A definite confirmation of the 
extent of chloroquine resistance in Sudan was first demonstrated by an in vivo 
study carried out in 1982 in some villages in Khartoum state (Altawil N, 
Akood N 1983).  
In 1980s eastern Sudan faced a number of disasters, including Nile floods, war 
and influx of refugees from Ethiopia. Under these conditions malaria 
outbreaks were frequent, with reports of substantial numbers of cases not 
responded to chloroquine. A study combining both in vivo and in vitro 
assessment conducted in 1986, in Gadarif, eastern Sudan indicated 43% of P. 
falciparum infections investigated were resistant to chloroquine. Generally CQ 
was assessed in 25 tests of which 22 indicated high prevalence of chloroquine 
resistance (Abdel-Hameed 2003 b).  
A protocol for assessment of the therapeutic efficacy of chloroquine against 
Plasmodium falciparum malaria was evaluated in Sudan. An in vivo test was 
implemented in five sentinel posts in areas of unstable malaria during the 
transmission season. A standard dose of oral chloroquine was administered to 
a random sample of patients with uncomplicated falciparum malaria attending 
primary health care units and they were followed-up for clinical and 
parasitological response for 14 days. Designations of "early treatment failure", 
"late treatment failure" and "adequate response" were based on clinical and 
parasitological criteria. Data analysis for prevalence of resistance was done for 
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each individual sentinel post, using two-stage Lot Quality Assurance 
Sampling. At 95% confidence level and 80% power, the prevalence of 
chloroquine resistance was found to be >25% in all five posts (Abdel-Hameed 
et al 2001).   
Chloroquine and sulfadoxine/pyrimethamine were evaluated and compared 
with Amodiaquine, in an MSF-Holland-run clinic in eastern Upper Nile state, 
south Sudan, 100% of patients treated with sulfadoxine/pyrimethamine and 
94% for amodiaquine. In children treatment failure aged < 5 years, the success 
rate was lower: 83% for chloroquine, 93% for amodiaquine. In adult no 
treatment failure were found, but children aged 5-15 years showed 
intermediate level. In addition, the investigators determined the initial 
genotypes of dhfr and dhps of 44 isolates from sulfadoxine/pyrimethamine -
treated group and > 80% were found to be wild type for dhfr and 100% for 
dhps. 2% had a single mutation and 16% had double mutations of dhfr. These 
data are in full agreement with the clinical effectiveness of SP (Ingrid V. F et 
al 2003).             
Medecins Sans Frontieres (MSF) conducted a randomized, an open labeled 
efficacy study in Kajo Kaji, in southern Sudan. The efficacy of chloroquine 
(CQ), sulphadoxine/pyrimethamine (SP), and amodiaquine (AQ) were 
measured. The overall parasitological failure rates at day 28 were 93% for CQ, 
69.9% for SP and 25.2% for AQ. Those results provide important missing data 
on antimalarial drug efficacy in southern area of Sudan and indicated none of 
the tested drugs could be used as monotherapy (Stivanello E et al 2004).  
In a study conducted in New Halfa, eastern Sudan, researchers evaluated 
efficacy of chloroquine, sulphadoxine/pyrimethamine SP and quinine. No 
treatment failures were observed among the patients given SP. Only 23.1% of 
the patients given chloroquine showed adequate clinical response, however, 
the rest showing early treatment failure (15.4%) or, more frequently late 
treatment failure (61.5%). 90.6% of the patients treated with quinine had 
adequate treatment response. These results and those of earlier investigators 
indicated that the problem of chloroquine resistance is getting worse in eastern 
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Sudan and the use of chloroquine as a first line drug for the treatment of 
uncomplicated malaria is now compromised" (Adam I et al 2004)          
Malaria Control Programme in Sudan developed a country plan of action for 
continuous monitoring antimalarial drugs resistance in permanent sentinel 
sites according to malaria endemecity. High failure rate of chloroquine (CQ) 
was found, in the north (43.4%), more badly, in the south was (80.2 %). 
While, failure rate sulphadoxine/Pyrimethamine (SP) alone, in the north was 
(4.4%). The combination of chloroquine and sulfadoxine/pyrimethamine (CQ 
+SP), showed variable failure rates in 2 posts in the north, of 14.5% and 5.9% 
respectively (Elamin et al 2007).  
Based on, the upper mentioned local studies and many others, not mentioned here; 
new antimalarial drug policy was introduced recently in the country in 2004. The 
Sudanese health authorities adopted artemesinin- based combination therapy (ACT) 
strategy to overcome resistance of the currently used monotherapy. The new protocol 
was formulated; it recommends artesunate + sulfadoxine/pyrimethamine and 
artemether lumefantrine as first and second lines respectively for the treatment of 
uncomplicated falciparum malaria (NMCP 2004 b).  
1.1.9    Artemisinin –based Combination Therapy (ACT) 
Malaria, a disease transmitted by the female Anopheles mosquito, has had 
devastating effects on human populations for more than 4000 years. Treatment 
of it with single drugs, such as chloroquine, sulfadoxine/pyrimethamine or 
mefloquine, has led to the emergence of resistant Plasmodium falciparum 
parasites that lead to the most severe form of the illness. Artemisinin-based 
combination therapies are currently recommended by WHO for the treatment 
of uncomplicated P. falciparum malaria. Artemisinin and semi synthetic 
derivatives, including artesunate, artemether and dihydroartemisinin, are short-
acting antimalarial agents that kill parasites more rapidly than conventional 
antimalarials, and are active against both the sexual and asexual stages of the 
parasite cycle. To delay or prevent emergence of resistance, artemisinins are 
combined with one of several longer-acting drugs: amodiaquine, mefloquine, 
sulfadoxine/pyrimethamine or lumefantrine which permit elimination of the 
residual malarial parasites. The clinical pharmacology of artemisinin-based 
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combination therapies is highly complex. The short-acting artemisinins and 
their long-acting counterparts are metabolized and/or inhibit/induce 
cytochrome P450 enzymes, and may thus participate in drug-drug interactions 
with multiple drugs on the market. Alterations in antimalarial drug plasma 
concentrations may lead to either suboptimal efficacy or drug toxicity and may 
compromise treatment (Aweeka FT, German FI 2008). 
The herb Artemisia annua has been used for many centuries, in Chinese 
traditional medicine, as a treatment for fever and malaria. In 1971, Chinese 
chemists isolated from the leafy portions of the plant the substance responsible 
for its reputed medicinal action. This compound is called Qinghaosu (QHS, 
artemisinin), it is a sesquiterpene lactone that bears a peroxide grouping and, 
unlike most other antimalarials, lacks a nitrogen-containing heterocyclic ring 
system. The compound has been used successfully in several thousand malaria 
patients in China, including those with both chloroquine-sensitive and 
chloroquine-resistant strains of Plasmodium falciparum. Derivatives of QHS, 
such as dihydroqinghaosu, artemether, and the water-soluble sodium 
artesunate, appear to be more potent than QHS itself. Sodium artesunate acts 
rapidly in restoring to consciousness comatose patients with cerebral malaria. 
Thus QHS and its derivatives offer promise as a totally new class of 
antimalarials (kalyman DL 1985). 
Since the middle of this century and especially since the 1960s and 1970s, 
Chinese scientists have put considerable effort and resources into the search 
for new antimalarial compounds extracted from Chinese traditional herbs. 
Archaeological findings indicate that qinghao (Artemisia annua L.) has been 
used as a traditional remedy in China for over two thousand years. Its 
antimalarial principle was finally isolated in 1971 and named artemisinin or 
qinghaosu (meaning the principle of qinghao in Chinese). Its rapid action, low 
toxicity and powerful effect against falciparum malaria made it a favored 
subject for research. In 1976, the unique structure of the molecule, 
characterized by an endoperoxide and an alternative O-C-O-C segment, was 
identified. The specific lactone reduction discovered during the determination 
of the structure opened the way for the synthesis of qinghaosu derivatives, and 
thereafter a series of more active and more oil- or water-soluble derivatives 
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was developed. Subsequent studies of the structure/activity relationship led to 
the discovery of dihydroartemisinin, artemether and artesunate. Now 
qinghaosu and these three derivatives are being used around the world as 
effective new antimalarial drugs in the fight against falciparum malaria, 
including multi-drug-resistant Plasmodium falciparum. At the present time 
new qinghaosu analogues or derivatives are being developed and studies of 
their structure/activity relationships, their antimalarial mechanisms, their 
interaction with ferrous ions and the DNA damage associated with these 
processes are being actively pursued. In addition, recent studies also indicate 
that some qinghaosu derivatives have other bioactivities, including 
antiparasitic (against Schistosoma japonicum, Toxoplasma gondii and so on) 
and anticancer activities. Research into qinghaosu and its derivatives has 
already produced and will no doubt continue to produce results of the utmost 
importance in the fight against malaria and other diseases (Li Y 1998). 
The existing armamentarium of drugs for the treatment and prevention of 
malaria is limited primarily by resistance (and cross-resistance between 
closely related drugs). However, most of these drugs still have a place and 
their life-span could be prolonged if better deployed and used, and also by 
rationally combining them based on pharmacodynamic and pharmacokinetic 
properties. Newer compounds are also being developed. The nature of malaria 
and its prevalence in the developing world call for innovative approaches to 
develop new affordable drugs and to safeguard the available ones. (Majori G 
2004). 
According to WHO, the concept of combination therapy is based on the 
synergistic or additive potential of two or more drugs, to improve therapeutic 
efficacy and also delay the development of resistance to the individual 
components of the combination. Combination therapy (CT) with antimalarial 
drugs is the simultaneous use of two or more blood schizontocidal drugs with 
independent modes of action and different biochemical targets in the parasite. 
In the context of this definition, multiple-drug therapies that include; a 
nonantimalarial drug to enhance the antimalarial effect of a blood 
schizontocidal drug are not considered combination therapy. Similarly, certain 
antimalarial drugs that fit the criteria of synergistic fixed-dose combinations 
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are operationally considered as single products in that neither of the individual 
components would be given alone for anti-malarial therapy, an example is 
sulfadoxine/pyrimethamine (WHO 2001).  
WHO currently recommends the following therapeutic options: 
1. artemether/lumefantrine;  
2. artesunate plus amodiaquine;  
3. artesunate plus sulfadoxine/pyrimethamine (in areas where 
sulfadoxine/pyrimethamine efficacy remains high); 
4. artesunate plus mefloquine (in areas with low to moderate transmission); 
and 
5. amodiaquine plus sulfadoxine/pyrimethamine, in areas where efficacy of 
both amodiaquine and sulfadoxine/pyrimethamine remains high (mainly 
limited to countries in West Africa).  
This non artemisinin-based combination therapy is reserved as an interim 
option for countries, which, for whatever reason, are unable immediately to 
move to ACTs (WHO 2001 b).  
The emergence and spread of drug resistant malaria represents a considerable 
challenge to controlling malaria. To date, malaria control has relied heavily on 
a comparatively small number of chemically related drugs, belonging to either 
the quinoline or the antifolate groups. Only recently, malaria control have the 
artemisinin derivatives been used but mostly in south East Asia. Experience 
has shown that resistance eventually curtails the life-span of antimalarial 
drugs. Controlling resistance is considered as a key to ensuring that the 
investment put into developing new antimalarial drugs is not wasted. Current 
efforts focus on research into new compounds with novel mechanisms of 
action, and on measures to prevent or delay resistance when drugs are 
introduced. Drug discovery and development are long, risky and costly 
ventures. Antimalarial drug development has traditionally been slow but now 
various private and public institutions are at work to discover and develop new 
compounds. Today, the antimalarial development pipeline is looking 
reasonably healthy. Most development relies on the quinoline, antifolate and 
artemisinin compounds. There is a pressing need to have effective, easy to use, 
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affordable drugs that will last a long time. Drug combinations that have 
independent modes of action are seen as a way of enhancing efficacy while 
ensuring mutual protection against resistance. Most research work has focused 
on the use of artesunate combined with currently used standard drugs, namely, 
mefloquine, amodiaquine and sulfadoxine/pyrimethamine. There is clear 
evidence that combinations improve efficacy without increasing toxicity. 
However, the absolute cure rates that are achieved by combinations vary 
widely and depend on the level of resistance of the standard drug. (Olliaro Pl, 
Taylor WR 2004).  
Combinations with these herbal derivatives with other antimalarial drugs have 
been found to gain many advantages compared to monotherapy. No 
documented resistance to artemisinin because it act rapidly and do not remain 
for long. Most of parasites are destroyed before the drug drop to sub-
therapeutic concentrations (MSFF 2003) 
The concept of combination therapy in malaria treatment is introduced to 
increase the efficacy of malaria treatment and to contain the development of 
resistance. Combination therapy which has been standard clinical practice in 
the treatment of various viral and bacterial infections such as HIV/AIDS and 
TB, now is applied for malaria treatment as well (White NJ et al 1999)   
In Gambia investigators conducted a study to determine the efficacy of 
artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria 
among Gambian children. Gambian Children were randomly administered 
pyrimethamine-sulphadoxine (25 mg/500 mg) with placebo, 4 mg/kg body 
weight pyrimethamine-sulphadoxine plus 1 dose of artesunate, or 
pyrimethamine-sulphadoxine plus 4 mg/kg body weight artesunate for 3 days. 
Combined treatment was well tolerated. Insignificant differences were found 
among children administered 1-dose and 3-dose artesunate, and were found 
less likely to be gametocytemic after treatment (von Seidlein L et al 2000).  
Numerous trials have demonstrated high efficacy and safety of artemisinin-
based combination therapy (ACT) under supervised treatment. In contrast, 
effectiveness studies comparing different types of ACT applied unsupervised 
are scarce. In Ghana investigators assessed tolerability and acceptance of 
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artesunate plus amodiaquine (ASAQ) against that of artemether-lumefantrine 
(AL) in Ghanaian children with uncomplicated Plasmodium falciparum 
malaria. Children received their first weight-adjusted dose under supervision. 
After the parent/guardian was advised of times and mode of administration the 
respective three-day treatment course was completed unobserved at home. 
Follow-up visits were performed by researchers to evaluate clinical and 
parasitological outcomes, adverse events, and haematological recovery. 
Length polymorphisms of variable regions of msp1 and msp2 were determined 
to differentiate recrudescence from reinfections. Acceptance levels of both 
treatment regimens were assessed by means of standardized interviews. 
Adequate clinical and parasitological responses after AL and ASAQ treatment 
were similar 88.3% and 91.7%, respectively. Unobserved AL and ASAQ 
treatment showed high adequate clinical and parasitological responses, though 
AL was inferior in preventing late clinical failures Haematological recovery 
and drug tolerability were not found to be significantly different in both study 
arms. (Kobbe R et al 2008). 
In Pakistan, resistance to choloroquine is on the rise and reported in up to 16- 
62% of Plasmodium falciparum. Four to 25% of Plasmodium falciparum also 
reported to be resistant to sulfadoxine-pyrimethamine and several cases of 
delayed parasite clearance have been observed in patients with Plasmodium 
falciparum malaria treated with quinine. Investigators had recommended the 
concept of artemisinin- based combination therapy (ACT) and emphasize the 
use of empiric combination therapy for all patients with Plasmodium 
falciparum malaria to prevent development of drug resistance and to obtain 
additive and synergistic killing of parasite (Khan MA et al 2004). 
In Thailand, the investigators determined the efficacy, safety and tolerability 
of an alternative short-course, artemisinin-based combination therapy for acute 
uncomplicated Plasmodium falciparum malaria, compared Artequick--a fixed-
dosed combination of artemisinin (80 mg), piperaquine (400 mg), and 
primaquine (4 mg), per tablet (A),with a standard regimen of artesunate-
mefloquine (B). All treatments were well tolerated, and no serious adverse 
effects occurred. No significant differences were found in fever- and parasite-
clearance times between the two study groups. The 28-day cure rates were 
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similarly high, at 98.5% and 100%, in groups A and B, respectively 
(Tangpukdee N et al 2008). 
Investigators in Indonesia performed a randomized comparative trial to 
quantify the effect of adding artesunate to sulfadoxine-pyrimethamine or 
sulfadoxine/pyrimethamine alone in the treatment of uncomplicated 
falciparum malaria. Treatment failure rates on day 28 were 4.4% and 15.2%, 
respectively (P = 0.16). Mean fever clearance time (1.3 versus 1.7 days) and 
mean parasite clearance time (1.4 versus 2.0 days) were both faster in the 
artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-
pyrimethamine group. Gametocyte carriage was lower following artesunate 
plus sulfadoxine-pyrimethamine than following sulfadoxine/pyrimethamine. 
Mild diarrhea, rash, and itching resolved without treatment (Tjira E 2001).   
In western Myanmar (Burma), investigators assessed whether 
dihydroartemisinin-piperaquine is a suitable alternative to artesunate-
mefloquine, they compared the safety, tolerability, efficacy, and effectiveness 
of the two regimens for the treatment of uncomplicated falciparum. 
Recrudescent parasitaemias were confirmed in only two patients; the day 42 
failure rate was 0.6% (95% CI 0.2-2.5) for dihydroartemisinin-piperaquine and 
0 (0-1.2) for artesunate-mefloquine. Whole-blood piperaquine concentrations 
at day 7 were similar for patients with observed and non-observed 
dihydroartemisinin-piperaquine treatment. Gametocytaemia developed more 
frequently in patients who had received dihydroartemisinin-piperaquine than 
in those on artesunate-mefloquine (Smithius F et al 2006) 
In Bangladesh, investigators determined the baseline therapeutic efficacy of 
artemether-lumefantrine used as a six-dose regimen for the treatment of 
uncomplicated Plasmodium falciparum malaria. The cure rate in a 42-day 
follow-up after an adjustment by polymerase chain reaction was 94.3%. The 
treatment led to rapid fever (mean +/- SD = 25.82 +/- 12.14 hours) and 
parasite (30.36 +/- 19.43 hours) clearance. Investigators suggested that 




Peru on the northern Pacific Coast, changed their treatment policy for 
uncomplicated Plasmodium falciparum malaria to sulfadoxine/pyrimethamine 
with artesunate (SP-AS). Because Peru was the first country in the Americas 
to adopt this combination therapy, researchers established a surveillance 
system in the region and assessed the frequency of new or worsening 
symptoms after starting therapy. Over a period of two years, 1,552, or 
approximately two-thirds of all patients with uncomplicated P. falciparum 
malaria who had received SP-AS were followed up. Of these, 8.8% reported at 
least one adverse effect, with the most common being vomiting, nausea, 
headache, abdominal pain, dizziness, and fever; no severe adverse effects 
related to SP-AS therapy were identified (Cairo J et al 2008). 
In Comoros Union, investigators described the efficacy of 3 combinations and 
compared the parasite clearance time. According to PCR adjusted outcome, 
the therapeutic efficacy of artesunate+amodiaquine and 
artesunate+sulfadoxine-pyrimethamine was 100%, whereas that of 
chloroquine+sulfadoxine-pyrimethamine was 98%. The key difference 
between these treatments was the higher parasite clearance rate on Day 2 
obtained with artesunate-containing combinations (P<0.001). (Ariey F et al 
2007). 
1.1.10   Objectives 
General objective: 
• To evaluate the therapeutic efficacy and safety of artesunate + SP, and 
artemether/lumefantrine the first and second lines antimalarial treatment in 
Sudan, against uncomplicated falciparum malaria in Sudanese patients. 
Specific objectives: 
• To: measure the clinical and parasitological response of patients suffering 
from malaria by determining the proportion of patients with early 
treatment failure ETF, late treatment failure LTF, late parasitological 
failure LPF or adequate clinical and parasitological response ACPR as 
indicator of efficacy. 




• To: formulate recommendation that might help health authority to develop 
needed decisions in the new malaria treatment protocol as well as it might 
be as a base to help younger researchers in future studies.  
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1.2 Materials & Methods 
1.2.1     Study Area 
The study was conducted during the peak of malaria transmission August to 
December 2004, in 6 health facilities, identified from 5 sentinel sites, the 
capitals of 5 states, which were selected according to standard criteria to 
represent malaria endemicity in Sudan.  
Sudan is largest country in Africa in terms of area, covering an area of 2.5 
square kilometer for about 9675000 square miles. In terms of latitudes and 
longitudes, the country lies between latitude 3.5 and 23 degrees north of 
Equator and longitudes 21.75 and 38.5 degrees east to Greenwich. The county 
forms an immense as it sloping gently downwards towards the north along 
plateau and mountains while the northeastern part of the country is 
characterized by mountains and hills sloping towards the Red Sea Coast. 
The principal physical feature of Sudan is the River Nile and its tributaries. 
The Nile system runs approximately 2.5 thousands miles from the south to the 
north. The tributary of White Nile is Bahr Elgebel which flows from Uganda 
and enters Sudan through the large swaps area in Sudd region. It joins Sobat 
River and they jointly form the White Nile. The Blue Nile, on its part 
originates in the Ethiopian high lands and joins the White Nile at Khartoum to 
form River Nile. Atbara River, which joins River Nile at Atbara town, is the 
only one tributary of the River Nile. The huge water flow comes from the Blue 
Nile and Atbara River. 
The Nile floods provides the country with the vast alluvial agriculture lands 
and the most fertile regions are between the White Nile and Blue Nile where 
alluvial sediments are formed by the annual floods of the rivers and their 
tributaries. The country greatest irrigation schemes are located in these later 
regions. Most of principal tows of Sudan cluster around the bank of the main 
rivers, especially at the confluence of the Blue and White Niles where a high 
population density is found.  
Climate ranges from equatorial in the extreme south to arid desert in the north. 
As the physical features and climate mainly determine the vegetation of the 
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region, the central plains are dominated by Savanna grass and woodland. The 
southern Sudan which is characterized by the tropical climate is covered with 
extensive swamps in the Sudd region. The vegetation in the western Sudan is 
dominated by Savanna. 
The population in Sudan is divided into 3 major racial tribes: 
1. The Nilotic race 
2. The Nilo-Hamitic and Sudanese racial tribes 
3. The Arabs 
According to 1993 census, the majority of population live in rural areas 
(68.1%) and (29.3%) urban while 2.6% are nomads. According to 2004 
statistical reports (census) total population in northern states 29,146,000 
(84.4%), while in southern states 5,366,000 (15.6%). 
Most parts of the Sudan experience a maximum average temperature of 100 
degree F. 
During several months of the year, dust storms erupt from time to time in 
central and northern parts of the country especially in summer months from 
March to July heralding the rainy season from July to October. Red Sea coast 
enjoy a maritime climate with some rains in the winter season.  
The study was conducted in 6 health facilities located in 5 states, criteria of 
selection of these states: representation of the epidemiological stratification 
and substrata of malaria in the country, population density and stability, 
existence of health referral system, seasonality and level of transmission and 
accessibility for supervision. Two of the study sites are located in the south 
states, the capitals of Upper Nile and Equatorial states:  
1. Malakal, the capital of Upper Nile state, state population is 1,506,000. White 
Nile River is crosses the state. The area is characterized by long grasses and 
forests full with swaps due long rainy season; the climate forms a suitable 
environment for malaria vector breeding sites, type of strata intense malaria 
transmission. Malakal total population is estimated by 180 thousands in 2004. 
The study was conducted in Malakal hospital, outpatient clinic. 
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2. Juba, the capital of Equatorial state, population is accounted for 1,341,000 
thousands. The state physical feature is tributary of White Nile Bahr Elgebel 
which flows from Uganda and enters Sudan through the large swaps area in 
Sudd region. The state is characterized by the tropical climate, covered with 
extensive swamps in the Sudd region large trees and forests. The malaria type 
in the site is hyper endemic. The study was conducted in Juba hospital.  
The other study sites located in 3 states in the northern part of Sudan which 
characterized by seasonal malaria transmission following the rainy season. 
The population in the northern states are known to have low acquired malaria 
immunity which leads to disease outbreak or malaria epidemics compared to 
the residence of the south who have natural acquired immunity due to the 
repeated infections, as reported before: (A major determinant of malaria 
epidemiology is the pattern of acquired immunity to P.falciparum infection, 
with individuals that can tolerate parasitaemias living in malaria endemic 
areas. Epidemiological studies have demonstrated that the burden of morbidity 
and mortality is concentrated among youngest group under conditions of 
intense perennial transmission) (Omosun Y.O et al 2005). Although the 3 
states of the northern region are all considered to be fall in one stratum which 
is seasonal malaria transmission area, but each one separately represents 
malaria substrata, as follows: 
1.  Damazin, the capital of Blue Nile state which located in the south east 
part of northern Sudan, bordered by Ethiopia and situated in the entry 
point for the Blue Nile River which arises near Tana Lake which located in 
the Ethiopian highlands, the state is located in about 700 km distance from 
Khartoum, with a population of 675,000. In terms of Latitude and 
longitude it lays between (11.76 and 28.3) the state represents rich savanna 
area. One of the characteristics of the state is (Elrosairis dam) the biggest 
hydro-electric dam which provides electricity to Khartoum, soil is rich as 
the result of alluvial. Availability of water swaps in addition to the other 
environmental factors lead to formation of vector breading sites, one 
health center was identified for conduction (Elrabiea health center), 
malaria is classified as meso-hyperendemic malaria (Burns MR et al 2008) 
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2. Kosti, the capital of White Nile state, located south to Khartoum about 300 
km, total population of 1,636000 living in an area of 38865 km2. The 
White Nile River crosses the state which contains agriculture schemes like 
plantation of sugar cane schemes in Kennana and Asalaia, the biggest 
factories of sugar production in Sudan beside plantation of other crops. 
Study site population is about 174 thousands. The type of malaria in this 
area is called irrigated malaria. Two health facilities were selected for 
conduction the study in this state, one for testing the first line artesunate + 
sulfadoxine/pyrimethamine (ASP) and the other for testing the second line 
artemether/lumefantrine (AL).  
3. Kassala state located in the eastern part of Sudan bordering Eritrea, 660 
km in distance from Khartoum, total population in the state 1,625000, state 
characterized by  mountains surrounding the state, other physical feature is 
Gash River, it is a seasonal river filled by the rains during autumn and 
becomes dry in summer, it cross the capital of state Kassala the study site 
in which about 234 thousands residents, other characteristic of the site is 
gardens of oranges, lemon and other citruses in Elsawgi plantation area, 
the location of the state assists in population movements across the border, 
this is considered as one of the factors which facilitate drug resistance. 
According to this situation the type of malaria is so called border malaria.   
The climate and natural condition during the study time 2004, annual average 
temperature in centigrade degrees, rainfalls during April – September  and 
annual relative humidity as indicated by the Sudan Metrological Authority in 




Climate (temperature, rainfall, humidity) in the study sites 







Juba 32.0 20.2 700 55 
Malakal 35.9 22.2 398 53 
Damazin 33.0 21.4 667 46 
Kosti 37.3 18.0 220 43 
Kassala 37.9 23.0 194.6 38 
 
Table 1.2.2 
The distribution of health facilities according to health levels in each of the targeted 
states in 2004. 







Equatorial 0 0 47 34 18 18 12 
Upper Nile 1 1 43 0 16 10 9 
Blue Nile 1 1 45 82 40 19 12 
White Nile 5 3 68 61 126 66 28 
Kassala 4 4 123 45 98 60 10 
 
Table 1.2.3 
Medical staff by state- study areas - (2004) 
State (sentinel site) Physician Pharmacist 
Equatorial   
Upper Nile (Malakal ) 52 12 
Blue Nile (Damazin) 50 4 
White Nile (Kosti) 162 12 





A country plan of action for continuous monitoring therapeutic efficacy of 
antimalarial drugs was formulated by the national malaria control programme. 
8 Permanent sentinel sites were identified covered the whole country, 
represent all malaria strata and substrata beside other criteria of selection, the 
8 permanent sentinel sites are capitals of 8 states as are shown in the following 
map (1).  
To follow the basic standards for conduction such studies, the present study 
was performed in the same permanent posts, in 5 states of them, from south to 
north: Equatorial, Upper Nile, Blue Nile, White Nile and Kassala. 6 health 
facilities were selected for conduction the present study, assessment of the 
therapeutic efficacy of the first line artesunate + SP and the second line 
artemether/lumefantrine, against uncomplicated falciparum malaria in local 
communities residing in the above mentioned 5 states as a study area. The 6 
health distributed as follows; one in each of the above mentioned states while 













1.2.2       Study population 
According to WHO 2003 protocol the following inclusion and exclusion 
criteria were strictly adhered to:    
Inclusion criteria 
1. Age from 6 months to 59 months for Malakal and Juba (intense 
transmission area), while in other northern states all age groups were 
included from 6 month. 
2. Confirmed malaria by microscope falciparum monoinfection (not mixed), 
with parasite density 1000-100000 per microlitre in northern and 2000-
200000 in the south.  
3. All symptoms and signs compatible to uncomplicated falciparum malaria, 
fever (body temperature more than or equal to 37.5 degree centigrade) or a 
history of fever on the last 24 hours. 
4. Absence of malnutrition defined as a child whose weight for height is 
below 3 standard deviation, or less than 70% of median of NCHS/WHO 
normalized reference values or who has symmetrical oedema involving at 
least feet.  
5. Ability and willingness to come on scheduled follow up visits, or easy 
access for the study team to reach patient at home. 
6. Informed consent from patients or patients guardians in case of children. 
Exclusion criteria  
We excluded from the study all patients with one or more of the following: 
generally it is opposite to the inclusion criteria: 
1. Patients with severe malaria, with at least one of the symptoms of severe 
malaria or mixed malaria infection. 
2. Presence of febrile illness beside malaria.  
3. patients with danger signs (inability to sit or stand, vomit everything, 
convulsion, lethargy or unconsciousness)  
4. Patients with hypersensitivity reaction to one of the drug component or 
with skin rash or eczema or any type of skin diseases were also excluded 
from the study due to the risk of hypersensitivity reactions of 
sulphonamide. 
5. Pregnant ladies and lactating mothers. 
32 
 
1.2.3       Study design 
The study is one arm prospective evaluation of clinical and parasitological 
response to directly observed treatment of artesunate + 
sulphadoxine/pyrimehamine (ASP) and artemether/lumefantrine (AL) in 
Sudanese patients with uncomplicated falciparum malaria. 
Medical study team: 
In each one of the 6 health facilities a medical study team who had the interest 
to conduct the present study with accuracy was prepared. It composed of: 
• Medical doctor, expert clinician or pediatrician, in south. 
• Qualified laboratory technician 
• Qualified nurse assisted the doctor in weighing the patients, administered 
the treatments and took medical close care after patients. 
• Driver  assisted in patients follow up 
1.2.4       Patients screening  
All patients with fever or a history of fever were assessed clinically and after 
exclusion of other causes of fever such as respiratory diseases especially in 
children, urinary tract infection otitis media and abscess they sent to the 
laboratory for malaria microscopic diagnosis, patients with malaria and other 
febrile illness were treated by the health center as routine practice. Patients 
with only falciparum malaria infection undertook for further assessment by the 
medical team.  Patients’ information was taken:  age, sex, body temperature, 
weight, local address and initial blood slide result of confirmation of 
falciparum malaria and parasite count.  
1.2.5       Laboratory assessment 
Each patient was asked to give a sample of blood from a finger brick. Thick 
blood smear was prepared, stained using 3% Giemsa stain solution for 45-60 
and read. Parasite density calculated by counting the asexual parasite against a 
set number of white blood cells (WBC) - typically 200 or 300- in the thick 
blood film, used a hand tally counter. Parasite density, expressed as the 
number of asexual parasite per microlitre, was calculated by dividing the 
number of asexual parasite by number of WBC multiplying by WBC density, 
assuming it 8000 WBC per microlitre. 
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A blood slide was considered as a negative when 100 thick film fields 
examined and did not show the presence of asexual parasites.     
1.2.6      Treatment and follow up 
Patients who fulfilled all of inclusion criteria were enrolled in the study. Good 
quality drugs were used:  
1. Artesunate + SP tablets, registered in Sudan, supplied by Dafra Pharma –
Belgium. Each tablet contains artesunate 100 mg + SP (500 mg 
sulfadoxine/pyrimethamine + 25 mg pyrimethamine). Standard 
recommended doses were given by study medical team according to 
patient body weight (directly observed treatments), on the three first days: 
day zero, day one and day two. On the first day (zero) a full dose of SP 
(25mg sulfadoxine /kg) and (4mg/kg) artesunate tabs given simultaneously 
in case of adults it means 5 tablets at once, then followed by artesunate 
(4mg\kg) daily for day one and day two, 24 hours apart.  
2. Artemether/lumefantrine, registered in Sudan, supplied by Novartis 
Pharma- Switzerland. Each tablet contains artemether 20 mg + 
lumefantrine 120 mg (fixed combination), doses were given to body 
weight as per national treatment protocol (annex 1), 6 dose regimen was 
used (2 doses\day) for the first 3 days; zero, day one and day two, twelve 
hours apart except day zero the second dose given after 8 hours from the 
first. 
The patient was allowed to sit in the clinic about 1/2 hour for clinical 
observation and if she/he vomited before this time another full dose of 
treatment was repeated. One dosage form was used as mentioned in the 
national protocol, and internationally, the two combinations all are in tablet 
form; there is no syrup formulation of them. Even for children, who could not 
swallow, the tablets were dissolved in a small quantity of water.     
Each patient was followed 28 days according to stipulated visits on the 
following days: zero, 1, 2, 3, 7, 14, 21 and day 28, in addition to any day if the 
patient felt unwell. On each visit blood films was prepared and examined for 
parasite count.  
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Clinical assessment was carried out on each of the scheduled visits by 
checking axillary's temperature and general medical checking, all observation 
of each patient and the result of parasite count were recorded by the clinician 
in the patient case report form (Annex 2).  
1.2.7    Study end-point 
The study end-point defined (WHO 2003) as the point at which the patient 
was no longer be followed up. It divided into completion of follow up period 
without treatment failure, treatment with treatment failure, loss to follow up 
and withdrawals.    
• Completion of follow up without treatment failure: 
The patient who ended its follow up period with absence of parasitaemia 
on day 28 irrespective to axillary temperature was classified as Adequate 
Clinical and Parasitological Response (ACPR). 
• Completion of follow up with treatment failure was divided into 3 
categories:  
1. Early Treatment Failure (ETF) defined as: 
− Development of danger sign or severe malaria on day 1, day 2, or 
day 3 in presence of parasitaemia.  
− Parasitaemia on day 2 higher than day 0 count irrespective of 
axillary temperature.  
− Parasitaemia on day 3 with axillary temperature equal to or higher 
than 37.5 centigrade degree.  
− Parasitaemia day 3 with 25% of count on day 0. 
2. Late Clinical Failure (LCF) defined as: 
− Development of danger signs or severe malaria after day 3 in 
presence parasitaemia without previously meeting any of criteria of 
Early Treatment Failure. 
− Presence of parasitaemia and axillary temperature equal to or higher 
than 37 centigrade degree on any day from day 4 to day 28 without 
previously meeting any of the criteria of early treatment failure. 
3. Late Parasitological Failure (LPF) defined as: 
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− Presence of parasitaemia on day 28 and axillary temperature less 
than 37 without meeting any of the criteria of early treatment failure 
or late clinical failure.  
The other 2 classifications for the patients who did not completed the follow 
up period and reached their end- point were classified as loss to follow up and 
withdrawals and defined as follows:   
• Loss to follow up 
− Described the patients who could not be found despite all efforts which 
exerted by the study team, the reason of such case described by the 
clinician in the patient case report form, for example: the patient 
classified as: loss to follow up- traveled from the study area during 
follow up period and the day of loss was mentioned. 
• Withdrawals 
− Described the patients who ended their participation voluntary, 
developed a concomitant illness, mixed malaria infection or used a self 
medication of antimalarial, in such a case the day of withdrawal and 
the reason was reported. 
The clinician and his medical team took care after the patients and assessed 
them closely to report any adverse drug reaction developed during the study 
duration in the patient form.   
1.2.8       Sample Size 
According to WHO protocol, the requested sample size was calculated by 
classical method depend upon the expected population of treatment failure 
from earlier studies (P), the confidence level (95%) and the precision (d) of 
10%. The expected population of treatment failure in artesunate + SP and 
artemether/lumefantrine were considered to be 5% according to WHO table in 
(Annex 3) it was equals to 18 patients but in order to be representative sample 
size WHO recommend a minimum of 50 patients should be included when the 
calculation result in lower number than 50. The sample size adjusted to 
include a 20% loss to follow up and withdrawals patients according to the 
formula: n = (1 + 0.20) x 50= 61  
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A number of 61 malaria patients were included in each of the health facilities, 
so the total number of the study calculated to be 6 x 61= 366 patients. 
1.2.9       Data management and analysis 
All case report forms were collected from each of the above mentioned site 
together with the blood slides which kept in slide boxes from damage. Each 
slide took the code number of the patient and the number of the day of which 
the blood smear was taken. The blood slides were submitted to Malaria 
Reference Laboratory for rechecking by two experts' laboratory technicians 
and kept for extra revision if needed for coming 2 years. 
The case report form included all needed information: age, sex, address of the 
patients, study site, drug name, drug manufacturer, manufacture and expiry 
date, total dose, drug concentration, body temperature, parasite count and any 
adverse drug reaction 
All data was entered in standardized data analysis Excel sheets 2004 available 
free via: www.rbm.who.in (Annex 4). Classification was obtained 
automatically, for each patient after all its information was entered in the 
Excel sheet. Analysis was done by Excel sheet, percentage of treatment 
outcome, percentage of loss to follow up and percentage of withdrawals. 
Further analysis was done by Epi-info statistical package for the baseline 
characteristic of the patients. 
Ethical consideration 
Ethical clearance certificate was obtained from Federal Ministry of Health 
(Annex 5). In addition to the study was conducted under direct supervision of 
qualified medical personnel. At all times, the safety, welfare and appropriate 
management of each individual patient took a priority over the conduction of 
the study. A written informed consent (Annex 6) was completed by the patient 
or patient parents/guardian in case of children after the study team explained 








Baseline characteristics per study area- ACTs Efficacy Study – Sudan 2004 
Drug A/L* AS+SP** 
Sentinel site Juba Kosti Malakal Damazin Kassala Kosti 
No. enrolled 75 64 77 72 50 70 









































































Treatment Response per study area – ACTs Efficacy Study- Sudan, 2004 
 
Study area Juba Kosti 2 Malakal Kassala Damazin Kosti 1 
Drug ARM/LUM AS + S/P 
Total 
examined 342 503 1233 1100 116 1568 
P.f. +ve 184 84 411 614 102 123 
enrolled 75 64 77 50 72 71 
Withdrawal 0 0 1(1.2) 0 0 0 
Loss to follow 
no (%) 3 (4.0) 4 (6.3) 4 (5.2) 0 (0) 1(1.4) 6 (8.5) 
ETF 2(2.8) 0 0 0 0 0 
LCF 0 0 0 2(4) 0 0 
LPF 0 0 0 0 0 0 
















* A/L – Artemether/ lumefantrine   
** AS+SP – Artesunate + Sulfadoxine-Pyrimethamine 
 
 
1.3.1       Base line characteristics 
The baseline characteristics described in (Table 1) above, the study included 
both sexes, with an equal more or less distribution in all sites, with lowest 
females' number was found in Kassala compared to the highest females' 
number which obtained in Damazin. Percentage of included females in each of 
the study areas as follows: 48%, 44%, 52%, 51%, 36%, and 46% in; Juba, 
Kosti 2, Malakal, Damazin, Kassala and Kosti 1 respectively. Age distribution 
in Juba and Malakal involved only children <5 years according to high 
endemicity of malaria as recommended by WHO, hence mean age was (1.13 
and 1.3 years) for the two sites respectively, the lowest mean age found in 
south compared to mean age in the north. Where all age groups were enrolled 
in the present study due to low malaria endemicity, age distribution in the 
northern sites included children from 6 month old to adults. The highest mean 
age was found to be in Kosti 2 (18.9 years) while the lowest mean age in 
Damazin (9.0 years).  The mean body temperature and parasite count, found to 
be as follows: the highest body temperature was found in Malakal while 
highest mean parasite count obtained from Juba, the two sites were belong to 
intense transmission area (hyper endemic) in south, those 2 characteristics 
appeared in children less than 5 years, the study participants according to 
(WHO protocol 2003).   . 
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1.3.2       Treatment Response 
Out come of treatment response showed in (table 2). By the summation of all 
examined patients attended in the 6 health facilities which distributed in 5 
states for the 2 combinations tests, we obtained a total of 4862 febrile patients 
were examined and screened, of them 1518 patients found to be positive for 
plasmodium falciparum infection, positivity rate was (31.0%), after excluded 
ineligible patients from the study, a total of 409 patients fulfilled the inclusion 
criteria and were enrolled in the study for the two combinations the first and 
second lines.  
By taking each line separately, as shown in the table 2 above: first for the 2nd 
line artemether/lumefantrine A/L group, it was performed in 2 sites:  Juba 
(south Sudan) and Kosti 2 (central Sudan). A total of 845 patients were 
screened, 342 (40.4%) and 503 (59.5%) in Juba and Kosti respectively, of 
them 268 (31.7%) patients were positive for plasmodium falciparum.  Of them 
a total of 139 patients were found to be clinically suitable and were enrolled in 
the study, distribution of them by study sites; Juba (77) and Kosti (64) 
patients, of the 139 enrolled patients, 7 patients (5.05%) lost to be followed up 
and withdrawn from the study, the rest of 132 patients completed the 28 days 
of follow up period and classified according to treatment response, 130 
(98.5%) patients adequately treated and classified as adequate clinical and 
parasitological Response (ACPR), with an exception of  2 (1.5%) patients 
from Juba (south) who classified as early treatment Failure (ETF), while all 
patients in Kosti were radically cured and classified as Adequate Clinical and 
Parasitological Response (ACPR) 100%.   
As shown in table 2, for the 1st line, artesunate + sulfadoxine/pyrimethamine 
group, the test conducted in 4 sentinel sites Malakal, Kassala, Damazin and 
Kosti, a total of 4017 febrile cases were screened and examined for malaria 
parasites from the 4 sentinel sites with distribution of cases  per study sites as 
follows: 1233 (30.7%), 1100 (27.3%), 116 (2.9%) and 1568 (39.0%) from 
Malakal, Kassala, Damazin and Kosti respectively. of them 1250 cases were 
positive for plasmodium falciparum monoinfection, slide positivity rate 
31.1%.  After taking clinical and other measures for inclusion/exclusion 
criteria, only 270 patients fulfilled all of inclusion criteria and enrolled in the 
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study, distributed in the study sites as follows: Malakal (77), Kassala (50), 
Damazin (72) and Kosti (71). Of them 11(4.07%) loss to follow up, one 
patient (0.3%) withdrew at the end 268 patients were analyzed for treatment 
response. Only 2 patients (0.7%) in Kassala were classified as late clinical 
failure (LCF) while 266 (99.3%) radically cured and classified as Adequate 
Clinical & Parasitological Response (ACPR).  
The other patients who did not meet the inclusion criteria were treated by the 
health facility staff according to regular clinical measures 
1.3.3       Parasite Clearance 
Rapid parasite clearance was observed in the first 48 hours, most of cases 
cleared their parasite while fever clearance was not interpretative because 
antipyretic medication was given. 
Mean parasite count was obtained using Epi-Info, on the 3 initial days; day0, 
day2 and day3 in the 4 sites, of AS+SP group. At the 3 sites of north Sudan: 
Damazin, Kassala and Kosti was as follows: 
In Damazin (Day 0 = 21924+_17748.7, Day 2 = 2.8+_17 and Day = 3 0.0 
+_0.0). 
In Kassala (Day 0 = 32240.8+_28372.9, Day 2 and day 3 = 00.0+_00.0)  
In Kosti 1 (Day 0 = 11418.1+_11082, Day 20 and Day 3 = 00.0+_00.0) 
In Malakal (day0 = 37297+\-27844, day2 =88 +\-603 and day3= 0.00+\-0.00) 
Compared to Artemether/Lumefantrine group in which mean parasite count 
was as follows; 
In Juba (day0 =20177+_42619, day2 =2431+_10775 and day3= 648+-3091) 
and 
In Kosti 2 (D =22090.6+_ 20650.6, Day 2 and Day 3 =00.0+_00.0). 
The relationship of average parasite count reduction was reflected in (Figure 
1) 
Rapid parasite clearance was observed accompanied the two combinations. 
The first line artesunate + sulfadoxine \ pyrimethamine was cleared the 
parasites more rapidly than the second line artemether\lumefantrine as showed 






















































1.3.4       Adverse Effects 
No serious adverse effects were reported during patients follow up duration, 
the 28 days, except very minor side effects were observed; 
Skin rash and nausea recorded in 5 (1.9%) of the participants with first line 
artesunate + sulfadoxine\pyrimethamine, skin rash reported in 2 patients and 
nausea reported in 3 patients.  
In the second line artemether lumefantrine group, adverse effects observed in 
6 (4.3%) of the patients, dizziness reported in 3 patients, abdominal pain 
observed in 2 patients and sleep disorders reported in one patient. 
In the present study the first line appeared to be safer than the second line.  
All side effects disappeared during follow up of patients without treatment or 





New antimalarial drug policy was adopted in the Sudan, recently in late 2004, 
it recommends the treatment and prevention of all forms and types of malaria, 
especially the predominant and dangerous one; falciparum malaria. National protocol 
for management of malaria was published by national malaria control programme, 
approved the use of artemisinin – based combinations (ACTs). After the decline of 
chloroquine efficacy, (as mentioned in chapter 1), like the situation in other African 
and Asian countries.  Resistance to conventional antimalarials triggered off new 
policies to circumvent the devastating consequences of malaria especially in the trans-
Saharan Africa. The use of artemisinin-based combinations as first line drug in 
treatment of uncomplicated malaria was then advocated and adopted by the World 
Health Organization (WHO).  (Esimone CO. et al 2008).  
Combination drug therapy for malaria is recommended both to prevent and to 
overcome drug resistance. Drug combinations developed for use in Asia are being 
deployed in Africa, where higher rates of malaria affect the therapeutic and public 
health objectives of malaria chemotherapy as well as drug safety. Rational 
consideration of drug mechanisms, pharmacokinetics (PK), pharmacodynamics (PD), 
and malaria epidemiology should result in more effective combination regimens that 
retain therapeutic and prophylactic efficacy in the face of resistance (Nyunt MM et al 
2007) 
The main outcome of the present study concerning the efficacy of artesunate + 
SP and artemether/lumefantrine showed high radical cure rate of 99.3% and 98.5% 
respectively. The findings of the present study are complied with the other similar 
results in Sudan, in African region and globally. 
In Sudan, numerous studies of assessment of chloroquine resistance were 
conducted the vast majority indicated that chloroquine was no longer adequate for 
treatment uncomplicated falciparum malaria (Elamin et al 2007), (Malik EM et al 
2006). Local data on the new combinations (ACTs) was also essential to assist health 
authorities in the descian making towards them. Many studies were conducted in 
evaluating the efficacy of new ACTs as well as the present study. Findings of the 
present study completely agreed others internal studies;  
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It complied with a study in Malakal, south Sudan aimed to determine which 
artemisinin-based combination therapies is more effective to treat uncomplicated 
malaria in local residence, conducted by (van den broek I et al 2005) who reported 
that: (Artesunate plus Sulfadoxine/Pyrimethamine and artesunate plus amodiaquine 
were both found to be efficacious in curing malaria infections by rapid elimination of 
parasites and clearance of fever, in preventing recrudescence and suppressing 
gametocytaemia. The combination of artesunate+ sulfadoxine\pyrimethamine 
appeared to be slightly more efficacious than Artesunate/Amodiaquine, with 4.4% 
versus 15% of patients returning with malaria during the 6-week period after 
treatment. Polymerase Chain Reaction- PCR- results were incomplete and assuming 
part of the indeterminate samples were recrudescent infections leads to an estimated 
efficacy ranging 97-98% for Artesunate+sulfadoxine\pyrimethamine and 88-95% for 
artesunate+ amodiaquine.)  
The present study results also agreed with results obtained by (Hamour S et al 
2005), who conducted a study in Nuba mountain region, evaluated the efficacy of 
artesunate + sulfadoxine\pyrimethamine (AS+SP) and artesunate\ amodiaquine 
(AS+AQ) for comparison, reported that: (PCR-corrected cure rates after 28 days were 
91.2% for AS+SP and 92.7% for AS+AQ, with equally rapid parasite and fever 
clearance. The Pfcrt K76T mutation occurred in 90.0% of infections, suggesting 
chloroquine would work poorly in this region and its use should be rapidly 
discontinued in this region. ASAQ is likely to be a better long-term option, provided 
AQ use is limited to the combination) 
Results of the present study also complied with evidence of a study conducted 
in New Halfa, eastern Sudan. Investigators determined the efficacy of artesunate-
sulfadoxine-pyrimethamine (AS-SP) for the treatment of uncomplicated, Plasmodium 
falciparum was compared with that of artesunate-amodiaquine (AS-AQ). AS-SP 
appeared slightly more efficacious than AS-AQ but the differences were not 
statistically significant. The PCR-corrected frequencies of cure were 97.5% for AS-SP 
and 95.2% for AS-AQ (P>0.05). (Ibrahim AM et al 2007). 
Obtained results of the present study agreed with results obtained by another 
local work conducted in New Halfa, eastern Sudan, investigators assessed the 
efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in 
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the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with 
those of SP alone. The true frequencies of cure by day 28 were therefore 100% for 
ASP and 86.7% for SP alone (P=0.02). ASP appeared markedly better, in terms of 
fever- and parasite-clearance times and the prevalence of post-treatment 
gametocytaemia, than SP alone (Adam et al 2005) 
It is of importance to mention that, the present study is considered to be the 
greater one among others conducted locally, whether mentioned above or not, because 
it performed in 6 health facilities covered 5 different states and included greater 
number of patients. Compared to others conducted in one or 2 health facilities in one 
state and included less numbers of patients.  
In the Africa, several similar studies were conducted assessed the efficacy of 
ACTs. Findings of the present study agreed with a study conducted in Tanzania, in 
which the investigators aimed to study the effectiveness of three drug combinations, 
compared with amodiaquine as monotherapy. They tested Amodiaquine, amodiaquine 
+ sulfadoxine-pyrimethamine, or amodiaquine + artesunate, or artemether-
lumefantrine six dose regimen. Drugs were taken orally, at home, unobserved by 
medical staff. Recrudescence rates of the 4 above mentioned therapies by day 28, 
after correction by genotyping, were 48.4%, 34.5%, 11.2%, and 2.8%. The highest 
obtained efficacy in artemether\lumefantrine group 97.2% ((Mutabingwa et al 2005).   
The difference in the upper mentioned study and the present study was found 
in the methodology, where in the present study, all doses were given at the health 
facility, supervised by the medical team, while in Tanzanian study drugs were took by 
patients at home because researchers aimed to assess the effectiveness together with 
efficacy.  
The second line in Sudan is fixed dose artemether/lumefantrine given to the 
patients in the present study in (6 dose regimen) over 3 days duration, It obtained cure 
rates of 98.5%.  It was the standard recommended dose because it was found to be 
superior over the 4 dose regimen, as appeared in other evidences before, in a study in 
Thailand which investigated oral fixed combination artemether/lumefantrine 
compared two six-dose schedules with the previously used four-dose regimen, in 
patients with uncomplicated multidrug-resistant falciparum malaria. No differences 
between the three treatment groups in parasite and fever clearance times, and reported 
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adverse effects. The two six-dose regimens gave adjusted 28-day cure rates of 96.9% 
and 99.12%, respectively, compared with 83.3% for the four-dose regimen (P < 
0.001) (VugMV et al 1999).  
In a similar study, conducted in Senegal, also indicated the fixed combination 
artemether/ lumefantrine 6 dose regimen is superior than the 4 dose regimen, 
researchers assessed efficacy and tolerability of artesunate plus amodiaquine 
(Arsucam), artesunate plus mefloquine (Artequin), artemether plus lumefantrine 
(Coartem; four doses and six doses), and amodiaquine plus sulphadoxine-
pyrimethamine. On day 28, all combinations resulted in an excellent clinical and 
parasitological response rate of 100% after correction for PCR results, except for the 
four-dose artemether-lumefantrine regimen (96.4%). (Faye B et al 2007).  
In another study conducted in Uganda aimed to compare the efficacy and 
safety of 3 leading combination therapies, artemether/lumefantrine was found to be 
more efficacious among all other combinations. Participants were randomized to 
receive 1 of 3 combination therapies (amodiaquine plus sulfadoxine-pyrimethamine, 
amodiaquine plus artesunate, or artemether-lumefantrine). Significant reductions in 
anemia 9.3% at enrollment versus 0.6% during the last 2 months of follow-up and 
asymptomatic parasitemia18.6% at enrollment versus 2.3%during the last 2 months of 
follow-up were observed according to routine testing. (Dorsey G et al 2007).  
In the selection process of the new combinations, the national technical 
advisory committee did not select amodiaquine with artesunate as first line. When 
they were trying to put which option is suitable for Sudan. Although amodiaquine as a 
partner drug to artesunate on comparison appeared to be as potent as 
sulfadoxine\pyrimethamine or slightly less potent as reported by (Adam et al 2005) in 
New Halfa study and (Van den Broek I et al 2005) in Malakal study or slightly more 
potent, as reported by (Hamour et al 2005) in Nuba Mountain as mentioned above. 
Their descian depend on an important fact that, amodiaquine was associated with 
serious adverse reactions, due to them it was deregistered and its use was stopped in 
the country since 1980s. 
Beside another fact; the evidence of amodiaquine cross- resistance with 
chloroquine as reported: Amodiaquine (AQ) and chloroquine CQ belong to the same 
class of 4 aminoquinoline, so it was assumed that the superiority of AQ, which 
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associated with less previous use, would be short-lived as cross resistance from CQ 
could develop shortly after its introduction. (Bloland, Ruebush 1996) and recently 
reported: (The high prevalence of potentially amodiaquine (AQ) resistant parasites 
raises questions about the utility of AQ as a partner drug for ACT in Ghana. The 
efficacy of AS+AQ in Ghana requires, therefore, continuous monitoring and 
evaluation (Adjei GO et al 2008) 
Amodiaquine, adverse reactions, also appeared in other countries, like 
Tanzania, where investigators assessed the efficacy and safety of different artemisinin 
combinations, included amodiaquine alone. The amodiaquine group was stopped 
early by the data and safety monitoring board. (Mutabingwa TK et al 2005 b). 
Amodiaquine was associated with adverse effects such as anorexia, weakness 
and neutropaenia as reported in Uganda, investigators assessed the efficacy and safety 
of amodiaquine + sulphadoxine-pyrimethamine (AQ+SP), artesunate + amodiaquine 
(AS+AQ), or artemether / lumefantrine (AL). Outcome measures included the risk of 
adverse events at 14 and 42 days after treatment.  At 14 days of follow-up, AQ+SP 
treatment was associated with a higher risk of anorexia, weakness, and subjective 
fever than treatment with AL, and a higher risk of weakness, and subjective fever than 
treatment with AS+AQ. Treatment with AL was associated with a higher risk of 
elevated temperature. Repeated episodes of neutropaenia associated with AS+AQ 
were detected in one participant. Considering only children less than five years, those 
who received AQ+SP were at higher risk of developing moderate or severe anorexia 
and weakness than those treated with AL. Extending the analysis to 42 days of 
follow-up had little impact on the findings (Maitex-sebuquzi C et al 2008). 
Amodiaquine induced vomiting and hepatitis, even when used in combination 
form with artesunate as documented recently, in artesunate plus amodiaquine fixed 
and loose dose forms in Burkina Faso.  Efficacy rates were 92.1% in both arms. 
Kaplan Meier PCR-corrected cure rates were similar: 93.7% fixed vs. 93.2% loose, 
both arms had rapid parasite and fever afebrile clearances. Drug-induced vomiting 
was (2.1%) and (1.6%) in the fixed and loose arms, respectively. One patient 
developed asymptomatic CTC grade 4 hepatitis (Sirimia SB et al 2009). 
Amodiaquine combined with artesunate induced adverse reactions in co 
morbid patients, as reported, in Uganda. Investigators Compared malaria treatment 
48 
 
outcomes between cohorts of HIV-infected and HIV-uninfected children. Malaria 
treatment was highly efficacious in both the HIV-infected and HIV-uninfected cohorts 
(28-day risk of recrudescence, 0% and 3.6%, respectively); however, there was a 
trend towards increased risk of recurrent malaria among the HIV-uninfected children 
(2.9% vs. 13.2%). Importantly, the risk of neutropaenia 14 days after initiation of 
treatment with artesunate plus amodiaquine was higher among HIV-infected children 
than among HIV-uninfected children (45% vs. 6%). The severity of all episodes of 
neutropaenia in HIV-uninfected children was mild to moderate, and 16% of episodes 
of neutropaenia in the HIV-infected cohort were severe or life-threatening. In the 
HIV-infected cohort, the risk of neutropaenia was significantly higher among children 
who received antiretroviral therapy than among those who did not receive 
antiretroviral therapy (75% vs. 26%) (Gasasira AF et al 2008)). 
Fast parasite and fever clearance was observed accompanied the new 
combinations, in the present findings which completely agreed with evidences before; 
Artemisinin fever clearance time is shortened to 32 hours as compared with 2-3 days 
with older agents. (Aweeka FT, German FI 2008 b). 
It is documented that artesunate the partner -artemisinin derivative- in the first 
line is responsible for this characteristic; this feature was observed in the present 
study; when the vast majority of patients in artesunate + sulfadoxine\pyrimethamine 
group clear their parasites in the first 24 hours of treatment, compared to the patients 
in second line artemether\lumefantrine group. It was agreed with, what reported 
before: (As drug resistance renders cheap antimalarial drugs ineffective, a promising 
candidate has emerged from an overlooked source: Asia. Used as herbal remedies in 
China for 2000 years, artemisinins haven't yet been approved for clinical use in 
Western countries. But abundant clinical data show that a water-soluble form called 
artesunate knocks down the number of parasites in the blood faster than any other 
drug does (Marshall E 2000).  
It is of importance to mention in the present study, on day 2, it was observed 
that about 98.2% of patients in artesunate + sulfadoxine\pyrimethamine group cleared 
their parasites compared to 78.2% of patients in artemether\lumefantrine group, which 
completely agreed with results of a study conducted in Comoros Union, Indian Ocean 
sub region, which described the efficacy of 3 combinations and compared their 
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parasite clearance time. Therapeutic efficacy of artesunate+amodiaquine (AS+AQ) 
and artesunate+sulfadoxine-pyrimethamine (AS+SP) was 100%, whereas that of 
chloroquine+sulfadoxine-pyrimethamine (CQ+SP) was 98%. The key difference 
between these treatments was the higher parasite clearance rate on Day 2 obtained 
with artesunate-containing combinations (Ariey F et al 2007b). 
Artesunate + sulfadoxine\pyrimethamine showed high efficacy and associated 
with rapid parasite clearance, even if follow up period was extended to 90 days, more 
days, than recommended by WHO, as the present study and other similar ones, the 28 
days duration, as reported by investigators:(In Southern Benin at day-28 
sulphadoxine-pyrimethamine (SP) monotherapy showed failure rate greater than 40%, 
while for SP combined with artesunate (SP-AS) the failure rate was 5.3%. Such a 
large difference could be explained by the relatively short 28-day follow-up period, 
with a substantial number of recurrent infections possibly occurring after day 28. 
After the 28-day follow-up, children treated with either chloroquine alone (CQ), SP or 
SP-AS, were visited at home twice a week until day 90 after treatment. A blood 
sample was collected if the child had fever (auxiliary temperature > or =37.5 degrees 
C). The PCR-corrected clinical failure at day 90 was significantly lower in the SP-AS 
group (SP-AS: 2.7%, SP alone: 38.2%; CQ: 41.1%).  Combining artesunate to SP 
dramatically increased the treatment efficacy, even when extending the follow-up to 
day 90 post-treatment, and despite the high percentage of failures following treatment 
with SP alone. Such a good performance may be explained by the low prevalence of 
the dhps 540 mutation, by the rapid parasite clearance with artesunate and by the level 
of acquired immunity (Nahum et al 2008). 
 Derivative therapy (artesunate, artemisinin and artemether) were pooled in 
order to compare the rapidity of clearance of Plasmodium falciparum parasitaemia 
and the incidence of reported adverse events with each treatment. Data from patients 
who received comparator treatment (parenteral artemisinin derivative or quinine) 
were also included. Primary endpoints included percentage reductions in parasitaemia 
at 12 and 24 hours. A parasite reduction of >90% at 24 hours was defined as 
parasitological success. Artemisinin and artesunate treatment cleared parasites more 
rapidly than parenteral quinine during the first 24 hours of treatment. A single higher 
dose of rectal artesunate treatment was five times more likely to achieve >90% 
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parasite reductions at 24 hours than were multiple lower doses of rectal artesunate, or 
a single lower dose administration of rectal artemether (Gemos M et al 2008). 
Rapid parasite and fever clearance was observed in also a study in 
Bangladesh. Investigators determined the baseline therapeutic efficacy of artemether-
lumefantrine used as a six-dose regimen. The cure rate in a 42-day follow-up after an 
adjustment by polymerase chain reaction was 94.3%. The treatment led to rapid fever 
(mean +/- SD = 25.82 +/- 12.14 hours) and parasite (30.36 +/- 19.43 hours) clearance. 
(Hague R et al 2007). 
In the present study fever clearance time was not interpretative because 
antipyretic was given to all febrile cases, during follow up days. Unlike the upper 
mentioned study, fever clearance time was determined by the effect of antimalarial 
only.  
Artemisinin derivatives as mentioned above has rapid parasite clearance, fever 
clearance and safe as well as, it lead to reduction of gametes –the infectious stage- 
which consequently lead to reduction of transmission. During follow up period of the 
present study, no gametocytes were appeared in blood smears of the patients. This 
agreed with other reports before:   
Qinghaosu or artemisinin has been found not to kill only asexual blood stage 
only but also the early stages of blood gametocytes. Gametocytocidal effect may play 
a role in interruption of malaria transmission (Kumar N & Zerg H.1990). 
The combined treatment of artesunate + sulfadoxine /pyrimethamine in 
Gambian children was safe, well tolerated, and effective. The addition of artesunate to 
malaria treatment regimens in Africa results in lower gametocyte rates and may lower 
transmission rates (Lorenz von Seidlen et al 2000). 
Results of study also complied with obtained local results reported (The 
frequencies of gametocytaemia during follow-up were, however, much lower in the 
ASP arm than in the SP-only, 0.0% v. 23.3% (Adam I et al 2005). 
It also complied with other internal study, which reported (No 
gametocytaemia were observed during the follow-up of patients, mild adverse effects; 
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nausea, vomiting, abdominal pain, dizziness and/or rash were detected in 14 patients 
(Ibrahim et al 2007). 
In extracted data compared sulfadoxine-pyrimethamine plus amodiaquine 
(SP plus AQ) with sulfadoxine-pyrimethamine plus artesunate (SP plus AS) for 
treatment of uncomplicated Plasmodium falciparum malaria. Investigators searched 
the Cochrane Infectious Diseases Group Specialized Register (October 2005), (The 
Cochrane Library 2005, Issue 4), MEDLINE (1966 to October 2005), EMBASE 
(1988 to October 2005), LILACS (October 2005), and reference lists. SP plus AS was 
more effective at reducing gametocyte carriage at day seven. SP plus AQ performed 
better in controlling treatment failure at day 28, but was not as good as SP plus AS at 
reducing gametocyte carriage at day seven. Data on adverse events are still lacking 
(Bukirwa H, Critchley J 2006). 
Similar findings were obtained from 6 trials in Kenya and Gambia, where 
researchers reported that: Artemisinin combination therapies ACT are more effective 
against sexual stage parasites (gametocytes), than previous first-line. The presence of 
slide-positive gametocytaemia prior to treatment significantly reduced ACT impact on 
gametocytaemia. Taking account of submicroscopic gametocytaemia reduced 
estimates of ACT impact in a high transmission setting in Kenya, but not in a lower 
transmission setting in the Gambia. Rapid treatment of cases before gametocytaemia 
is well developed may enhance the impact of ACT on transmission (Okell L C et al 
2008) 
In other study in Sudan, the investigators evaluated the addition of 
gametocytocidal drug such as primaquine to artemisinin combination therapy (ACT) 
in areas of seasonal malaria transmission, by treatment of asymptomatic carriers of 
malaria parasites, whose parasitaemia persists at low densities throughout the dry 
season.  Participants were randomized to receive artesunate/sulfadoxine-
pyrimethamine (AS+SP) combination for three days with or without a dose of 
primaquine (PQ) on the fourth day. Addition of primaquine to artemisinin 
combination treatment did not improve elimination of parasitaemia and prevention of 
gametocyte carriage (Elsayed B et al 2007).  
Investigators in the upper mentioned study in Sudan found the addition of 
primaquine did not improve elimination of parasitaemia and prevention of carriage in 
52 
 
carriers, not agreed with reseachers in Thailand, who recommended addition of 
primaquine to Artemisinin-based combination therapy (ACT), and reported that; 
although all patients were negative for asexual parasites by day 7 after completion of 
the artesunate-mefloquine course, gametocytemia persisted in some patients. Thus, a 
gametocytocidal drug, e.g., primaquine, may be useful in combination with an 
artesunate-mefloquine regimen to clear gametocytes, so blocking transmission more 
effectively than artesunate alone, in malaria transmission areas (Tangpukdee N et al 
2008). 
It is of interest to mention that, during follow period, no serious adverse 
reactions were observed, in children or in adults. Except mild side effects; such as 
nausea, skin rash with artesunate + sulfadoxine\pyrimethamine reported in (1.9%) of 
patients. Slightly serious ones and frequent associated with artemether\lumefantrine 
observed in (4.3%) of the patients; such as abdominal pain, dizziness and sleep 
disorders. All side effects disappeared during follow up period without treatment and 
with no need to discontinue the test. Observations of the present study regarding ACT 
safety, complied with others, with reports; (Artemisinin, artesunate and artemether are 
well-tolerated in both adults and children, with no evidence to date of serious clinical 
toxicity. (Price RN 2008). 
 It complied also with a study in Senegal assessed efficacy and safety of 
different artemisinin combination, reported that: (No unexpected side-effect was 
observed and all side-effects disappeared at the end of treatment. No serious side-
effect requiring premature termination of treatment was observed (Faye B et al 2007 
b). 
It complied with a local study reported that: Adverse effects of treatment; 
nausea, itching and giddiness were observed with similar frequencies in the two 
treatment arms,10.0% of the patients given Artesunate +Sulfadoxine\pyrimethamine 
ASP v. 13.3% of the patients given sulfadoxine/pyrimethamine alone. (Adam I et al 
2005 b) 
Adverse effect in the present study was consistent with findings of other local 
study, assessed efficacy and safety of artesunate + sulfadoxine/pyrimethamine versus 
artesunate + amodiaquine, mild adverse effects nausea, vomiting, abdominal pain, 
dizziness and/or rash, were detected in 14 patients. (Ibrahim AM et al 2007)   
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It complied also with earlier report; Qinghaosu or artemisinin derivatives are 
very well tolerated and there is no evidence of serious clinical toxicity in man. The 
neurotoxicity seen in animals after high doses of certain compounds has not been 
reported in humans (Ambriose Thomas P 1999). 
Observations of the present study were constant with a study conducted in 
2001 in Peru on the northern Pacific Coast, investigators assessed the frequency of 
new or worsening symptoms after starting sulfadoxine/pyrimethamine with artesunate 
(SP-AS),. Over a period of two years, 8.8% reported at least one adverse effect, with 
the most common being vomiting, nausea, headache, abdominal pain, dizziness, and 
fever; no severe adverse effects related to SP-AS therapy were identified. (Cairo J et 
al 2008) 
It complied with other study in Ghana, researchers assessed efficacy and 
safety of artesunate-amodiaquine (AS+AQ) and artemether-lumefantrine (AL). 
Adequate clinical and parasitological response in subjects: 
 94.2% and 95.3% on day 28 in the AL and AS+AQ groups, respectively.The 
incidence of adverse events, such as pruritus, fatigue and neutropaenia were similar in 
the two treatment groups. No patient showed signs of hearing impairment, and no 
abnormal neurological signs were observed during one year of follow-up. Other 
adverse events were mild in intensity and overlapped with known malaria symptoms. 
No adverse event exacerbation was observed in any of the subjects who received 
multiple treatment courses with these ACT regimens during one year follow-up. 
(Adjei GO et al 2008) 
No cardiac abnormalities were observed in patients of the present study 
accompanied the use of artemether/lumefantrine. Unlike a report of QTC 
prolongations, in a study in Thailand, in which investigators assessed the efficacy-
safety and pharmacokinetics of the six-dose regimen of artemether-lumefantrine and 
mefloquine\artesunate in randomized trial. Both drugs induced rapid clearance of 
parasites and malaria symptoms. The 28-day cure rates were 95.5% for artemether-
lumefantrine and 100% for mefloquine-artesunate. The most frequent adverse events 
were headache, dizziness, nausea, abdominal pain, dyspepsia, vomiting, and skin rash. 
Overall, only 2% of patients in both groups showed QTc prolongations but without 
any cardiac complication, and no differences were seen between patients with and 
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without measurable baseline plasma levels of quinine or mefloquine. Plasma levels of 
artemether, dihydroartemisinin, and lumefantrine were consistent with historical data 
for the same dose regimen (Lefèvre G et al 2001) 
Longer period of follow up, determined serious adverse effect as reported in 
Mpumalanga province, South Africa. Where a pharmacovigilance system was 
developed, detected serious adverse drug reactions (ADRs) and signals related to 
artesunate plus sulfadoxine/pyrimethamine.   During home follow-up visits of 
reported cases of malaria, three fatal adverse events were identified where recent use 
of artesunate plus sulfadoxine/pyrimethamine treatment was reported. Two cases were 
attributed to poor response to treatment, while one case was considered possibly 
related to artesunate plus sulfadoxine/pyrimethamine treatment. Clinic and hospital 
surveillance reported six ADRs in association with ulfadoxine/pyrimethamine 
treatment, five being treatment failures and one being a non-serious rash. During 
active hospital surveillance, 38 inpatients exposed to sulfadoxine/pyrimethamine were 
identified, including one child who experienced pancytopenia following treatment 
with sulfadoxine/pyrimethamine 11 days before admission; this adverse effect was 
considered to be possibly due to sulfadoxine/pyrimethamine treatment. The 
confidential enquiry into malaria-related deaths identified three adverse events, 
including a death where the contribution of treatment could not be excluded. A 
therapeutic efficacy study of 95 patients followed over 42 days identified one case of 
repeated vomiting possibly associated with artesunate + sulfadoxine/pyrimethamine. 
(Branes KI et al 2007). 
The use of ACTs improved haemoglobin level, as showed in a study in 
Tanzania, on the efficacy and safety of artesunate plus amodiaquine (AS+AQ) and 
artemether plus lumefantrine (AL)(Coartem). Efficacy after PCR adjustments the 
corresponding figures raised to 100% and 93.8% in AL and AS+AQ groups, 
respectively. The mean haemoglobin improved moderately from day 0 to day 28 by 1 
g/dl in AL and 0.4 g/dl in AS+AQ in both treatment groups and was statistically 
significant (p < 0.001) (kabanywanyi et al 2007). 
Haemoglobin level was not measured in the present study, it considered as one 
limitation, since malaria associates with reduction of haemoglobin, even develop 
anemia in some patients.   
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Although artemisinin combination therapies ACTs were highly effective, safe, 
well tolerated and reduced malaria transmission.  Therefore, they considered to be the 
best choice in the treatment of uncomplicated malaria, as shown in the upper 
mentioned similar studies. The selection of the partner drug must follow certain 
measures and criteria to protect the combination from resistance development, and to 
prolong the lifespan. Although there were no evidence of resistance to ACTs, but 
recently, researchers reported emergence of resistance due to some factors as below; 
Investigators in Mali, compared the efficacy and safety of artesunate (AS) + 
amodiaquine (AQ) versus AS + sulfadoxine-pyrimethamine versus AS monotherapy. 
Molecular markers of drug resistance were determined. After identification of 
recrudescence by genotyping, both artemisinin-based combination therapies (ACTs) 
reached at Day 28 versus 98.3% and 96.5% for AS, respectively. AS + SP 
significantly selected DHFR and DHPS mutations associated with sulfadoxine and 
pyrimethamine resistance, and AS + AQ equally selected PfCRT and PfMDR1 point 
mutations associated with chloroquine and AQ resistance. No significant adverse 
event attributable to any of the study drugs was found. The ACTs were efficacious 
and safe, but the selection of markers for resistance to the partner drugs raises 
concerns over their lifespan in areas of intense malaria transmission (Djimide et al 
2008). 
In a study, in Cambodia, also investigators reported a risk of emergence 
resistance, due to some contributory factors. They determined the efficacy of 
mefloquine/artesunate, in falciparum malaria and chloroquine in vivax malaria. 
Among P. falciparum infected subjects, the PCR corrected treatment failure rates 
determined by survival analysis at 28 and 42 days were 13.1% and 18.8%, 
respectively. Treatment failure was associated with increased pfmdr1 copy number, 
higher initial parasitaemia, higher mefloquine IC50, and longer time to parasite 
clearance. One P. falciparum isolate, from a treatment failure, had markedly elevated 
IC50 for both mefloquine (130 nM) and artesunate (6.7 nM). Among P. vivax infected 
subjects, 42.1% suffered recurrent P. vivax parasitaemia. None acquired new P. 
falciparum infection. The results suggest that artesunate-mefloquine combination 
therapy is beginning to fail in southern Cambodia and that resistance is not confined 
to the provinces at the Thai-Cambodian border. It is unclear whether the treatment 
failures are due solely to mefloquine resistance or to artesunate resistance as well. The 
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findings of delayed clearance times and elevated artesunate IC50 suggest that 
artesunate resistance may be emerging on a background of mefloquine resistance 
(Rogers WO et al 2009) 
In a local study conducted Nuba mountain region, assessed efficacy of artesunate+ 
SP, amodiaquine + artesunate and chloroquine, also investigators analyzed pre-
treatment blood samples for mutations at the P. falciparum chloroquine transporter 
(Pfcrt) gene (associated with CQ resistance), and at the dihydrofolate reductase (Dhfr) 
gene (associated with pyrimethamine resistance). The Pfcrt K76T mutation occurred 
in 90.0% of infections, suggesting CQ would work poorly in this region. Overall, 
82.5% carried mutations at Dhfr (N51I, C59R or S108N, but not I164L), but triple 
mutants (more predictive of in vivo SP failure) were rare (3.1%). (Hamour S et al 
2005).  
As shown in the present study the change of malaria treatment from 
ineffective, cheap monotherapies as chloroquine, to effective but expensive 
combinations ACTs. The implementation of new treatment policy requires many 
activities; it was not an easy process, to ensure the rational use through out the 
country, of course many challenges and obstacle around. The activities which 
accompanied the new drug policy as:  formulations of plans to ensure the availability 
and accessibility of the new combinations to those who are poor and sick 
communities via opportunity as global fund, it the most difficult task in a wide 
country with poor resources as Sudan. The local situation is typical as many endemic 
countries as reported: (Most malaria-endemic countries in Africa and Asia have 
adopted artemisinin combination therapy (ACT) as antimalarial drug policy. Several 
ACT drugs exist and others are in the pipeline. If properly targeted, they have the 
potential to reduce mortality from malaria substantially. The major challenge now is 
to get the drugs to the right people. Current evidence suggests that most of those who 
need the drugs do not get them. Simultaneously, a high proportion of those who are 
given antimalarials do not in fact have malaria. Financial and other barriers mean that, 
in many settings, the majority of those with malaria, particularly the poorest, do not 
access formal healthcare, so the provision of free antimalarials via this route has only 
limited impact. The higher cost of ACT creates a market for fake drugs. Addressing 
these problems is now a priority) (Whitty CJ et al 2008). 
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Implementation of the new treatment policy in Sudan, needed hard work such 
as:  training and strengthening of capacity building, avail of combination through 
global fund opportunity, establishment of post marketing surveillance system PMS 
and pharmacovigilance system with coordination with medicines regulatory 
authorities and operational researches on monitoring new combinations efficacy. All 
those activities besides controlling of malaria by vector control by distribution of 
insecticide treated nets through approved plans. Rise of community awareness by 
health education programmes. Difficulties in the implementation phase were constant 
with other reports:         
Despite being recommended by WHO since 2001, overall deployment of ACT 
has been slow. Limiting factors are high cost, limited knowledge and public 
awareness on the concept of combination therapy (CT) and ACT in particular, limited 
knowledge on safety of ACTs in pregnancy, operational issue such as inappropriate 
drug use, lack of suitable drug formulations, lack of post-marketing surveillance 
(PMS) systems, and the imbalance between demand and supply. Through concerted 
efforts of multilateral organizations, the local scientific community with involvement 
of policy-makers progress has been on several fonts leading to improved ACT uptake 
rates in the last 2 years. Of 43 countries that had adopted ACT by February 2005, 18 
(42%) adopted the policy in 2004. Preference to co-formulated 
artemether/lumefantrine has led to a surge in its demand with consequent shortage. 
Alternative ways for increased production of ACTs are urgently needed otherwise 
most policies will remain adopted on paper. Despite limitations, opportunities are 
opening up for effective malaria control. Insecticides, insecticide-treated nets (ITNs) 
and ACTs are proven efficacious controls available that should be accessed by many. 
Substantial funding is now available for biomedical malaria research and for policy 
implementation. While the Global Fund is the financial engine behind the scaling up 
of ACT uptake, delays in cash flow after grant approval has led to many countries 




2.1.1       Biopharmaceutics 
The physiochemical characteristics of active pharmaceutical ingredient (API), 
the dosage form or the medicine, and the route of administration are critical 
determinants of the in-vivo performance, safety and efficacy of the drug 
product. The properties of the drug and its dosage form are carefully 
engineered and tested to produce stable drug product that upon administration 
provides the desired therapeutic response in the patient. Both pharmacist and 
the pharmaceutical scientist must understand these complex relationships to 
comprehend the proper use and development of pharmaceuticals.  
To illustrate the importance of the drug substance and the drug formulation on 
absorption and distribution of the drug to the site of action, one must first 
consider the sequence of events that precede elicitation of a drug therapeutic 
effect. First, the drug in its dosage form is taken by the patient either by an 
oral, intravenous, subcutaneous, transdermal, etc.., route of administration. 
Next, the drug is released from the dosage form in a predictable and 
charcterizable manner. Then, some fraction of the drug is absorbed from the 
site of administration into either the surrounding tissue, into the body (as with 
oral dosage form), or both. Finally, the drug reaches the site of action.  If a 
drug concentration, at the site of action exceeded the minimum effective 
concentration (MEC), a pharmacological response results. The actual dosing 
regimen (dose, dosage form, dosing interval) was carefully determined in 
clinical trials to provide the correct drug concentrations at the site of action. 
This sequence of events is profoundly affected – in fact, sometimes 
orchestrate- by the design of dosage form, the drug itself or both.  
Historically, pharmaceutical scientists have evaluated the relative drug 
availability to the body in-vivo after giving a drug product to an animal or 
human, and then comparing specific pharmacologic, clinical, or possible toxic 
responses. In addition, the bioavailability (a measure of systemic availability 
of a drug) may differ from one product to another containing the same drug, 
even for he same route of administration. This difference in the drug 
bioavailability may manifested by observing the difference in the therapeutic 
59 
 
effectiveness of a drug product. In other words, the nature of the drug 
molecule, the route of delivery, and the formulation of dosage form can 
determine whether an administered drug is therapeutically effective, toxic, or 
has no apparent effect al all. 
Biopharmaceutics is the science that examines this interrelationship of the 
physiochemical properties of the drug, the dosage form in which the drug is 
given, and the route of administration and the extent of systemic drug 
absorption. Thus Biopharmaceutics involves factors that influence (1) the 
stability of the drug within drug product, (2) the release of the drug product (3) 
the rate of dissolution/release of the drug to at the absorption site, and (4) the 
systemic absorption of the drug. .(Shargel L, et al 2005)                   
2.1.2       Pharmacokinetics  
After the drug is released from its dosage form, the drug is absorbed into the 
surrounding tissue, the body, or both. The distribution through and elimination 
of the drug in the body varies for each patient but can be characterized using 
mathematical models and statistics. Pharmacokinetics is the science of the 
kinetics of drug absorption, distribution, and elimination (ie, excretion and 
metabolism). The description of a drug distribution and elimination is often 
termed drug disposition. Characterization of drug disposition is an important 
prerequisite for determination or modification of dosing regimens for 
individuals and groups of patients. The study of pharmacokinetics involves 
both experimental and theoretical approaches. The experimental aspect of 
pharmacokinetics involves the development of biologic sampling techniques, 
analytical methods for measurement of drugs and metabolites, and procedures 
that facilitate data collection and manipulation. The theoretical aspect of 
pharmacokinetics involves the development of pharmacokinetic models that 
predict drug disposition after drug administration. The application of statistics 
is an integral part of pharmacokinetic studies. Statistical methods are used for 
pharmacokinetic parameter estimation and data interpretation ultimately for 
the purpose of designing and predicting optimal dosing regimens for 
individuals or groups of patients. Statistical methods are applied to 
pharmacokinetic models to determine data error and structural model 
deviations. Mathematics and computer techniques form the theoretical basis of 
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many pharmacokinetic methods. Classical pharmacokinetics is a study of 
theoretical models focusing mostly on model development and 
parameterization. .(Shargel L, et al 2005)                       
2.1.3      Clinical pharmacokinetics 
During drug development process, large numbers of patients are tested to 
determine optimum dosing regimens which are then recommended by 
manufacturer to produce the desired pharmacologic response in the majority of 
the anticipated patient population. However, intra- and interindividual 
variations will frequently results in either a sub therapeutic or toxic response, 
which may then require adjustment to dosing regimens. Clinical 
pharmacokinetics is application of pharmacokinetics methods to drug therapy. 
Clinical pharmacokinetics involves a multidisciplinary approach to 
individually optimized dosing strategies based on the patient’s disease state 
and patients – specific consideration. 
Pharmacokinetics is also applied to therapeutic drug monitoring for very 
potent drug such as those with a narrow therapeutic range, in order to optimize 
efficacy and to prevent any adverse toxicity. For these drugs, it is necessary to 
monitor the patient, either by monitoring drug plasma concentration (eg, 
theophylline) or by monitoring a specific pharmacodynamic endpoint such as 
prothrombin clotting time (eg, warfarin). Pharmacokinetic and drug analysis 
services necessary for safe drug monitoring are generally provided by the 
clinical pharmacokinetics services. Some drugs frequently monitored are the 
aminoglycosides and anticonvulsants. Others drugs closely monitored are 
those used in cancer chemotherapy, in order to minimize adverse 
effects.(Shargel L, et al 2005)                       
2.1.4       Pharmacodynamic  
Pharmacodynamic refers to the relationship between the drug concentration at 
the site of action (receptor) and the pharmacologic response, including 
biochemical and physiologic effects that influence the interaction of the drug 
with the receptor. The interaction of the drug molecule with the receptor 
causes the initiation of a sequence of molecular events resulting in a 
pharmacologic or toxic response. Pharmacokinetic- pharmacodynamic models 
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are constructed to relate plasma drug level to drug concentration in the site of 
action and establish the intensity and time course of the drug. .(Shargel L, et al 
2005)                      
2.1.5       Measurement of Drug concentrations 
Because drug concentrations are important element in determining individual 
or population pharmacokinetics, drug concentrations are measured in biologic 
samples, such as milk, saliva, plasma, and urine. Sensitive, accurate, and 
precise analytical methods are available for direct measurement of drugs in 
biologic matrices. Such measurement are generally validated so that accurate 
information is generated for pharmacokinetic and clinical monitoring. In 
general, chromatographic methods are most frequently employed for drug 
measurement, because chromatography separates the drug from other 
materials that may cause assay interference. .(Shargel L, et al 2005)                       
2.1.6       Sampling of Biologic Specimens 
Only a few biologic specimens may be obtained safely from the patient to gain 
information as to the drug concentration in the body. Invasive methods include 
sampling blood, spinal fluid, synovial fluid, tissue biopsy, or biologic material 
that requires parenteral or surgical intervention in the patient. In contrast, 
noninvasive methods include sampling of urine, saliva, feces, expired air, or 
any biologic material that can be obtained without parenteral or surgical 
intervention. The measurement of drug and metabolite concentration in each 
of these biologic materials yields important information, such as the amount of 
drug retained in, or transported into, the region of the tissue or fluid, the likely 
pharmacologic or toxicologic outcome of drug dosing and metabolite 
formation or transport.(Shargel L, et al 2005)                       
2.1.7       Drug Concentration in Blood, plasma or Serum 
Measurement of drug concentration (levels) in blood, serum or plasma is the 
most important direct approach to assessing the pharmacokinetics of the drug 
in the body. Whole blood contains cellular elements including red blood cells, 
white blood cells, platelets, and various proteins, such as albumins and 
globulins. In general, serum or plasma is most commonly used for drug 
measurement. To obtain serum, whole blood is allowed to clot and the serum 
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is collected from the supernatant after centrifugation. Plasma is obtained from 
supernatant of centrifuged whole blood to which an anticoagulant, such as 
heparin, has been added. Therefore, the protein content of serum and plasma is 
not the same. Plasma perfuses all tissues of the body, including the cellular 
elements in the blood. Assuming that a drug in the plasma is in dynamic 
equilibrium with tissues, then changes in the drug concentration in plasma will 
reflect changes in the tissue drug concentration. (Shargel L, et al 2005) 
2.1.8       Plasma Level-Time Curve 
The plasma level-time curve is generated by obtaining the drug concentration 
in plasma samples taken at various time intervals after a drug product is 
administered. The concentration of a drug is plotted on rectangular-coordinate 
graph paper against the corresponding time at which the plasma samples was 
removed. As a drug reaches the general (systemic) circulation, plasma drug 
concentration will rise up to a maximum. Usually, absorption of a drug is 
more rapid than elimination. As the drug is being absorbed into the systemic 
circulation, the drug is distributed to all the tissues in the body and also 
simultaneously being eliminated. Elimination of a drug can proceed by 
excretion, biotransformation or a combination of both. 
The relationship of the drug level-time curve and various pharmacologic 
parameters; MEC and MTC represent the minimum effective concentration 
and minimum toxic concentration of a drug, respectively. The onset of time 
corresponds to the time required for the drug to reach the MEC. The intensity 
of pharmacologic effect is proportional to the number of a drug receptors 
occupied, which is reflected in observation that higher plasma drug 
concentration produce greater pharmacologic response, up to a maximum. The 
duration of drug action is the difference between the onset time and the time 
for the drug to decline back to the MEC. The peal time is time of maximum 
drug concentration the plasma and is a rough marker of average rate of drug 
absorption. The peak concentration is maximum drug plasma concentration 
and is related to the dose, the rate constant for absorption, and the elimination 
constant of the drug. The area under the curve AUC is related to the amount 
of a drug absorbed systemically.  
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2.1.9     Pharmacokinetics of Oral absorption 
The pharmacokinetics of drugs following intravenous administration is 
simpler to model compared to extravascular delivery. Extravascular delivery 
routes, particularly oral dosing, are important and popular means of drug 
administration. Pharmacokinetic models after extravascular administration 
must consider systemic drug absorption from the site of administration, eg, the 
lung, gut, etc…. to the plasma. Extravascular delivery is further complicated 
by variables at the absorption site including possible drug degradation and 
significant inter- and interpatient differences in the rate and extent of 
absorption. The variability in systemic drug absorption can be minimized to 
some extent by proper Biopharmaceutics design of dosage form to provide 
predictable and reliable therapy. 
The systemic drug absorption from gastrointestinal tract (GI) or from any 
other extravascular site depends on (1) the physiochemical properties of the 
drug, (2) the dosage form, and (3) the anatomy and physiology of the 
absorption site. For oral dosing other factors affect rate and extent of 
absorption such as surface area of GI tract, stomach emptying rate, GI 
mobility and blood flow. In pharmacokinetics, the overall rate may be 
described as either a first-order or zero-order input process. Most 
pharmacokinetics models assume first order absorption unless an assumption 
of zero-order absorption improves the model significantly or has been verified 
experimentally. (Shargel L, et al 2005)                            
2.1.10    Overview of Global Studies of Artemisinins Pharmacokinetics  
Artemisinin and its derivatives, artesunate and artemether, represents a new 
class of antimicrobial drug, with potent activity against Plasmodium 
falciparum. Although they show excellent efficacy in both severe and 
uncomplicated malaria, dosage regimens still need to be optimized and 
pharmacokinetic profiles defined. In the treatment of uncomplicated malaria, 
the artemisinin drugs should be used in combination with a long acting 
antimalarial to protect both drugs against the emergence of resistance. In the 
treatment of severe malaria, parenteral artemether is at least as effective as 
quinine and is simpler to use. The rectal preparations of artesunate and 
artemisinin at the rural health level will facilitate early initiation of treatment 
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of falciparum malaria and this may reduce the proportion of patients 
progressing to severe illness. All of the artemisinin drugs have comparable 
efficacy, the choice of derivative should be based upon availability, cost and 
quality of the preparation. Artemisinin, artesunate and artemether are well-
tolerated in both adults and children, with no evidence to date of serious 
clinical toxicity.    
(Price RN 2000). 
(Liu S et al 2009) reported that; (Malaria threatens 300-500 million people and 
kills more than one million people world-wide annually. Artemisinin has been 
widely used as part of the artemisinin-based combination therapies against 
malaria. However, its supply is seriously short due to very small amounts of 
production of artemisinin in Artemisia annua. Molecular biologic researches 
aimed at increasing the artemisinin yield in plant have received more and more 
attention and therefore corresponding quantification methods for artemisinin 
analysis are urgently needed. A variety of methods for determination of 
artemisinin have been developed but they cannot be applied when only very 
little plant material is available or the material should be kept live, which often 
occurs in molecular biologic researches. Investigators developed a simple, fast 
and low toxic micro-scale analysis procedure for determination of artemisinin 
in a single leaf or flower of living Artemisia annua using improved gas 
chromatography with electron-capture detection. The recovery of >95% was 
achieved by vortex of a piece of fresh leaf in 1 mL ethyl acetate for 2 min at 
room temperature. This method provides a powerful tool for biosynthesis 
study of artemisinins, high-throughput screening high-yield clone in an early 
stage, or real-time quality control of Artemisia annua crop). (Liu S et al 2009).   
Investigators in China compared the kinetics parameters of the herbal leaves 
of Artemisia annua L. (annual wormwood) which contains the antimalarial 
artemisinin, to the modern solid dosage forms of artemisinins and reported the 
following; (Aqueous preparations of the dried herb are included in the 
pharmacopoeia of the People's Republic of China for treatment of fever and 
malaria. Fourteen healthy male volunteers received one liter of tea prepared 
from nine grams of Artemisia annua leaves. Blood samples were taken and 
artemisinin was detected by reversed phase high-performance liquid 
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chromatography. The mean +/- SD maximum plasma concentration of 
artemisinin was 240 +/- 75 ng/mL and the mean +/- SD area under the plasma 
concentration-time curve was 336 +/- 71 ng/mL x hr. Artemisinin was 
absorbed faster from herbal tea preparations than from oral solid dosage 
forms, but bioavailability was similar. One liter of an aqueous preparation of 
nine grams of Artemisia annua contained 94.5 milligrams of artemisinin 
(approximately 19% of the usually recommended daily dose). Artemisinin 
plasma concentrations after intake of this herbal tea are sufficient for clinical 
effects, but insufficient to recommend such preparations as equivalent 
substitutes for modern artemisinin drugs in malaria therapy) (Räth K et al 
2004) 
In a study in Sweden, investigators aimed to assess the inductive properties of 
artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and 
CYP2C19 enzymatic activity. The population pharmacokinetics of S-
mephenytoin and its metabolites S-nirvanol and S-4'-hydroxymephenytoin, 
including enzyme turn-over models for induction, were described by nonlinear 
mixed effects modeling. Rich data (8-16 samples/occasion/subject) 
investigators collected from 14 healthy volunteers who received mephenytoin 
before and during ten days of artemisinin administration. Sparse data (3 
samples/occasion/subject) were collected from 74 healthy volunteers who 
received mephenytoin before, during and after five days administration of 
artemisinin, dihydroartemisinin, arteether, artemether or artesunate. The 
production rate of CYP2B6 was increased 79.7% by artemisinin, 61.5% by 
arteether, 76.1% by artemether, 19.9% by dihydroartemisinin and 16.9% by 
artesunate. The production rate of CYP2C19 increased 51.2% by artemisinin, 
14.8% by arteether and 24.9% by artemether. Investigators concluded, all 
studied artemisinin derivatives induced CYP2B6. CYP2C19 induction by 
arteether and artemether as well as CYP2B6 and CYP2C19 induction by 
artemisinin was confirmed. The inductive capacity is different among the 
artemisinin drugs, which is of importance when selecting drugs to be used in 
antimalarial combination therapy such that the potential for drug-drug 
interactions is minimized (Elsherbiny DA et al 2008) 
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Researchers in Western Australia, assessed the effect of mefloquine on 
artesunate pharmacokinetics in 20 volunteers given artesunate for 3 days, 
followed > or =21 days later by combination therapy for 3 days. The areas 
under the concentration-time curve from 0 h to infinity for 
dihydroartemesinin, the active metabolite of artesunate, were similar on day 3 
of the two dosing periods (P = 0.12), implying no interaction (Davis TM et al 
2008) 
Rectal administration of artemisinin derivatives is a potentially lifesaving 
emergency treatment of severe malaria. Many different preparations are 
marketed in tropical countries, but their pharmacokinetic disposition and 
clinical efficacy may vary. To review the pharmacokinetics, efficacy, and 
safety of rectally administered artesunate, artemisinin, dihydroartemisinin, and 
artemether. Investigators searched the following data source MEDLINE, 
EMBASE, Cochrane Database of Clinical Reviews, Global Health, Web of 
Science, and CINAHL computerized databases up to December 2006, along 
with reviewing unpublished data from conference proceedings, pharmaceutical 
companies, and regulatory applications. The researchers were included all 
studies involving rectal administration of an artemisinin derivative to healthy 
volunteers or patients with measurement of plasma drug concentrations or 
rates of initial parasite clearance. Both single-arm and comparative trials were 
included. The extracted data showed: Forty-five studies were identified, of 
which 39 eligible studies were included in the review. Primary efficacy 
outcome measures included parasite density as a percentage of baselines at 12 
and 24 hours following the first dose. Pharmacokinetic variables included 
maximum plasma concentration (C (max), time to C (max) (T (max)), and area 
under the plasma concentration-time curve (AUC). Weighted means were 
calculated from available data. Thirty-two studies provided valid clinical 
efficacy data: 19 of artesunate, 10 of artemisinin, 2 of dihydroartemisinin, and 
1 of artemether. All demonstrated prompt parasite clearance, with evidence of 
a dose-dependent effect for artesunate. Mortality rates in severe malaria 
(weighted means, 0%-13%) were consistent with those expected. Eight studies 
compared rectal artemisinin with conventional parenteral treatment (quinine, 
artemether, or artesunate) for severe malaria. Despite similar clinical 
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outcomes, rectal artemisinin derivatives initiated parasite clearance more 
rapidly than parenteral treatment (percentage of baseline at 12 hours, < or 
=27% vs > or =56%, respectively). Eighteen pharmacokinetic studies were 
identified, including 13 of artesunate. There was marked interindividual 
variability in most pharmacokinetic variables, but artesunate achieved an 
earlier T (max) and higher C (max) and area under the plasma concentration-
time curve than other artemisinin derivatives. Available rectal preparations of 
artemisinin derivatives differ in their pharmacokinetic disposition. Most 
available evidence pertains to artesunate and artemisinin. Despite marked 
interindividual variability in bioavailability, rectal preparations appear to have 
acceptable therapeutic efficacy, including in severe illness (Karunajeewa HA 
et al 2007). 
2.1.11  Objectives 
General objective; 
To determine the pharmacokinetics parameters of the first line 
antimalarial drug, artesunate plus sulfadoxine /pyrimethamine in 
healthy Sudanese volunteers.  
Specific objectives:  
To obtain local data on pharmacokinetics parameters concerning 
artesunate alone and in combination with sulfadoxine/pyrimethamine 
To compare the drug half-life, volume of distribution, drug 
concentration and clearance in healthy volunteers with results of 
similar studies in other countries. 
To assess the effect of gender, weight, and Sudanese diet on 
pharmacokinetics parameters of the new combination. 
To investigate the rational of the current dose of the first line or 








2.2.1     Study area 
The study was conducted during the time March to May /2007, in Khartoum 
city, the capital of Sudan which is located in the area around the conjunction 
of the White Nile and Blue Nile to form the River Nile. In terms of climate the 
period of the study was during summer, the temperature ranged between 30 
degree centigrade during night and 37 degree centigrade at day time.  
Different racial groups were residing in Khartoum city. The subjects were 
selected from one race that belongs to Arabs tribes, not pure Arabs as the 
majority of Sudanese are mixture of different Nubian tribes and Arabs. 
2 points were selected for the conduction of the laboratory work. The first 
point was laboratory of Ahmed Gasim Hospital for Open Heart Surgery which 
located in Khartoum north. The second point was the Pharmacology Research 
Laboratory – faculty of Pharmacy – Khartoum University. The 2 laboratories 
were well equipped and suitable for the needed experimental activities. 
2.2.2       Study population  
The study subjects were healthy volunteers selected according to the following 
inclusion criteria: 
• Their ages ranged between 20-40 years, both sexes. 
• With normal renal and hepatic functions 
• Free from infectious disease such as (malaria –HIV/AIDS- hepatitis) 
• With normal blood pressure, normal chest and abdomen on medical 
examination and with normal laboratory investigation results of blood 
chemistry analysis, not anaemic. 








Baseline characteristics for group 1 (males) 
No. Age /years Weight/kg Height/cm 
1 25 48 168 
2 22 78 175 
3 27 56 178 
4 24 78 185 
5 21 78 181 
6 23 74 174 
7 23 74 176 
8 22 48 170 
9 31 47 168 
 
Table 2.2.2 
Baseline characteristics for group-2 (females) 
No. Age /years Weight/kg Height/cm 
1 35 75 158 
2 20 64 167 
3 21 61 164 
5 20 59 165 
6 22 75 161 
8 22 57 166 












According to the above mentioned criteria 24 subjects (12 males + 12 females) 
were selected and screened medically and by laboratory investigations needed 
for determination of the healthy subjects. Of them 3 males and 3 females were 
excluded from the study after the investigations results , the 3 males were 
excluded due to clinical reasons where as the 3 females withdraw their consent 
voluntary. At the end 18 healthy volunteers were found to meet all of the 
inclusion criteria and included in the study, during the experimental 
procedures one of the females (no. 4) ended her consent voluntary, while 
another female (no.10) excluded for clinical reasons, so we remained with 7 
females and 9 males, a total of 16 volunteers who completed the experiment. 
 
The selection of volunteers was done by passing the following investigations 
and obtained normal limits: physical examination of chest and abdomen, blood 
pressure, urine general, blood film for malaria, blood morphology (HB%, 
TWBC, MCV, MCH, Platelets, lymph, polymorph, esino-baso-monophil), 
Renal Function test (serum blood urea, serum creatinin) and liver function test 
(serum total protein, serum albumin, serum total bilirubin, direct bilirubin, 
S.G.O.T and S.G.P.T) and virology tests for HIV/AIDS and hepatitis. The 
results of laboratory tests were summarized in following tables 3 and 4 
Table1, showed baseline characteristics for group 1, the males healthy 
volunteers, their ages ranged from 21 to 31 years with mean age 24 years +_ 











Investigation Results (males healthy volunteers)-group 1 
No. u c p a b d s S A Hb wbc mcv mch PLT L po ebm
1 25 0.6 71 43 0.5 0.4 10 15 172 90 3.3 84.1 28.2 144 70 21 9 
2 26 0.5 78 37 0.5 0.2 12 20 218 110 5.8 83.6 28.3  43 56 1 
3 19 0.8 76 38 0.2 0.1 8.4 15 190 104 5.2 80.7 28.7 253 50 44 6 
4 23 0.8 74 39 0.6 0.3 12 18 201 0.4 5.3 81.7 27.3  31 29 10 
5 30 0.9 80 40 0.5 0.3 39 15 149 108 4.8 90 30.4 235 44 52 4 
6 33 0.8 74 41 0.3 0.2 15 11 156 84 4.4 77 23 292 50 45 5 
7 34 0.7 75 43 0.2 0.1 10 17 206 95 5.7 86.1 27.4 298 38 56 6 
8 27 0.8 77 45 0.4 0.1 10 10.7 185 98 4.3 92 30 280 62 35 3 
9 30 1.0 75 43 0.4 0.1 9.0 10 156 104 4.7 88.9 29.2 208 52 52  
 
Table 2.2.4 
Investigation Results (females healthy volunteers)-group 2 
No. U c p a b d s S A Hb wbc mcv mch PLT L po ebm
1 22 0.9 61 43 0.5 0.3 10 34 176 72 5.3 74.8 21.5 290 48 51 1 
2 29 0.4 71 45 0.8 0.6 10 11 116 70 3.6 69.3 20.5 381 53 31 16 
3 28 0.5 70 42 0.9 0.7 20 21 120 78 5.6 83.6 26 249 48 52  
4 23 0.7 69 44 1.3 0.1 13 11 117 77 4.8 82.5 26.5 220 42 58  
5 22 1.4 70 48 0.3 0.1 18 10 165 84 4.5 85.6 279 268 52 40 8 
6 23 1 67 50 0.7 0.5 11 11.8 81 84 5.0 85.4 28.5 281 50 50  
8 22 0.5 70 43 0.2 0.1 10 17 58 74 4.3 82.6 25.6 178 46 52 2 
9 18 0.8 74 50 0.4 0.1 13 15 107 74 6.6 72.5 21.4 309 50 48 2 






All values of laboratory investigation results are shown on table 3 and 4, and 
all are within the normal reference values. Key of abbreviations of laboratory 
tests and their reference values are shown on table 5 page 73.  
 
Note:  
− Female no.7 withdrew her consent voluntary so we are remained with 9 
subjects; female no. 4 withdrew her consent voluntary during the 
procedures of the experiment and no.10 excluded for clinical reason on the 




− Investigation results were found to be within the normal values for every 
volunteer as well as the physical medical examinations for chest and 
abdomen was found to be clear. All volunteers were free from malaria, 
HIV/AIDS and hepatitis.      
− After all fulfilment of the volunteers all of inclusion criteria, the 
experiment was explained and written informed consent was taken from 
each one of the 18 volunteers (9 males and 9 females) then they enrolled in 




Key of laboratory investigation abbreviations & normal values: 
Abbreviation meaning Normal values 
u Urea 10 - 50 mg/dL 
c creatinin 0.4- 1.3 mg/dL 
p Total protein 60 – 80 g/L 
a Serum albumin 35 – 50 g/L 
b Serum bilirubin Up to 1.1 mg/L 
d Direct bilirubin 0.25 mg/dL 
s S.G.O.T 10- 50 microgram/L 
S S.G.P.T 10- 50 microgram/L 
A Alkaline phosphates Up to 258 microgram/L 
Hb hemoglobin 11- 16 g/dl 
wbc white blood corpuscles 3000- 9500 ul 




27- 31 pg 
PLT Plate lets 150 000- 450 000 
L lymphocytes 25 – 40% 
Po polymorph  











2.2.3    Study medical team 
− Medical doctor for checking the volunteers before and during the 
experiment 
− 2 laboratory technicians for taking blood samples and assist in labelling of 
the hepernized vials and cryo tubes , centrifugation and other laboratory 
work 
− 2 nurses who assist the technicians. Beside the principal investigator who 
managed all the procedures of the experimental work.   
2.2.4     Study design & procedure 
The study was experimental cross- over clinical trial for determination of the 
pharmacokinetic parameters of the first line antimalarial combination 
(artesunate + sulfadoxine/pyrimethamine) therapy in healthy Sudanese 
subjects, taking artesunate alone as monotherapy in the first round and in 
combination with sulfadoxine/pyrimethamine (SP) in the second round, with a 
wash out period of 3 weeks interval. The subjects were divided into 2 groups 
A & B. group A:  (males) healthy volunteers who were assigned for the first 
point -Ahmed Gasim Hospital Laboratory. 
While Group B was (females) healthy volunteers their point was 
Pharmacology Research Laboratory. All of the healthy volunteers agreed to 
follow the procedure of the study; they committed to have one type of meal 
and one type of soft drink on the day before and during the day of the 
experiment to control the conditions of the experiment.  
The tested drug on the first round was artesunate alone 200 mg in tablet form, 
each tablet contained 100 mg artesunate. Each volunteer prepared for the 
experiment by the nurse who put venous catheter, each one have a code 
number then all of them took 2 tablets with glass of water at one time, then 5 
ml of venous blood was taken by the technicians with a disposable syringe, the 
blood pushed into labelled hepernized vial to prevent coagulation. The 
experimental work started in early morning at 7.30 AM and the blood samples 
collection started at 8 AM and ends at 8 PM in 12 hours duration. Timing was 
controlled by a watch for accurate time interval as follows:  at zero time when 
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they swallowed the tablets, then after ½ an hour, one hour, 1.5 hour, 2.0 hour, 
2.5 hour, 3 hours later, 3.5 hours, 4 hours, 4.5 hours, 5 hours, 6 hours, 9 hours, 
and after 12 hours later. Each volunteer gave 14 blood samples. The 
hepernized blood samples were put into a centrifuge to separate the plasma 
from blood serum then the plasma took by a pipette and pushed into a labelled 
cryo-tube which took the volunteer code number ( from 1 to 9), sex code 
(F/M) drug code (AS) and the sample number code ( from 0 to 13). 
The second round was done after 3 week interval from the first round on the 
combination of artesunate and sulphadoxine/pyrimethamine (ASP). In that 2nd 
round 2 females were excluded from the study, one because of her illness 
during the time of study while the other withdrew her consent, so we remained 
with 7 females and 9 males, a total of 16 healthy volunteers for the second 
round. Each volunteer took 2 tablets of 100 mg/tab. + 3 tablets (SP -500 
sulfadoxine/25 pyrimethamine/tab.) the 5 tablets took at once with a glass of 
water, then all procedures of the first round were considered except in the 
combination therapy, we considered 24hours duration for blood sampling, so 
one more sample taken after 24 hours from the start of the experiment, so all 
volunteers came next day at 8 AM to give the last sample of blood, on that 
case each volunteer had 15 plasma samples. The plasma samples were 
collected in the labelled cryo tubes, the label took the volunteer code number 
(from 1 to 9) with exception of the 2 excluded females, sex (F/M), drug code ( 
CO) for combination, sample code (from 0 to 14). The collected plasma 
samples (480) cryo tubes were all put into -80 degree centigrade for 
preservation until the time of analysis by HPLC for determination of PK 
parameters. The plasma samples were sent to Kuwait by air for analysis, after 
taking all scientific measures to reach the University of Kuwait in the best 
needed condition. The procedure, reagents and apparatus of the conduction of 
PK analysis and determination of PK parameters is described below.  
2.2.5     Quality assurance 
The medical team who conducted the study were qualified and expert in the 
laboratory work. The general conditions of the experiment were well 
controlled in regard to the following: type of food and drink (one type of 
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meals such as meat, cheese, olive, salads and drinks such as water, orange 
juice and tea for all in the duration of the study time).  
The other requirements of the standard operating procedures were; controlled 
time interval, blood samples took inside dark room and warped all cryo tubes 
which contained the plasma samples into dark socks to prevent degradation of 
artesunate by light. 
All instruments of the experiment were checked to ensure their accuracy 
before experiment.   
2.2.6     Ethical consideration 
Certificate of Ethical consideration was obtained from the Ethical Board of 
Federal Ministry of Health (mentioned in part 1). A written (Annex 7) and 
verbal informed consent was obtained by every volunteer and every one had 
the right to end his/her consent voluntary. The welfare of each individual 
volunteer is a priority over the conduction of the study.                            
Quantification of Artesunate and Dihydroartemsinin in Human Plasma 
by Liquid Chromatography-Tandem Mass Spectrometry 
2.2.7     Experimental Chemicals and reagents 
Artesunate (ART), dihydroartemsinin (DHA) and internal standard (IS), 
artemsinin were kindly supplied by Dafra pharma (Belgium). Water was 
purified using a Milli-Q water device (Millipore, Bedford, MA, USA). The 
Oasis® HLB solid phase extraction (SPE) cartridges were purchased from 
Waters Corporation (Milford, MA, USA). All other chemicals and reagents 
were of analytical grade and solvents were of HPLC grade. 
2.2.8     Instrumentation  
The chromatographic system, Waters Alliance 2690, consisted of a solvent 
delivery system, and an auto sampler (Waters Assoc., Milford, MA, USA). 
Separation of the analytes was performed on a Symmetry® C18 column (5 µm, 
3.9 x 50 mm) and a guard column of the same material. The mobile phase 
used consisted of methanol-ammonium acetate (10 mM), (85:15, v/v) and 
delivered at a flow rate of 0.2 ml/min to a positive electro spray ionization 
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interface (ESI+) of a tandem triple quadrupole mass spectrometer (Quattro 
LC, Micromass, Manchester, UK). Tuning parameters of MS and MS-MS 
were optimized by direct infusion of solutions of ART, DHA and the IS in the 
mobile phase into the ionization probe at a flow rate of 10 µL/min using a 
syringe pump. The ion source and desolvation temperatures were set at 100 
and 275°C, respectively. The capillary voltage was adjusted at 3.5 kV. The 
cone voltage was adjusted at 15, 20 and 25 V for ART, DHA and IS, 
respectively. The collision energy was adjusted at 10 eV and collision gas 
pressure at < 1.0e-4 mbar. The MRM transitions at m/z 402.2>267.2, 
302.3>267.3, and 300.3>209.2 were selected for quantification of ART, DHA 
and IS, respectively. The data were processed by employing MassLynx NT 
Software (Version 4.1, Micromass, Manchester, UK). 
2.2.9 Standard solutions, calibration standards and quality control samples 
Stock solutions (1.0 mg/mL) of artesunate (ART) and dihydroartemisinin 
(DHA) were prepared separately by dissolving 10 mg of each compound 
powder in 10 ml acetonitrile. A 1.0 ml aliquot of either ART or DHA stock 
solution (1.0 mg/mL) was further diluted with methanol to yield a working 
standard solution of 1.0 µg/mL. On the other hand, a stock solution of the 
internal standard, artemisinin (IS), was prepared by dissolving 10 mg of the IS 
powder in 10 ml acetonitrile and then it was further diluted in methanol to 
yield a working standard solution of 10 µg/ml. All solutions were stored at -
20oC pending analysis. The calibration curves of ART and DHA were 
prepared by spiking drug-free human plasma with concentrations of 1, 5, 20, 
40, 100, 200, 500, 1000 and 2000 ng/mL. The spiked plasma samples (10 mL) 
were aliquoted (600 µL) into Eppendorff polypropylene tubes and kept frozen 
at – 80oC pending analysis. 
Similarly, quality control (QC) samples were prepared in drug-free human 
plasma at concentrations of 10, 50, 300 and 1500 ng/mL. The spiked plasma 
samples were aliquoted (600 µL) into Eppendorf polypropylene tubes and kept 




2.2.10 Assay procedure 
Prior to assay, frozen human plasma samples including calibrators, QC 
samples or volunteer samples were thawed at ambient temperature and then 
vortex-mixed for 30 seconds before extraction. The extraction procedure was 
carried out using Oasis® HLB SPE cartridges. For each sample, a SPE 
cartridge was conditioned with 1 mL methanol and then equilibrated with 1 
mL acetic acid (1.0 M). A 500 µL aliquot of each plasma sample followed by 
25 µL of the IS (10 µg/mL) were loaded onto the activated cartridges and 
mixed gently for 30 sec. After loading, the cartridges were then washed with 2 
mL acetic acid and 20%methanol in 1.0 M acetic acid. ART, DHA and the IS 
were then eluted with 2 mL of 40% ethyl acetate in chlorobutane under a 
vacuum of 5 mm Hg into a clean glass test tube. The eluent was evaporated 
under stream of nitrogen gas and then reconstituted with 200 µL mobile phase. 
A 100 µL aliquot of this solution was transferred to the autosampler and then 





















MRM of 3 channels,ES+
302.3>267.3
3.499e+003








MRM of 3 channels,ES+
402.2>267.2
1.517e+004







MRM of 3 channels,ES+
300.3>209.2
7.807e+002








Typical MRM chromatograms of a drug-free human plasma supplemented with 100 






























MRM of 3 channels,ES+
302.3>267.3
2.974e+004








MRM of 3 channels,ES+
402.2>267.2
1.347e+005







MRM of 3 channels,ES+
300.3>209.2
1.093e+005










Correlation coefficient: r = 0.997917, r^ 2 = 0.995839
Calibration curve: 0.00886363 * x + -0.0178081
Response type: Internal Std ( Ref 1 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: Null, Axis trans: None
ng/ml













































Correlation coefficient: r = 0.997649, r^ 2 = 0.995304
Calibration curve: 0.00254716 * x + 0.00514843
Response type: Internal Std ( Ref 1 ), Area * ( IS Conc. / IS Area )
Curve type: Linear, Origin: Exclude, Weighting: Null, Axis trans: None
ng/ml

















Plasma concentration [mean (SD)] of artesunate in healthy volunteers [n=16] 
versus time following the administration of artesunate and artesunate combined with 
sulfadoxine/pyrimethamine 
  
Artesunate Artesunate + SP 
Time (hr) Mean (SD) plasma concentration of 
artesunate 
Mean (SD) plasma 
concentration of artesunate 
0 0 0 
0.5 50.9 (63.6) 15.5 (12.2) 
1 123.8 (233.8) 36.1 (71.4) 
1.5 25.3 (20.9) 74.0 (105) 
2.0 14.0 (16.1) 43.4 (53.3) 
2.5 14.9 (15.7) 17.0 (12.9) 
3.0 10.9 (12.4) 9.7 (7.1) 
3.5 10.9 (10.6) 16.4 (27.3) 
4.0 17.7 (19.0) 8.4(5.6) 
4.5 8.5 (7.7) 5.2 (3.9) 
5.0 13.1 (5.9) 4.5 (3.8) 
6.0 7.6 (5.5) 2.7 (1.4) 
9.0 2.0 (1.0)  






Plasma concentration [mean (SD)] of artesunate in healthy volunteers [n=16] 























































Plasma concentration [mean (SD)] of dihydroartemisinin in healthy volunteers 
[n=16] versus time following the administration of artesunate and artesunate 
combined with sulfadoxine/pyrimethamine  
Artesunate Artesunate + SP Time 
(hr) Mean (SD) plasma concentration of dihydroartemesinin 
Mean (SD) plasma concentration 
of dihydroartemesinin 
0 0 0 
0.5 164.3 (287.3) 76.1 (121.7) 
1 447.2 (417.9) 229.3 (395.3) 
1.5 636.2 (450.5) 585.5 (761.3) 
2.0 342.9 (205.6) 752.1 (572.9) 
2.5 256.5 (138.5) 414.3 (220.6) 
3.0 186.5 (111.7) 286.3 (195.8) 
3.5 138.6 (60.3) 236.7 (196.0) 
4.0 115.8 (43.3) 147.5 (88.2) 
4.5 73.2 (39.7) 122.6 (70.4) 
5.0 59.8 (28.9) 100.9 (73.8) 
6.0 40.1 (31.3) 62.7 (40.2) 
9.0 20.3 (15.9) 19.1 (16.4) 
12.0 10.8 (5.5) 10.2 (10.2) 
 
Each individual volunteer had a table showed maximum plasma concentration 















Plasma concentration [mean (SD)] of dihydroartemisinin in healthy volunteers 
[n=16] versus time following the administration of artesunate and artesunate 
























































The pharmacokinetic parameters for ART and DHA were estimated by 
standard non-compartmental models. The maximum plasma concentration (Cmax) and 
time needed to attain this concentration (Tmax) were directly obtained from the drug 
plasma profiles; the drug plasma elimination half-life (t1/2) values were calculated as 
Ln2/kel. Areas under the plasma concentration-time curves (AUC0-∞) were calculated 
using the linear trapezoidal rule. The oral clearance (CL/F) was calculated as 
(Dose/AUC0-∞) and the volume of distribution (Vd/F) was calculated as (1.44 X t1/2 X 
Dose/AUC0-∞). The pharmacokinetic computations were performed using WinNonLin 
software (Version 5.10, Pharsight, USA, 2005). The computed pharmacokinetic 
parameters for artesunate and its metabolite dihydroartemisinin DHA, when 
artesunate used alone or in combination with sulfadoxine/pyrimethamine, are shown 





Mean +_ standard deviation (SD) of Pharmacokinetics parameters for 
dihydroartemisinin combined with sulfadoxine/pyrimethamine in healthy volunteers, 
(n =16)  
DHA _ Comb. 









Cl (L/h)/ Kg 
DHA Comb. 
F1 2.414 1894.999 2.000 1048.100 4.8999 1.4072 
F2 2.099 901.309 6.000 157.400 10.4988 3.4672 
F3 1.818 1881.600 1.500 1154.700 4.5697 1.7425 
F5 2.103 1595.147 2.000 1096.600 6.4466 2.1251 
F6 3.198 2543.030 2.000 1950.100 4.8373 1.0486 
F8 2.221 1250.545 4.000 313.600 8.9892 2.8058 
F9 2.492 1972.296 2.000 1489.000 4.7969 1.3343 
M1 1.066 3827.966 1.500 1979.500 0.0486 1.0885 
M2 1.446 1967.694 1.500 1731.900 0.0244 1.3031 
M3 1.013 347.166 6.000 68.500 0.1622 10.2874 
M4 1.744 1163.358 2.000 490.800 0.0113 2.2041 
M5 0.493 911.977 4.500 166.000 0.0472 2.8116 
M6 0.446 716.417 2.500 238.100 0.0111 3.7725 
M7 1.748 955.773 2.000 396.300 0.0419 2.8278 
M8 0.892 2479.147 1.500 2133.100 0.1137 1.6807 
M9 1.661 2097.499 3.000 854.900 0.1368 2.0288 
Mean 1.7 1656.6 2.75 954.3 2.8 2.6 




AUC inf.: Area under the curve infinity 
DHA: didydyartemisinin 
Tmax (h): time of maximum concentration 
Cmax (ng/ml): maximum concentration in ng per ml.  
Comb. : Combination with sulfadoxine/pyrimethamine 
VDL/Kg: volume of distribution in liter per kilogram body weight  
Cl (L/h)/ Kg: clearance in liter per hour per kilogram body weight  





Mean +_ standard deviation (SD) of Pharmacokinetics parameters for 
dihydroartemisinin alone in healthy volunteers, (n =16)  
DHA_  Alone 









Cl (L/h)/ Kg 
DHA Alone 
F1 1.457 1273.001 1.500 418.600 4.4044 2.0948 
F2 2.705 2001.016 1.000 1076.100 6.0954 1.5617 
F3 1.360 1631.267 1.500 924.000 3.9434 2.0099 
F5 2.064 803.248 3.000 134.600 12.5636 4.2202 
F6 3.589 1824.301 1.500 1317.700 7.5696 1.4617 
F8 2.462 1474.995 1.000 876.200 8.4494 2.3788 
F9 1.984 1271.249 1.500 384.400 5.9265 2.0701 
M1 0.743 1913.827 1.000 1280.000 2.3345 2.1771 
M2 0.59 1144.46 0.500 1129.900 1.9060 2.2404 
M3 0.863 489.426 1.500 170.000 9.0857 7.2972 
M4 0.413 1739.082 1.500 936.200 0.8776 1.4744 
M5 0.759 763.449 0.500 359.400 3.6782 3.3586 
M6 0.456 2156.105 1.500 1580.700 0.8240 1.2535 
M7 0.993 1247.09 1.500 989.700 3.1043 2.1672 
M8 0.921 1014.785 3.000 265.500 5.4573 4.1060 
M9 1.525 1456.055 3.000 532.900 6.4290 2.9225 
Mean 1.4 1387.7 1.5 773.5 5.2 2.7 




AUC inf.: Area under the curve infinity 
DHA: dihydyartemisinin 
Tmax (h): time of maximum concentration 
Cmax (ng/ml): maximum concentration in ng per ml.  
Comb. : Combination with sulfadoxine/pyrimethamine 
VDL/Kg: volume of distribution in liter per kilogram body weight  
Cl (L/h)/ Kg: clearance in liter per hour per kilogram body weight  





Mean +_ standard deviation (SD) of Pharmacokinetics parameters for 
artesunate combined with sulfadoxine/pyrimethamine in healthy volunteers, (n =16)  
Artes   Comb. 







VDL/Kg Artes  
Comb. 
Cl (L/h)/ Kg 
Artes  Comb. 
F1 2.813 105.031 2.000 79.100 103.0209 25.3894 
F2 2.853 149.644 2.000 55.000 85.9571 20.8829 
F3 0.290 203.273 1.500 292.600 6.7405 16.1294 
F5 1.348 144.778 2.000 143.400 45.5287 23.4140 
F6 0.316 147.155 2.000 189.000 8.2474 18.1215 
F8 0.733 87.350 3.500 97.500 42.4995 40.1689 
F9 0.515 91.990 1.500 76.900 21.2366 28.6072 
M1 0.148 223.653 1.000 288.200 3.9790 18.6301 
M2 0.201 72.039 1.500 112.500 10.3408 35.5932 
M3 0.684 65.994 3.500 16.100 53.3799 54.1174 
M4 0.219 43.966 0.500 31.200 18.4412 58.3208 
M5 0.277 50.933 0.500 21.900 20.0927 50.3428 
M6 0.351 50.259 1.500 25.900 27.1974 53.7753 
M7 0.41 44.395 2.000 36.300 36.0343 60.8793 
M8 0.172 234.048 1.500 354.200 4.4290 17.8026 
M9 0.337 74.271 1.500 41.600 27.8231 57.2943 
Mean 0.7 111.8 1.7 116.3 32.2 36.22 
S D 0.9 64.5 0.8 108.5 28.8 17.01 
 
T1/2: half-life 
AUC inf.: Area under the curve infinity 
DHA: didydyartemisinin 
Tmax (h): time of maximum concentration 
Cmax (ng/ml): maximum concentration in ng per ml.  
Comb. : Combination with sulfadoxine/pyrimethamine 
VDL/Kg: volume of distribution in liter per kilogram body weight  
Cl (L/h)/ Kg: clearance in liter per hour per kilogram body weight  





Mean +_ standard deviation (SD) of Pharmacokinetics parameters for 
artesunate alone in healthy volunteers, (n =16)  
Artes  Alone 





F1 2.288 128.487 1.000 47.500 68.5070 20.7543 
F2 3.567 500.580 1.000 850.400 32.1249 6.2428 
F3 0.426 93.988 1.000 141.200 21.4544 34.8841 
F5 1.350 181.049 2.500 36.000 36.4569 18.7233 
F6 0.215 105.353 1.000 69.600 7.8635 25.3117 
F8 0.293 64.559 0.500 61.300 22.9564 54.3502 
F9 1.205 76.768 1.500 51.800 59.5793 34.2798 
M1 0.182 139.764 0.500 223.200 7.8274 29.8122 
M2 0.174 76.803 0.500 143.800 8.3984 33.3853 
M3 0.229 94.996 1.500 60.200 12.4426 37.5954 
M4 0.597 53.182 1.000 73.400 41.4898 48.2136 
M5 0.294 62.292 0.500 88.000 17.4618 41.1629 
M6 0.461 388.29 1.000 481.800 4.6278 6.9605 
M7 0.287 19.18 1.500 17.900 58.3545 140.9143 
M8 1.118 171.647 2.000 55.700 39.1470 24.2747 
M9 0.271 63.397 0.500 31.500 26.2006 67.1223 
Mean 0.8 138.8 1.1 152.0 29.0 39.9486 




AUC inf.: Area under the curve infinity 
DHA: didydyartemisinin 
Tmax (h): time of maximum concentration 
Cmax (ng/ml): maximum concentration in ng per ml.  
Comb. : Combination with sulfadoxine/pyrimethamine 
VDL/Kg: volume of distribution in liter per kilogram body weight  
Cl (L/h)/ Kg: clearance in liter per hour per kilogram body weight  









In the present study, in part 1 of this thesis the therapeutic efficacy of the new 
artemisinin combinations (ACT), artesunate plus sulfadoxine/pyrimethamine 
(AS+SP) and artemether/lumefantrine (AL), the first and second lines for the 
treatment of uncomplicated falciparum malaria, was obtained. Results showed 
excellent therapeutic response, of 99.3% and 98.6% cure rates, for the first and second 
lines respectively. In the second phase of this study part 2, the pharmacokinetic 
parameters was determined for artesunate alone and in combination with 
sulfadoxine\pyrimethamine, the first line for the treatment uncomplicated falciparum 
malaria, in Sudan. Since it is widely used, it was selected for determination of 
pharmacokinetics data.  
Findings of the present study, concerning the derived parameters, statistical 
calculations, tables and figures perfectly complied with typical previous ones which 
described models assumes first-order input across the gut wall and first –order 
elimination from the body. As reported in text books by (Shargel L, et al 2005)                   
 (This model applies mostly to the oral absorption of drugs in solutions or 
immediate release forms such as; tablets, capsules and suppositories. In addition drugs 
given by intramuscular or subcutaneous aqueous injections may also be described 
using a first order process). 
The results of the present study compared with a study conducted by 
investigators in Tanzania, which evaluated the clinical efficacy and safety of oral 
artemisinin and oral artesunate as well as artemisinin pharmacokinetics during and 
after resolution of falciparum malaria.  The difference between the two studies, the 
researchers in Tanzanian study obtained pharmacokinetics parameters in falciparum 
malaria patients, as well as efficacy data was obtained, whereas in the present study, 
healthy volunteers were taken as subjects, so a single dose was administered, efficacy 
data was obtained in malaria patients, part 1 of this thesis. Investigators reported that: 
(The time to parasite clearance (PCT) after oral artesunate (26.4 +/- 3.6 h) was shorter 
(P = 0.002) than after artemisinin (31 +/- 3.6 h). The fever subsidence time (FST) 
after oral artesunate (18.9 +/- 4.0 h) was also shorter (P = 0.04) than after artemisinin 
(21.8 +/- 4.6 h). Parasites were detected in 4 (20%) and 7 (35%) patients after 
completing treatment with artesunate and artemisinin respectively. In these patients 
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the parasitaemia reappeared at the 3rd or 4th week of follow-up. No clinical 
abnormality was observed during the study period. Artemisinin plasma 
concentrations, determined by high performance liquid chromatography with post-
column derivatization and detection by ultraviolet light, were followed up to 8 h after 
drug administration on days 1 and 6. Artemisinin absorption was rapid, the maximum 
plasma concentrations (Cmax) being attained at about 3 h. Artemisinin areas under 
the plasma concentration-time curve (AUC) and the Cmax values were about 6 times 
higher after the first dose on day 1 than on day 6. This decrease in artemisinin plasma 
concentration is suggestive of an increase in metabolic capacity due to pronounced 
auto induction) (Alin H M et al 1996).  
Comparing pharmacokinetics data of the two studies, rapid absorption of 
artemisinin was observed in Tanzanian malaria patients whereas more rapid 
absorption of artesunate was reported in healthy volunteers in the present study. 
Maximum plasma concentration was attained after 3 hours and 1.5 hours respectively, 
in the two studies. Reappearance of parasitaemia in Tanzanian malaria patients of 20 
% and 35 % for artesunate and artemisinin respectively (high failure rate), not agreed 
with results obtained in part 1 of this thesis where combination of artesunate + 
sulfadoxine/pyrimethamine was used, obtained excellent efficacy with only 0.7% 
patients appeared parasiteamic after treatment. Dramatic reduction in parasite biomass 
in the present compared with investigators findings, which is justified by the use of 
artemisinin derivative as monotherapy in the treatment of malaria by investigators 
instead of combination therapy. As reported by (Aweeka FT, German FI 2008): 
(Artemisinin and semi synthetic derivatives, including artesunate, artemether and 
dihydroartemisinin, are short-acting antimalarial agents that kill parasites more 
rapidly than conventional antimalarials, and are active against both the sexual and 
asexual stages of the parasite cycle. To delay or prevent emergence of resistance, 
artemisinins are combined with one of several longer-acting drugs: amodiaquine, 
mefloquine, sulfadoxine/pyrimethamine or lumefantrine which permit elimination of 
the residual malarial parasites).  
Not all artemisinin derivatives are rapid and potent in action, in a study in 
Thailand; investigators obtained pharmacokinetic data evaluate the therapeutic 
potential of Artemotil (beta-arteether) -a long acting artemisinin -in Thai patients with 
severe Plasmodium falciparum malaria. Investigators reported; (Intramuscular 
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administration was used at; a low dose and a high dose. Cmax values of 63.7 ng/mL at 
6.1 hours and 140.8 ng/mL at 5.7 hours were reached in low-dose and high-dose 
patients, respectively. Drug concentrations decreased slowly with half-lives of 12.5-
22.4 hours on day 0 and 31.6-40.7 hours on day 4 for both dosage regimens. Although 
the maintaining dosage on the last day was much lower than the loading dose on day 
0, the area under the curve (AUC) and Cmax on day 4 were significantly increased 
(2.85-4.55 fold), suggesting drug accumulation in the blood. Dihydroartemisinin 
(DHA), an active metabolite of Artemotil, was detected in most patients. The mean 
ratios of DHA and Artemotil were 0.16-0.19 in both dosage regimens for the entire 
study period. Similar to previous reports, all patients showed a slow response to 
treatment with mean values of 77.2 hours for the fever clearance time (FCT) and 75.8 
hours for the parasite clearance time (PCT). The patients treated with the high dosage 
regimen had higher AUC values and higher antimalarial efficiency (cure rate = 48%) 
than the low-dose subjects (cure rate = 23%). Despite the high accumulation and 
longer exposure time (9-11 days) when compared with other artemisinin agents, due 
to the slow prolonged absorption of Artemotil from injection sites, the two dosage 
regimens did not show a better therapeutic effects than other artemisinin drugs, 
including alpha/beta-arteether dissolved in peanut oil used in Indian patients (Li O et 
al 2004).  
Comparing results of artemotil efficacy (Li Q et al 2004) with results of 
artesunate plus sulfadoxine/pyrimethamine & artemether/lumefantrine efficacy (part 
1), of this thesis in which the two artemisinin combinations showed an excellent 
therapeutic response and rapid action of (99.3% & 98.6%) cure rates respectively in 
Sudanese patients. Compared to slow action and poor therapeutic which obtained of 
(48% & 23%) cure rates for artemotil in Thai patients. As well as not agreed with in 
part 2 of this thesis, findings of pharmacokinetics parameters concerning C max 
values was much higher and shorter half- lives in the two regimens was obtained. Of 
773.5 ng/ml at 1.5 hours and 954.2 in 2.7 hours for dihydroartemisinin in mono and 
combined regimen respectively, compared to Cmax values of 63.7 ng/mL at 6.1 hours 
and 140.8 ng/mL at 5.7 hours were reached in low-dose and high-dose in Thai 
patients, respectively   
 Comparing results of the present study, with results of another similar local 
study, in which investigators determined the pharmacokinetic parameters of a single 
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dose of 200 mg oral and rectal artesunate in healthy Sudanese volunteers, rapid 
absorption was observed following oral artesunate administration, converted to its 
biological metabolite dihydroartemisinin. Investigators used a reversed phase high 
performance liquid chromatography with post column derivatization and subsequent 
ultraviolet detection, whereas analytical method in the present study was done by 
Liquid Chromatography-Tandem Mass Spectrometry in the present study. 
Pharmacokinetic parameters were derived from artesunate and its metabolite 
dihydroartemisinin from plasma of healthy volunteers due to highest sensitivity of the 
apparatus in the present study. Investigators derived pharmacokinetic parameters from 
the main metabolite alpha-dihydroartemisinin data due to the rapid disappearance of 
artesunate (undetectable) from the plasma, reported the following results: 
(Dihydroartemisinin following oral administration of artesunate had a significantly 
higher AUC (0-infinity) (P<0.05 95% confidence interval (CI) -1168.73, -667.61 ng x 
h/mL(-1)) and Cmax (P<0.05; 95% CI -419.73, -171.44 ng/mL(-1)), and had shorter 
tmax (P<0.05; 95% CI -0.97, -0.10 h) than that following rectal artesunate. There was 
no statistically significant difference in the elimination half-life between both routes 
of administration (P>0.05; 95% CI -0.14, 0.53 h). The relative bioavailability of rectal 
artesunate was [mean (coefficient of variation %) 54.9 (24.8%) %]. On the basis of 
these data an 8 hourly dosing regimen per day with rectal artesunate is proposed). 
(Awad MI et al 2004)  
In recent years, artemisinin and particularly one of its derivatives, Artesunate 
(AS) has become an essential alternative for treatment of both uncomplicated and 
severe falciparum malaria in Asia and Africa as well. Therefore, this compound is still 
and increasingly in the focus of interest because of quick acting of these drugs, is able 
to help even unconscious to overcome the malaria attack, when administered by 
injection. A reported by (Benakis et al 2006) in a study conducted in Vietnam, 
assessed the efficacy and pharmacokinetic for artesunate rectal, in Vietnamese 
children, with uncomplicated plasmodium falciparum malaria. Investigators used 
HPLC technique with electrochemical detector for quantification of artesunate and 
dihydroartemesinin. They derived the following observations: (The onset of action is 
observed within the first half hours, therapeutic levels of the drug obtained 89 
microg/ml of artesunate compared to 84 microg/ml of dihydroartemesinin. The 
dihydroartemesinin levels were somewhat higher than those of artesunate, a peak 
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concentration was reached after 6 h starting medication of about 151 microg/ml for 
artesunate as compared to 276 microg/ml for dihydroartemesinin. The variations as a 
function of frequency of dihydroartemesinin uptake are much less marked than those 
observed for artesunate. Some sort of a plateau of dihydroartemesinin and artesunate 
is built up, lasting at least from 9 to 12 hours with dihydroartemesinin level of about 
190 microg/ml and artesunate of 90 microg/ml. In the case of single-dose 
administration, the levels of both compounds were below the detection threshold after 
three hours. With regard to the parasite counts, although there were inter-individual 
variations, it should be noted that after 48 hours a high proportion of the patients was 
completely clear of parasites. Similar results were observed with regard to the body 
temperature. Repeated administration of artesunate can extend the duration of 
therapeutic plasma levels of the drug ( Benakis A et al 2006). Comparing results of 
Vietnamese study with results of the present study; rapid absorption was obtained in 
both studies in the first half hour, although the route of administration were different 
(rectal in Vietnamese study and oral in the present study), oral route in the present 
study, obtained higher level of artesunate and dihydroartemesinin of 123 ng/ml and 
752 ng/ml respectively compared to what reported by (Benakis A et al 2006) and 
(Awad MI et al 2004) when both derived analysis by single rectal dose and comply 
with what reported by (Awad MI et al 2004) that oral dose obtained higher level of 
dihydroartemesinin than rectal dose. The findings of the Vietnamese study and 
previously mentioned Sudanese study supported the artesunate rectal application 
principle, because it is resulting in high efficacy both for the velocity of drug uptake 
as well as the better therapeutic response. In Sudan, artesunate rectal is used as pre- 
referral treatment for severe malaria cases in remote areas, before referral them to the 
nearest hospital for further management as mentioned in the national protocol.  
In a study in Ghana, investigators compared pharmacokinetic of intrarectal 
(i.r.) artesunate (ARS) in malaria patients (n =34), in low and high dose with 
intravenous (i.v.; 2.4 mg/kg of body weight). They obtained that: The median relative 
bioavailability of dihydroartemisinin (DHA), the active antimalarial metabolite of 
ARS, was higher in the low-dose i.r. group (10 mg/kg) than in the high-dose i.r. group 
(20 mg/kg) (58 versus 23%; P = 0.018). Investigators found that; there was wide 
interpatient variation in the area under the concentration-time curve after i.r. ARS 
administration (up to 9-fold in the high-dose group and 20-fold in the low-dose 
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group), similar findings was obtained with the present study, also there was inter-
individual variation (up to 3 folds in DHA alone and 8 folds in DHA combination) 
although subjects were different, malaria patients (rectal) and healthy volunteers 
(oral) in investigators study and present study respectively. Investigators found that; 
i.r. administered ARS was more rapidly absorbed in the low-dose group than the high-
dose group (median [range] absorption half-lives, 0.7 h [0.3 to 1.24 h] versus 1.1 h 
[0.6 to 2.7 h] [P = 0.023]. i.r. administered ARS was eliminated with a median (range) 
half-life of 0.8 h (0.4 to 2.7 h) (low-dose group and 0.9 h (0.1 to 2.5 h) (high-dose 
group) (P = 1). The fractional clearances of DHA were 3.9, 2.6, and 1.5 liters/kg/h for 
the 20-mg/kg, 10-mg/kg and i.v. groups, respectively (P = 0.001 and P = 0.06 for the 
high-and low-dose i.r. groups compared with the i.v. groups, respectively). The 
median volumes of distribution for DHA were 1.5 liters kg (20 mg/kg, i.r. group), 1.8 
liters/kg (10 mg/kg, i.r. group), and 0.6 liters/kg (i.v. group) (P < 0.05 for both i.r. 
groups compared with the i.v. group). Parasite clearance kinetics was comparable in 
all treatment groups. i.r. administered ARS may be a useful alternative to parenterally 
administered ARS in the management of moderate childhood malaria and should be 
studied further (Krishna S et al 2001). 
In Ghana health authorities had adopted artesunate (AS) is used in 
combination with amodiaquine (AQ) as first-line treatment for uncomplicated malaria 
as the case in many countries. The investigators in Ghana studied the effect of 
concomitant AS administration on the pharmacokinetics of AQ and compared 
concentrations of desethylamodiaquine (DEAQ), the main metabolite of AQ, in 
plasma between patients with different variants of the cytochrome P4502C8 
(CYP2C8) gene. (Adjiei G O et al 2008) reported that :(The population clearance of 
DEAQ appeared to increase nonlinearly with body weight, and the central volume of 
distribution of DEAQ was higher (P < 0.001) in the AS-plus-AQ group than in the 
AQ-only group. The maximum plasma DEAQ concentration was higher (P < 0.001), 
and the population distribution half-life was shorter (P < 0.01), in the AQ-only group 
than in the AS-plus-AQ group. The total areas under the plasma DEAQ 
concentration-time curves (P = 0.68) and elimination half-lives (P = 0.39) were 
similar for the two groups. There was a high frequency (0.179) of the non-wild-type 
allele of CYP2C8, but no differences between CYP2C8 genotypes with regard to AQ 
efficacy or safety were evident.) (Adjiei G O et al 2008).  Although the tested drugs 
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were different in the present study and Ghana study, but there was similarity in that; 
significant shorter half-lives obtained with monotherapy of artesunate alone and its 
metabolite dihydroartemisinin than in combination with sulfadoxine (P = 0.001 and 
P=0.002), respectively. Area under the curve (AUC) were similar in the two studies 
no significant difference between mono and combined therapy (P= 0.3) and (P=0.68) 
in the present study and in Ghana study respectively.    
Artesunate is rapidly hydrolyzed in vivo to dihydroartemisinin, and this 
contributes the majority of antimalarial activity. For dihydroartemisinin, a one-
compartment model assuming complete conversion from artesunate and first-order 
appearance and elimination kinetics gave the best fit to investigators data and the data 
of the present study. Similar findings; the mean population estimate of apparent 
clearance (CL/F) was 2.64 (l/kg/h) with 66% inter-individual variability which 
completely agreed with the present findings of (CL/l/h/kg) was 2.67 with inter-
individual variation. The apparent volume of distribution (V/F) was 2.75 (l/kg) with 
96% inter-individual variability compared to volume of distribution Vdl/kg was 2.8 in 
the present study. The estimated dihydroartemisinin population (mean elimination) 
half-life was 43 min, which was higher in the present study mean half-live was 1.4 
hour. Gender was associated with increased mean CL/F by 1.14 (95% CI: 0.36-1.92) 
(l/kg/h) for a male compared with a female, - unlike the present study no gender 
association was obtained, similar AUC in ART alone and in combination with SP 
(P=0.39). Subjects in the two studies were different; malaria patients and healthy 
volunteers as well as route of administration were different; rectal and oral. 
Investigators found; weight was positively associated with V/F. Larger V/Fs were 
observed for the patients requiring early rescue treatment compared with the 
remainder, independent of any confounders. No associations between the 
parasitological responses and the posterior individual estimates of V/F, CL/F, and 
AUC0-6h were observed.) (Simpson JA, et al 2006).  
Investigators assessed pharmacokinetic interactions and tolerability of 
artesunate and amodiaquine and their main active metabolites dihydroartemisinin and 
desethylamodiaquine in healthy volunteers. (Orrell C,et al 2008) reported that: (When 
given in combination, the mean AUC was lower for dihydroartemisinin [ratio 67% 
(95% CI 51-88%); P = 0.008] and desethylamodiaquine [ratio 65% (95% CI 46-90%); 
P = 0.015] when compared with monotherapy. Adverse events of concern occurred in 
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four volunteers (27%): grade 3 transaminitis (n = 1), neutropaenia (n = 2), and 
hypersensitivity (n = 1). The total drug exposure to both drugs was reduced 
significantly when they were given in combination. The clinical significance of these 
interactions is unclear and must be studied in malaria patients. The frequency and 
nature of adverse events among the healthy volunteers were of concern, and suggest 
laboratory monitoring would be needed in malaria patients treated with artesunate 
plus amodiaquine) (Orrell C,et al 2008). Unlike investigators results, in the present 
study results total drug exposure (P=0.001) significantly increased (high AUC) of the 
active metabolite dihydroartemisinin DHA, when given in combination which support 
results obtained with the high therapeutic efficacy of ASP of 99.3% in part 1 (mean 
DHA 1656.6 +_ 868.0, ranged from 347.2 to  3827.9, range 3480.8 CL 95.0%) 
compared to monotherapy (mean DHA 1387.7 +_ 476.9, ranged from 489.4 to 
2156.1, range 1666.7 CL 95.0%), No serious adverse effects were observed in the 
healthy volunteers in the present study except mild ones which did not need treatment 
or discontinuation of the study; one female complained of mild nausea disappeared 
during the day, other one complained of skin rash followed the day of administration 
and lasted after 3 days. Because the partner drug with artesunate was different, in the 
present study sulfadoxine/pyrimethamine safer than amodiaquine which was used by 
investigators, part 1 of this thesis presented amodiaquine adverse effects.       
In a study in Gabon, investigators determined the pharmacokinetics and 
bioavailability of artesunate given by the intramuscular (IM) route for children with 
severe malaria. Absorption of IM ARS was rapid, with the maximum concentration of 
DHA in serum being achieved in less than 1 h in most children. The absolute 
bioavailability of DHA was a median of 86.4% (range, 11.4 to 462.1%), the median 
steady-state volume of distribution was 1.3 liters/kg (range, 0.5 to 7.9 liters/kg), and 
the median clearance was 0.028 liters/kg/min (range, 0.001 to 1.58 liters/kg/min). 
There were no major adverse events attributable to ARS. (Nealon C. et al 2002).  
Comparing the two studies; the present study oral artesunate was used for 
healthy volunteers and Nealon C et al study in which intramuscular (IM) for malaria 
patients. Faster absorption (T Max) was shorter with IM, in Nealon et al study in less 
than one hour in most subjects compared to oral artesunate in the present study all 
subjects achieved (C Max.) after more than one with mean T max of (1.56 +_ 0.7%) 
hour except 2 males subjects no. 2 and no. 5 achieved maximum concentration in half 
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an hour. Median volume of distribution (VDL/kg) and mean clearance (CL /h/kg) of 
dihydroartemisinin in the present study were greater (VDL/kg) of 4.9 liters/kg (range 
0.8 to 12.6 liters/kg) and clearance /kg/ hour (CL /h/kg) of 2.6 (range 1.3 to 7.3 
liters/kg/hour) compared to median steady-state volume of distribution was 1.3 
liters/kg (range, 0.5 to 7.9 liters/kg), and the median clearance was 0.028 liters/kg/min 
(range, 0.001 to 1.58 liters/kg/min). in investigators study.       
Oral route of administration was found to be convenient and popular in all 
communities. Studies supported the use of oral dosing after compared the 
pharmacokinetic and pharmacodynamic parameters with other routes of 
administration, as shown in a study in Vietnam researchers obtained comprehensive 
pharmacokinetic and pharmacodynamic data for artesunate (ARTS) and its active 
metabolite dihydroartemisinin (DHA) following i.v. and oral administration of ARTS 
to patients with acute, uncomplicated falciparum malaria. Overall, the parasite 
clearance time PCT50 and fever clearance time (FCT) were 6.5 h and 24 h, 
respectively. There was no correlation between PCT50 or FCT and AUC, Cmax or 
MRT for DHA.  Despite rapid clearance of ARTS and DHA in patients with 
uncomplicated falciparum malaria, prompt parasite and fever clearance were 
achieved. High relative bioavailability of DHA following oral ARTS administration, 
and clinical outcomes comparable with those after i.v. ARTS, support the use of the 
oral formulation in the primary care setting (Batty KA et al 1998) 
In practice vast majority of drugsare eliminated by 5 half –lives, the hafe life of DHA 
alone (1,6+_ 0.7) is significantly shorter than in DHA combined with SP ( 2.75+_1.5) 
P= 0.002, so the effect of DHAcombination is expected to cease at a mean time of 
13.85(7,5) hours. By this result the study confirmed that; the established dose 
mentioned in national malaria treatment protocol is the optimum dose for treatment 









Conclusion & Recommendation 
1. The therapeutic efficacy of the two new combination; artesunate + 
sulfadoxine/pyrimethamine (AS+SP) and artemether/lumefantrine (AL), the first 
and second lines respectively as per the national protocol, showed excellent 
response, radical cure rate of( 99. 3%) for the first line and (98.5 %) for the second 
line 
2. The two combination were safe during follow up period of the study (28 days for 
each patient) in a total of 400 patients enrolled for efficacy and safety tests in part 
1 of this thesis, for the 1st line mild adverse effects were reported in 1.9% of 
patients (n = 268) and for the 2nd line reported in 4.3% of the patients (n = 132). 
3. The two treatment combinations were well tolerated in both adult and children in 
form of oral tablets, reduction of tablet numbers of the 2nd line is recommended.  
4. Local data of pharmacokinetics parameters of the 1st line the artemisinin 
combination therapy (ACT) was obtained - requested by the technical advisory 
committee of updating antimalarial treatment protocol- showed fast absorption of 
oral administration and the combination therapy showed longer duration and 
higher concentration over the monotherapy which indicated better therapeutic 
response.   
5. The obtained results of pharmacokinetics PK parameters, tables, figures, 
calculations and statistical data perfectly agreed with typical data of other 
countries and comply with what mentioned in textbooks. 
6. There was no gender association in pharmacokinetics parameters with no effect in 
food because it was controlled in one type of food and drink.  
7. Further studies of pharmacokinetics are recommended and needed for malaria 
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Case recort form 
Example case record forms – (a) 28-day follow-up in low to moderate transmission area 
District/province: Town: Health facility's name: Study Site 
Height(cm): Weight(kg):  Sex(M/F): Age(years): Full name: Identity number: Patient 
Contact home address:  Name of guardian:  
Total dose (mg base): Expiry date: Batch number: Manufacturer: Drug name: Anti-malarial Drugs 
Result Urinary test(name): Total dose (mg): Date: Drug: Previous intake (Y/N/Unknown):  
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 Day 
               Date 
               Danger sign (Y/N) 
               History of fever last  24 h (Y/N) 
               Axillary temperature (°C) 
               Asexual parasite count (per µl) 
               Treatment (mg/kg) 
               Concomitant treatment 
               Possible side effects of Anti-malarials 
               Obsevations 
118 
 
District/province: Town: Health facility's name: Study Site 
 Height(cm):  Sex(M/F):  Full name: Identity number: Patient 
28 27 26 25 24 23 22 21 20 19 18 17 16 15 Day 
              Date 
              Danger sign (Y/N) 
              History of fever last  24 h (Y/N) 
              Axillary temperature (°C) 
              Asexual parasite count (per µl) 
              Treatment (mg/kg) 
              Concomitant treatment 
              Possible side effects of Anti-malarials 
              Observations 
 Loss to follow-up (Loss) Withdrawn (WTH) 
Adequate clinical 





Late clinical  
failure (LCF) 
Early treatment              
failure (ETF) Overall assessment: 
    Reason for  WTH         Day of assessment: 
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 ﺑﺴﻢ ﺍﷲ ﺍﻟﺮﲪﻦ ﺍﻟﺮﺣﻴﻢ
  
  (ﻔﺎﻧﺘﺮﻳﻦﻟﻮﻣ\ﺍﺭﺗﻴﻤﻴﺜﺮ)ﻭ( ﺑﺮﳝﺜﺎﻣﲔ\ﺳﻠﻔﺎﺩﻭﻛﺴﲔ+ﺍﺭﺗﻮﺳﻨﻴﺖ)ﺩﺭﺍﺳﺔ ﻓﻌﺎﻟﻴﺔ ﺃﺩﻭﻳﺔ ﺍﳌﻼﺭﻳﺎ ﺍﳌﺰﺩﻭﺟﺔ ﺍﳉﺪﻳﺪﺓ 
  ﻟﻌﻼﺝ ﻣﺮﺿﻲ ﺍﳌﻼﺭﻳﺎ ﻏﲑ ﺍﳌﻌﻘﺪﺓ
  ﺇﻗﺮﺍﺭ ﻣﻮﺍﻓﻘﺔ
.................................................................................ﺃﻧﺎ
ﺩﺧﻮﻝ . 2ﺩﺧﻮﱄ  . 1ﺑﻜﺎﻣﻞ ﻗﻮﺍﻱ ﺍﻟﻌﻘﻠﻴﺔ ﻭﺭﺿﺎﻱ ﺃﻭﺍﻓﻖ ﻋﻠﻲ ....................... 
ﻟﻠﺪﺭﺍﺳﺔ  ﺃﻋﻼﻩ ﻭﺍﻟﱵ ﺷﺮﺣﺖ ﱄ،ﺃﻭﺍﻓﻖ .... ............................ ﺍﺑﻨﱵ \ﺇﺑﲏ 
ﻋﻠﻲ ﺃﺧﺬ ﺍﻟﻌﻼﺝ ﰲ ﺍﻟﺰﻣﻦ ﺍﶈﺪﺩ ﺑﻠﻌﻴﺎﺩﺓ ﺑﻌﺪ ﻇﻬﻮﺭ ﺍﳌﻼﺭﻳﺎ ﻟﻌﻼﺟﻬﺎ ﻭﺇﺟﺮﺍﺀ ﺍﻟﻜﺸﻒ ﺍﻟﻄﱯ 
ﻭﺍﲰﺢ ﺑﺄﺧﺬ ﻋﻴﻨﺔ ﻣﻦ ﺩﻡ ﺇﺻﺒﻌﻲ ﺑﻌﺪ ﻭﺧﺰﻩ ﺑﺎﻻﺑﺮﺓ ﺍﳌﺨﺼﺼﻪ ﻟﺬﻟﻚ ﻟﺘﻘﺪﳝﻪ ﻟﻠﻔﺤﺺ 
 ﺃﺣﻀﺮ ﻟﻠﻌﻴﺎﺩﺓ ﳌﻘﺎﺑﻠﺔ ﺑﺎﳌﻌﻤﻞ ﳌﻌﺮﻓﺔ ﺗﻮﺍﺟﺪ ﺍﳌﻼﺭﻳﺎ ﺑﺪﻣﻲ ﺍﻡ ﻻ ﺑﻌﺪ ﺍﺧﺬ ﺍﻟﻌﻼﺝ ،ﻭﺃﻥ
ﺍﻟﻄﺒﻴﺐ ﻭﺍﻟﻔﺮﻳﻖ ﺍﻟﻄﱯ ﺍﻟﻌﺎﻣﻞ ﻣﻌﻪ ﰲ ﺍﻷﻳﺎﻡ ﺍﶈﺪﺩﺓ ﻭﻓﻖ ﻟﺴﲑ ﺍﻟﺪﺭﺍﺳﺔ ﻭﺇﻥ ﱂ ﺃﺳﺘﻄﻊ 
  ﺍﳊﻀﻮﺭ ﻻ ﺃﻣﺎﻧﻊ ﰲ ﺯﻳﺎﺭﺓ ﺍﻟﻔﺮﻳﻖ ﺍﻟﻄﱯ ﳌﱰﱄ ﳌﺘﺎﺑﻌﱵ 
  ﱄ ﺍﳋﻴﺎﺭ ﲟﻮﺍﺻﻠﺔ ﺍﻟﺪﺭﺍﺳﺔ ﺍﻭ ﺍﳋﺮﻭﺝ ﻣﻨﻬﺎ ﰲ ﺃﻱ ﻭﻗﺖ ﺃﺷﺎﺀ
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ﺃﻋﻼﻩ ﺍﻟﱵ ﺷﺮﺣﺖ ﱄ ﻭﺃﻥ ﺍﺧﺬ ﻋﻼﺝ ﺍﳌﻼﺭﻳﺎ ﺍﻭﺍﻓﻖ ﻋﻠﻲ ﺩﺧﻮﱄ ﺍﻟﺪﺭﺍﺳﺔ ﺍﳌﺬﻛﻮﺭﻩ 
  ﺍﳉﺪﻳﺪ ﰲ ﺟﻠﺴﺘﲔ ﺍﳉﻠﺴﻪ ﺍﻻﻭﱄ
ﲜﺮﻋﺔ ( ﻓﺎﻧﺴﺪﺍﺭ+ ﺍﻻﺭﺗﻮﺳﻨﻴﺖ)  ﺟﺮﻋﻪ ﻭﺍﺣﺪﺓ ﻭﰲ ﺍﳉﻠﺴﺔ ﺍﻟﺜﺎﻧﻴﺔ( ﺍﻻﺭﺗﻮﺳﻨﻴﺖ) 
  ﻭﺍﺣﺪﺓ
 ﺳﻲ ﺳﻲ ﰲ ﺍﻟﺰﻣﻦ ﺍﶈﺪﺩ 5 ﺳﻲ ﺳﻲ ﻣﻦ ﺩﻡ ﻭﺭﻳﺪﻱ ﺑﻮﺍﺳﻄﺔ ﺣﻘﻨﺔ 5ﻭﺍﻭﺍﻓﻖ ﻋﻠﻲ ﺃﺧﺬ 
  ﺮﺓ ﻭﻓﻖ ﻟﺴﲑ ﺍﻟﺪﺭﺍﺳﺔ ﻣ41 ﺃﻭ 31ﺧﻼﻝ ﺍﳉﻠﺴﺔ ﰲ ﻋﺪﺩ ﻣﺮﺍﺕ 
  ﱄ ﺍﳋﻴﺎﺭ ﰲ ﺍﻻﺳﺘﻤﺮﺍﺭ ﰲ ﺍﻟﺪﺭﺍﺳﺔ ﺍﻭ ﺍﳋﺮﻭﺝ ﻣﻨﻬﺎ ﰲ ﺍﻱ ﻭﻗﺖ ﺍﺷﺎﺀ
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Female volunteer’s data 
 
Volunteer 1 F1 









Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 8.8 8.4 28.7 272 
2 1 47.5 53.6 10.2 245.7 
3 1.5 35.6 418.6 8.4 179 
4 2 38.5 279.4 79.1 1048.1 
5 2.5 9 179.2 28.7 666 
6 3 23.1 156.6 7.6 170.7 
7 3.5 18 223.4 6.3 225.7 
8 4 8.5 190.3 2.6 81 
9 4.5   4.7 118 
10 5 5.5 89.7 6.1 172.2 
11 6 6.7 78.6 2.7 47.4 
12 9 2.7 57.9 ─ 32.9 
13 12 ─ 13.9 ─ 13.9 
14 24 NA NA ─  
 
 









Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 9.9 11.4 15.1 21.3 
2 1 850.4 1076.1 22.3 32.4 
3 1.5 24.3 993.7 29.6 62.1 
4 2 10.8 470.6 55 153.4 
5 2.5 9.8 254.5 22.8 112.9 
6 3 ─ 193.4 20.9 75.5 
7 3.5 ─ 143.7 15.3 62.3 
8 4 ─ 116.8 13.5 60.1 
9 4.5 ─ 65.9 12 46.7 
10 5 ─ 70.7  40.8 
11 6 ─ 62.8  157.4 
12 9 ─ 28.8 ─ 48.1 
13 12 ─ 13.5 ─ 21.7 





Volunteer 3 F3 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 36.9 99.5 46.4 426 
2 1 141.2 911.5 60.2 484.2 
3 1.5 6.1 924 292.6 1154.7 
4 2 1.7 296.9 5.5 634.7 
5 2.5 1.2 221.5 ─ 302.2 
6 3 ─ 158.2 ─ 171.6 
7 3.5 ─ 100.3 ─ 114.7 
8 4 ─ 87.2 ─ 78.9 
9 4.5 ─ 41.6 ─ 125.6 
10 5 ─ 39.5 ─ 45.2 
11 6 ─ 30.1 ─ 30.5 
12 9 ─ 20.4 ─ 9.8 
13 12 ─ 17.3 ─ ─ 














Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5  9.5 8.1 59.3 
2 1  58.7 20.3 219.3 
3 1.5 17.9 128 40.5 129.4 
4 2 24.3 75.3 143.4 1096.6 
5 2.5 36 127.2 28.4 516 
6 3 18.5 134.6 7.5 282.2 
7 3.5 26.4 107.1 9.7 242.6 
8 4 24.1 83.7 6.2 113.8 
9 4.5 20.7 104.2 5.8 70.9 
10 5 11.8 90.4 ─ 67.7 
11 6 14.6 97.3 ─ 47.7 
12 9  29.1 ─ 18 
13 12 5.7 8.8 ─ 6.6 





Volunteer 5 F5 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 61.2 121.5 13.6 4.5 
2 1 69.6 569 23.8 64.8 
3 1.5 66 1317.7 8.3 63.6 
4 2 3.5 190.1 189 1950.1 
5 2.5 8.5 397.9 42.1 848.4 
6 3 1.7 130.4 9.7 404.6 
7 3.5 ─ 92.6 3.4 200.5 
8 4 ─ 92.8 3 153.6 
9 4.5 ─ 60.1 1 120.8 
10 5 ─ 66.4 ─ 93.5 
11 6 ─ 40.3 ─ 67.8 
12 9 ─ 28.1 ─ 43.4 
13 12 ─ 18.5 ─ 36.4 














  Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 61.3 212.7 5.4 13 
2 1 60.9 876.2 5.2 22 
3 1.5 4.9 638.9 2.4 9.9 
4 2 1.5 267 12.2 37.6 
5 2.5   ─ 166.7 11 109.4 
6 3   ─ 118.8 16.1 120 
7 3.5   ─ 74 97.5 253.7 
8 4   ─ 103.5 9.6 313.6 
9 4.5   ─ 56.2 5.1 311 
10 5   ─ 55.4 4.1 311.1 
11 6   ─ 35.9 1.3 102.8 
12 9   ─ 17.2   ─ 47.4 
13 12   ─ 10.5   ─ 15.8 













 Volunteer 8  
F8 






  Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 13.3 22.1 17.6 6.7 
2 1 20.8 167 16.7 94.5 
3 1.5 51.8 384.4 76.9 297.7 
4 2 27.7 378.2 62.6 1489 
5 2.5 12.4 259.4 5 523.4 
6 3 8.1 252 2.6 310.9 
7 3.5 4.8 154.6 1.3 185 
8 4 3.9 172.7   154.5 
9 4.5 2.7 99.1   ─ 96.9 
10 5   88.6   ─ 110.3 
11 6 1.1 67.3   ─ 67.6 
12 9   ─ 31.2   ─ 33.9 
13 12   ─ 7.3   ─ 14.4 




Male volunteer’s data 
 
Volunteer 9 M1 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 223.2 264 4.7 2.8 
2 1 49.6 1280 288.2 1617.9 
3 1.5 5.6 744.3 140.4 1979.5 
4 2 1.1 523.4 12.8 1444.8 
5 2.5  428 1.3 689 
6 3 ─ 176.5  441.7 
7 3.5 ─ 185.2  828.5 
8 4 ─ 114.4  216.7 
9 4.5 ─ 60.1  108.6 
10 5 ─ 30.1 ─ 90.1 
11 6 ─ 2.1 ─ 38.5 
12 9 ─ 1 ─ 5.1 
13 12 NA NA ─ 1.1 







Volunteer 10 M2 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 143.8 1129.9 6.7 45.5 
2 1 4.9 396.6 7.1 24.9 
3 1.5 2.7 271.7 112.5 1731.9 
4 2 2.2 123.8 11.8 729.5 
5 2.5 ─ 87.5 3.6 405 
6 3 ─ 64.7 2.2 227.5 
7 3.5 ─ 56.4 ─ 170.8 
8 4 ─ 65.9 ─ 109.4 
9 4.5  39.1 ─ 89.7 
10 5 ─ 23.3 ─ 78.5 
11 6 ─ 6.8 ─ 49.7 
12 9 ─  ─ 11.8 
13 12 NA  ─  

















Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 8 45.2 5.6 8.7 
2 1 6.5 37.7  8.1 
3 1.5 60.2 170 12.9  
4 2 16.2 103.8 8.7  
5 2.5 12.9 87.5   
6 3 12 80.1   
7 3.5 6.1 56.4 16.1  
8 4 37.6 96.3 14.1  
9 4.5 8.3 56.8 11.4  
10 5 19.1 57.6 11.3  
11 6 ─ 25.8 4.1 68.5 
12 9 ─ 10.1  8.8 
13 12 ─   6.8 















Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 16.4 76.1 31.2 212.4 
2 1 73.4 687.1 9.6 365.1 
3 1.5 5.9 936.2 23.2 420.9 
4 2 3.3 575.7 17.5 490.8 
5 2.5  532.4 3.6 314.3 
6 3 2.1 232.3 2.5 138.9 
7 3.5  126.2 ─ 96.7 
8 4 ─ 126.1 ─ 46 
9 4.5 ─ 64.5 ─ 42.2 
10 5 ─ 57.5 ─ 31.7 
11 6  6 ─ 22.8 
12 9 ─ 2.7 ─ 7.3 
13 12 NA  ─ 2.1 













Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 88 359.4 21.9 81.1 
2 1 15.2 288.8 13.9 145.5 
3 1.5 8.7 261.9 9.2 126.8 
4 2 2.9 228.1 5.8 131.3 
5 2.5 2.7 111.8  126.6 
6 3 2.2 81.4 5.3 130 
7 3.5 2.6 114.1 9.4 107.6 
8 4 0.8 31.4 19.3 124.2 
9 4.5 1.1 16.1 8.4 166 
10 5 ─ 12.6 2.4 107.5 
11 6 ─  ─ 128.8 
12 9 ─  ─ 1.9 
13 12 NA  ─  









Volunteer 14 M 6 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5   11.4 24.5 
2 1 481.8 578.3 1 203.9 
3 1.5 44.8 1580.7 25.9 185.4 
4 2 4.5 795.2 11.8 87.5 
5 2.5  405.9 24 238.1 
6 3 1 251.3 7.1 199.5 
7 3.5  151.5 5.5 114.4 
8 4 ─ 128.2 7.1 119.5 
9 4.5 ─ 55.8 4.3 122.9 
10 5 ─ 31.3 1.6 43 
11 6 ─ 5.9  11.3 
12 9 ─ 1.3 NA 6.4 
13 12 NA   1 




Volunteer  15 M 7 
A -ALONE 
 
A+F       





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 7 18.3 1.3 5.7 
2 1 3.6 33.6 3.3 8.8 
3 1.5 17.9 989.7 5.5 21.2 
4 2 5 571 36.3 396.3 
5 2.5 1.6 237.8 27.8 389.8 
6 3 1.4 154.6 6.5 391.8 
7 3.5 1.4 154.6 3.2 267.7 
8 4 ─ 104.3 1.2 103.5 
9 4.5 ─ 73 1.5 64.4 
10 5 ─ 52.7 1.3 50.8 
11 6 ─ 11.2 ─ 28 
12 9 ─ 5.7  7.8 
13 12 NA   3.4 







Volunteer  16 M8 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 3.1 7.2 14.6 26 
2 1 15.7 13.1 41.2 116.6 
3 1.5 29 93 354.2 2133.1 
4 2 55.7 154.8 18.1 900.4 
5 2.5 52.1 191.9 5.1 499 
6 3 40.9 265.5 12.7 375.4 
7 3.5 25.4 214   
8 4 47.9 187.8 9.7 185.6 
9 4.5 9.7 176.4 1.3 123.9 
10 5 15.8 122.6 ─ 84.1 
11 6 8 78.8 ─ 40.4 
12 9 1.3 34.4 ─ 3.8 
13 12 ─ 3.6 ─ 1.3 




Volunteer 17 M9 





Art DHA Art DHA 
0 0 0 0 0 0 
1 0.5 31.5 79.1 0 8.6 
2 1 15.5 127.1 18.2 15.3 
3 1.5 23.4 325.7 41.6 287.7 
4 2 25.1 453.6 24.7 691.3 
5 2.5 18 415.3 18 474.4 
6 3 9 532.9 24.9 854.9 
7 3.5 2.5 264.2 12.6 444 
8 4 1.4 150.7 5.6 352.4 
9 4.5  128.6 2 230.9 
10 5  68.5  187 
11 6 ─ 52 ─ 94.2 
12 9 ─ 16.5 ─ 19.7 
13 12 ─ 3.4 ─ 7.7 
14 24 NA NA ─ 3.4 
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